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ABSTRACT
Evasion of apoptosis and resistance to chemotherapy are major therapeutic
challenges for acute leukemias. Presumably as a means to promote cell survival,
multiple elements of the cyclic AMP (cAMP) pathway are aberrantly regulated in
acute leukemias. Furthermore, increased intracellular cAMP (icAMP) is known to
induce apoptosis. Therefore, modulation of icAMP has long been a target in
leukemias. The central hypothesis of this dissertation is that malignant cells produce
and remove excess intracellular cAMP to evade apoptosis and promote survival.
Consequently, inhibition of cAMP efflux could selectively trigger leukemia cell death.
We designed a novel assay to assess icAMP efflux from cells, and used this in a high
throughput screen to identify several molecules as inhibitors of cAMP efflux (ICE). We
determined that cAMP efflux mechanisms are relatively absent in normal peripheral
blood mononuclear cells (PBMCs), but are active in leukemia cell lines. We also
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validated the ability of ICE to increase cAMP pathway activity. We demonstrated that
ICE selectively induce apoptosis in leukemia cells. Because chemotherapy resistance
can occur by cAMP efflux transporters, this dissertation also addresses the possibility
of using ICE in combination with current therapeutics. We demonstrate that
combinations of ICE with leukemia chemotherapeutic agents produce synergistic
effects against acute leukemia cells in vitro and ex vivo. In conclusion, we believe that
our data support inhibition of efflux as a mechanism in cAMP pathway targeting that
merits further investigation for the development of cancer therapeutics.
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CHAPTER 1: Introduction

1.1 Acute leukemias — Novel therapeutics are urgently required
1.1.1 Biology and etiology of acute leukemias
While not the most prevalent malignancy in the United States, leukemia ranks
among the top ten cancers in terms of both morbidity and mortality [8]. These
hematological malignancies involve aberrant proliferation of blood cells with
immature phenotypes. Acute leukemias are typically identified by the presence of >
20% blast cells in the peripheral blood or bone marrow [12]. Due to inherent
characteristics related to a reduced differentiation state, and the ability to rapidly
propagate, acute leukemias have worse prognoses than chronic leukemias. Over the
last ten years, the rates of acute myeloid (AML) and acute lymphoblastic leukemia
(ALL) diagnoses have modestly increased by 2.2% and 0.6%, respectively [14].
Because these diseases are subject to the growth of blast cells, there is a strong need
for the development of novel approaches to treat these malignancies.
As such, our work specifically focuses on acute AML and B-cell lineage ALL (BALL). AML is most prominent in elderly adults over 65 years in age. Annually, 21,450
cases are diagnosed in the United States, and 10,920 cases succumb to the disease [8].
The five year overall survival for this disease is a disheartening 28.3% for adults [8]
and about 60% for children [17]. B-ALL primarily affects children under 17 years of
age, with about 6,000 new cases diagnosed and 1,500 deaths each year [18]. This
disease is considered > 80% curable, however there is much room for improvement.
1

The primary classification of acute leukemia is based on the presence of
chromosomal abnormalities and translocations and immunotyping. For example, 2530% of B-ALL have hyperdiploidy [19], while a surprising 40-50% of AML are
cytogenetically normal [12]. An analysis of primary AML samples determined an
average of 13 mutated genes per sample [20]. It has also been reported that > 80% of
B-ALL cases contain deletions within genes related to B cell development [14]. De
novo B-ALL genomes also contain 10-20 gene coding mutations [21]. The main role of
these genetic alterations in acute leukemia cells is to promote survival.
Most commonly, the etiology of acute leukemias is attributed to the combination
of mutations that increase pro-survival signaling and reduce tumor suppressor genes
[22]. Many factors are potentially implicated in leukemogenesis, and most include
aberrancies that increase cell proliferation. Due to potential mutations, rapid growth,
and deviant signaling, leukemia cells have the capacity to overcome normal
mechanisms that would typically result in cell death. For example, AMLs overexpress
vascular endothelial growth factor (VEGF), and this promotes angiogenesis of the
surrounding bone marrow [23]. This altered microenvironment results in vascular
leakage of the surrounding endothelium and increased production of nitric oxide
(NO) [24]. Because NO is immunosuppressive [25], this leukemia-microenvironment
feedback system allows malignant cells to escape cell death through the normal
immune response.

2

1.1.2 Treatment paradigms in acute leukemias
Treatment for acute leukemia typically begins with induction therapy, wherein
chemotherapeutics are used to induce remission of the disease. In this approach, the
goals are to reduce the population of blast cells and/or induce them to differentiate.
Most commonly, this stage of treatment involves drugs that are used in many other
cancers and diseases, and hence their mechanisms of action are non-specific for
leukemia. These drugs are aimed at killing all cells that are proliferating by inducing
DNA damage or interfering with cell replication mechanisms. For some AML and BALL patients, allogeneic stem cell transplants are a treatment option as well.
The standard of care for AML is the use of cytosine arabinoside (cytarabine; AraC)
with an anthracycline (e.g., daunorubicin, idarubicin, doxorubicin) for 7-10 days [26].
Over 80% of patients can achieve a complete response with this treatment, but often
relapse will occur over time [27]. This is followed by consolidation therapy, which is
typically high dose AraC [28]. Refractory or relapsed AML is also treated with high
dose AraC, or the FLAG (fludarabine, AraC, granulocyte colony-stimulating factor (GCSF)) regimen, but these result in modest complete remission rates of 32% and
47.5%, respectively.
B-ALL induction therapy involves 4-6 weeks of a glucocorticoid (e.g.,
dexamethasone or prednisone), asparaginase, vincristine, and an anthracycline. This
is followed by several months of consolidation and maintenance therapies, which
consist of some induction agents, as well as 6-mercaptopurine or 6-thioguanine, or
methotrexate [19]. Like AML, the time elapsed between remission and relapse was
3

associated with better overall survival. In one longitudinal study of pediatric B-ALL
patients, only 8.8% of participants relapsed within 5 years [29], although other
reports have indicated relapse rates of about 15-20% [23]. Nonetheless, a small
percentage of B-ALL patients are vulnerable to the development of extramedullary
disease in the central nervous system (CNS) [30].
For both AML and B-ALL, remission is often determined by the minimal residual
disease in the patient. Most commonly, this is classified as < 1 leukemic blast in
10,000-100,000 cells in the bone marrow [19, 30]. The length of remission varies by
patient, although some mutations and translocations have been associated with
longer event free survival (EFS). For example, AML cases with NPM1 mutations are
considered to have favorable risk,

while those containing an internal tandem

duplication of fms-related tyrosine kinase 3 (FLT3-ITD) have adverse risk [31].
However, it should be noted that about 40% of AML cases are deemed ‘cytogenetically
normal’ [12]. In B-ALL, the ETV6-RUNX1 fusion protein is associated with better
treatment response and longer time to relapse [32]. Rearrangements of the mixedlineage leukemia (MLL) gene are considered prognostically less favorable[32].
Despite the fact that these and other cytogenetic factors are characteristically
associated with prognosis, many patient responses to treatment are individual, and
even those with similar cytogenetic factors could have opposite responses to the
same therapy.
The treatment paradigms for acute leukemias are not without fault. Primarily due
to their lack of selectivity for leukemic cells, leukemia chemotherapeutic agents (LCA)
4

can cause systemic damage to the patient. Most notably, anthracyclines and other
chemotherapeutics exhibit cardiotoxicity. This is probably because, like cancer cells,
the heart is highly metabolically active. Survivors of pediatric ALL are at increased
risk for the long-term development of heart disease [33]. LCA are associated with
damage to the liver and kidneys, as these are the primary organs for drug metabolism.
Patients with ALL are also at risk for osteonecrosis [34, 35]. Furthermore, leukemia
treatments have been related to long-term cognitive impairment, including memory,
attention, and executive function deficits [36, 37]. Hence, the development of drugs
that are more selective for malignant cells could seriously reduce the incidence of
adverse side effects suffered by patients.

1.2 cAMP-dependent pathway - A meaningful target in hematological
malignancies
1.2.1 The cellular roles of cAMP and its regulation
In 1958, the first second messenger in cells, 3',5'-cyclic adenosine
monophosphate (cAMP) [38], was identified. This molecule is critically important for
all cells, and is at the crux of many cellular processes that regulate growth, survival,
differentiation, and the transcription of a myriad of genes. cAMP signal transduction
can result in activation of pro-survival or death pathways, depending upon cell type
and conditions [39]. The primary downstream effectors of cAMP are protein kinase
A (PKA) and exchange proteins activated by cAMP (EPAC). While these two effectors
can activate multiple transcription factors, the one most commonly associated with
5

cAMP pathway signaling is the cAMP response element binding (CREB). CREB activity
is associated with transcription of many pro-survival genes, including cyclins A, D1,
and D2 [40].
Canonical cAMP synthesis involves activation of any of nine transmembraneassociated adenylyl cyclases (tmAC), which are stimulated by Gαs-coupled receptors.
Activation of Gi-coupled receptors inhibits tmAC activity, and hence reduces
intracellular cAMP (icAMP). Because cAMP signaling occurs spatially throughout the
cell, it can also be generated by an alternative mechanism, soluble adenylyl cyclase
(sAC; ADCY10). This enzyme is responsible for cAMP production in cytosolic
microdomains, such as the cytoplasm, or within the nucleus or mitochondria [41-43].
Unlike tmACs, sAC is activated by bicarbonate (HCO3-) or oxidative stress [42, 44].
Elevated icAMP triggers intrinsic apoptosis by PKA signaling. PKA can activate the
transcription factor cAMP response element binding (CREB) protein to up-regulate
expression of the pro-apoptotic protein Bim [2]. Additionally, sAC stimulation of PKA
can cause translocation of pro-apoptotic Bax into mitochondria [45, 46].
icAMP concentrations can be modulated by two different mechanisms. The most
commonly studied cAMP regulators are phosphodiesterases (PDEs). These enzymes
hydrolyze cyclic nucleotides. The PDEs 1-4, 7, 8, 10, and 11 are capable of degrading
cAMP to 5’-AMP [47]. The fact that cAMP can exist outside the cell (ecAMP) was first
described in 1963 [48]. Decades later, it was determined that icAMP can be extruded
from cells by its active removal via the ATP-binding cassette (ABC) transporters.
Members of the multidrug resistance (MRP) family of transporters, ABCC4 (MRP4),
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ABCC5 (MRP5), and ABCC11 (MRP8), are reported to efflux cAMP [47]. The primary
focus of this dissertation is modulation of this process by small molecules .
Because cAMP activity occurs in discrete locations, many cAMP regulatory
proteins can be complexed to facilitate signaling. A-kinase anchoring proteins
(AKAPs) are scaffolding proteins that allow adenylyl cyclases, PKA, and PDEs to be
kept in close proximity to one another [49]. Hence, the compartmentalization of
icAMP into microdomains near the plasma membrane, mitochondria, nucleus, or
regulatory proteins, is a critical determinant of its concentration and activity [50-52]
(Figure 1.1).

Figure 1.1 Basic schematic of cAMP compartmentalization and effectors.
cAMP (green) is produced by transmembrane (tmAC) or soluble (sAC) adenylyl cyclases.
Intracellular cAMP (icAMP) is downregulated by PDEs or efflux by ABC transporters to the
extracellular space (ecAMP). EPAC, exchange proteins activated by cAMP. PKA, protein kinase A. ROS,
reactive oxygen species.
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1.2.2 Overview of cAMP targets in acute leukemias
Considering that (a) icAMP regulation is altered in hematopoietic malignancies,
and (b) increased icAMP reduces blood cell survival, the cAMP pathway has long been
of interest as a target for leukemia therapeutics [39, 47, 53-55]. Many cAMPassociated proteins are dysregulated in acute leukemias. The primary tmAC
expressed in lymphoid cells is adenylyl cyclase 7 [56], and the expression of this
protein inversely correlates with AML survival [57]. PDE activity is 10-20-fold higher
in leukemia and lymphoma cells in comparison to normal blood cells [58]. It should
also be noted that glucocorticoids, which are used to treat B-ALL, have been shown to
downregulate PDE activity [59]. Of note, genomic studies on primary AML and adult
ALL samples have reported overexpression of CREB and/or its active,
phosphorylated form [60-65], and another study identified downregulation of ICER
(inducible cAMP early repressor), an antagonist of CREB [66]. In B-ALL samples, there
is an increased incidence of mutations in transcripts for CREBBP, the binding protein
for CREB. These CREBBP mutations were associated with dominant-negative or
deleted activity [67, 68]. In sum, acute leukemia cells are associated with both
increased pro-survival cAMP activity by having increased CREB signaling, as well as
downregulation of pro-apoptotic factors associated with the cAMP pathway.
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1.2.3 History of cAMP targeting in cancer (with a focus on hematological
malignancies)
Most previous attempts to modulate cAMP for cancer therapeutics have focused
on the use of cAMP analogs, or by targeting canonical proteins of the pathway
through: 1) stimulation of cAMP production by Gαs-coupled receptors, or 2)
inhibition of cAMP degradation by PDEs. These efforts have had modest success, and
will be summarized here.
Few cAMP modulating agents targeting cancer have been tested in clinical trials.
Despite demonstrating anticancer effects in vitro and in vivo, phase I clinical trials
with the analog 8-Cl-cAMP in patients with refractory solid tumors resulted in
hypocalcemia and toxicity to normal tissues [69-71]. A phase II clinical trial evaluated
the use of the PDE-inhibitor theophylline for CLL patients. Of the 25 CLL patients
treated with theophylline, only one achieved a complete response, and 18 patients
maintained a stable disease state [72].
Nonetheless, cAMP pathway modulation has been well investigated as a target in
hematopoietic malignancies in vitro and in vivo. Elevation of icAMP by the use of cAMP
analogs has demonstrated the ability to induce cell cycle arrest (G1 or G2 phase),
differentiation, and/or intrinsic apoptosis in leukemia, lymphoma, myeloma, and
normal B cells in vitro, most often through PKA-mediated mechanisms [2, 3, 10, 7377]. Similar results have been reported from studies where cAMP production was
stimulated via activation of tmAC [78-81]. PDE inhibitors have also been employed to
increase cAMP signaling in hematopoietic cells. Meyers, et al. provided evidence that
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PDE4 inhibition induced cell death in B-CLL cell lines, but not in normal B and T cells
[56]. This selectivity is plausible, since leukemia and lymphoma cells have exhibited
elevated PDE expression and activity [55, 58, 82]. Mitton, et al. used small molecule
CREB inhibitors to reduce the expression of pro-survival genes in AML cells in vitro
and in vivo, and they showed that this approach induced cell cycle arrest and
apoptosis. Nevertheless, it is important to note that elevated icAMP can also rescue
blood cancer cells from apoptosis, although those studies involved activation of cAMP
signaling after substantial DNA damage had occurred in the treated cells [83-88].
Consequently, there is still substantial evidence to support cAMP pathway targeting
in hematological malignancies.

1.3 Targeting cAMP transporters/efflux – an unexplored approach to
modulation of the cyclic nucleotide pathway
While the intracellular concentrations of cyclic nucleotides are canonically
regulated by degradation by PDE microdomains [52], efflux mechanisms by ABC
transporters are less explored. This class of proteins consists of 7 families (ABC-A
through ABC-G), in which two molecules of ATP are used to translocate substrates
into the extracellular space. As previously mentioned, cAMP and cGMP are
transported by members of the ABCC (MRP) family, ABCC4 (MRP4), ABCC5 (MRP5),
and ABCC11 (MRP8). These transporters are distributed variably throughout the
body, with ABCC4 having highest expression in the bladder, kidney, and prostate [89].
The affinity of these transporters varies for cAMP or cGMP. ABCC5 has a greater
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affinity for cGMP, whereas ABCC4 is preferential for cAMP [90]. ABCC4, ABCC5, and
ABCC11 regulate xenobiotic metabolism, and they can efflux antiviral drugs (PMEA,
ganciclovir) as well as chemotherapeutic agents (fluorouracil, mercaptopurine,
thioguanine, campothecins, methotrexate). Importantly, these proteins also serve a
role in the transport of natural, endogenous substrates. These include eicosanoids
(e.g., prostaglandins E1 and E2, leukotriene C4), estradiol-17β-glucuronide, folic acid,
bile acids (taurocholate, glycocholate), and some steroids (e.g., DHEAS) [91].
Furthermore, the cyclic nucleotide transporters also play a major role in relieving
oxidative stress, as they remove glutathione conjugates from the cell [92].
Past work in which cAMP efflux was inhibited by small molecules was performed
in epithelial cell lines, and primarily focused on cAMP concentration changes and the
activity of pathway-associated proteins [93, 94]. The efflux capacity of leukemia cells
has been reported as an important factor for predicting patient outcomes [95].
However, the analysis of cAMP-specific efflux activity has not been extensive. The
expression of ABCC4 is inversely correlated with hematopoietic cell differentiation
[96]. Previous studies relied on the use of indiscriminate ABC transporter inhibitors
(e.g., probenecid) or silencing RNA to block expression of cAMP effluxing proteins
[97-99]. These approaches, however, lacked the efficiency and breadth necessary for
resolving the utility of targeting cAMP efflux for cancer therapeutics. The recent
development of a high throughput-amenable assay to assess cAMP efflux activity
would allow for this trait to be measured quickly on a sample-by-sample basis
(Chapter 2) [100, 101].
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It should be underscored that competition between substrates can allow them to
inhibit one another. Hence, it is possible that some molecules identified as inhibitors
of a given transporter may instead reduce the efflux of other substrates, but not
actually block the activity of that transporter. Extensive mechanistic studies must be
conducted to validate the mechanism of action of efflux inhibitors on transporters. It
should be noted that all substrates of a transporter have the potential to inhibit the
transport other substrates of the same transporter. Therefore, molecules that affect
similar pathways could initially be identified as efflux inhibitors, but may in fact
potentially have mechanism(s) of action that are unrelated to antagonism of
transport proteins.

1.4 Summary and Discussion
The introduction to this work has highlighted the need for new treatment
regimens for acute leukemias. We have described the vital roles that cAMP signaling
plays in the regulation of cell proliferation, survival, and apoptosis. We provided
justification for targeting the cAMP pathway, since pathway-associated proteins are
dysregulated in these malignancies. We also introduced the concept that the
reduction of cyclic nucleotide efflux activity could potentially provide multiple
anticancer benefits. As such, we hypothesize that malignant cells produce and remove
excess icAMP to evade apoptosis and promote survival. Therefore, inhibition of cAMP
efflux should increase icAMP and selectively trigger leukemia cell death. We propose
that small molecule cAMP efflux inhibition, specifically by repurposed drugs, has the
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potential to expedite the translation of cAMP pathway-targeted therapeutics. Because
we propose that elevated cAMP efflux activity is an adaptation of malignant cells that
is not apparent in normal blood cells, drugs developed from this approach would be
selective for leukemia or other cancer cells as compared to normal blood cells or
tissue.
To test this hypothesis, we first designed and patented a novel assay to assess
icAMP efflux from cells, by measuring cellular retention of a fluorescent cAMP analog
(F-cAMP). We then adapted this assay for use in a high throughput flow cytometry
(HTFC) screen (Chapter 2) [100, 101]. After screening two collections of off-patent
FDA-approved drugs and biologically active compounds, we identified and validated
six compounds as inhibitors of cAMP efflux (ICE) (Chapters 2 and 3) [6, 100].
In Chapter 3, we describe work to support the main components of our
hypothesis. We determined that cAMP efflux mechanisms are relatively absent in
normal peripheral blood mononuclear cells (PBMCs), but are active in leukemia cell
lines. We also validated the ability of ICE to increase cAMP pathway activity. We
demonstrated that ICE induce apoptosis, and that this process requires functional
sAC. Furthermore, ICE reduced the viability of leukemia cell lines and ex vivo primary
patient samples at much lower concentrations than required for PBMCs, supporting
our hypothesis that cAMP efflux inhibition is a selective target for malignant cells. Our
data suggest that cAMP efflux targeting is independent of leukemia cell line genetic
rearrangement or mutation status.
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With that promising data, we developed and optimized approaches for testing
ICE in pre-clinical studies. We completed work with T-cell ALL (T-ALL) cells to
optimize HTFC approaches for determining chemotherapeutic effects on primary
sample viability ex vivo (Chapter 4). We therein determined that hypoxia was not a
significant factor for affecting most responses to tyrosine kinase inhibitors.
To facilitate the analysis of drug interactions and to determine potential drug
interactions, Chapter 5 introduces SynScreen software, an application that allows for
high throughput data from multiple experimental replicates to be compared
simultaneously. This software served as a basis for the development drug
combination studies.
Because chemotherapy resistance can occur by cAMP efflux transporters [102,
103], this dissertation also addresses the possibility of using ICE in combination with
current therapeutics to produce synergistic effects against leukemias (Chapter 6).
Synergism produced by these drug combinations would be beneficial for decreasing
leukemia cell burden, and potentially to reduce the likelihood of resistance, drugrelated toxicities, and/or relapse.
We complete this dissertation with a discussion of the role of one ICE compound,
clioquinol, and several disease states (Chapter 7). We propose that the occurrences
of subacute myelo-optic neuropathy (SMON) may be associated with single
nucleotide polymorphisms (SNPs) in cAMP efflux transporters. We also suggest that
the efficacy of clioquinol in Alzheimer’s disease [104] may be related to its effects on
the cAMP pathway.
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The summation of the proposed studies could provide support for a new class of
antileukemia drugs to be tested in clinical trials. The goal of the current project is to
establish a framework for testing the possibility of repurposing the identified
compounds as a potential future therapeutic option. The proposed work is significant
because it could substantiate inhibition of efflux as a paradigm shift in cAMP pathway
targeting for cancer therapeutics.

15

CHAPTER 2: A high throughput flow cytometry assay for
identification of inhibitors of 3’, 5’-cyclic adenosine
monophosphate efflux
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227-244, Humana Press, 2016.
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2.1 Summary
Assays to identify small molecule inhibitors of cell transporters have long been
used to develop potential therapies for reversing drug resistance in cancer cells. In
flow cytometry, these approaches rely on the use of fluorescent substrates of
transporters. Compounds which prevent the loss of cell fluorescence have typically
been pursued as inhibitors of specific transporters, but further drug development has
been largely unsuccessful. One possible reason for this low success rate could be a
substantial overlap in pump substrate specificities and functions between
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transporters of different families. Additionally, the fluorescent substrates are often
synthetic dyes that exhibit promiscuity among transporters as well.

Here, we

describe an assay in which a fluorescent analog of a natural metabolite, 3’,5’-cyclic
adenosine monophosphate (F-cAMP), is actively effluxed by malignant leukemia
cells,. The F-cAMP is loaded into the cell cytoplasm using a procedure based on the
osmotic lysis of pinocytic vesicles. The flow cytometric analysis of the fluorescence
retained in F-cAMP loaded cells incubated with various compounds can subsequently
identify inhibitors of cyclic AMP efflux (ICE).

2.2 Introduction
ATP-binding cassette (ABC) transporters are often associated with multidrug
resistance in relapsed cancers. ABC transporters are also implicated in the initiation
and progression of metastatic malignancies due to their increased expression in
cancer stem cells [105, 106]. As a result, the development of novel approaches to
study ABC transporter activity to identify small molecule modulators or inhibitors is
vital for translation to cancer therapy. Previously, high throughput assays for
transporter inhibition have relied upon the use of inside-out vesicles containing
specific transporters, or of cancer cell lines which have been induced or engineered
to acquire drug resistance [107-110]. In both cases, these approaches have been
largely dependent on measuring the intracellular fluorescence of synthetic substrates
remaining in cells after exposure to compounds. While several small molecules
identified in this manner were capable of reducing the multidrug resistance of cancer
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cells in vivo, few of these molecules have been successful in clinical trials [108, 111,
112]. This may be due in part to the limitations of these transporter efflux assays.
Often, synthetic fluorescent dyes known to be substrates of a particular
transporter are used as probes to screen for hit compounds. A major limitation of
this technique is the considerable similarity in cell transporter structures, and
therefore substrates are capable of being effluxed by a multitude of transporters
[113]. Thus, the inhibitory compounds identified in these assays fail to exhibit
specificity toward the originally investigated transporter.

Other attempts at

measuring efflux of cellular metabolites have used radioactive conjugates of
substrates to evaluate changes in intracellular concentrations. However, this results
in lower throughput data collection [97]. The approach described here differs from
earlier methods because it uses a fluorescent conjugate of a natural metabolite of cell
membrane transporters, 3’,5’-cyclic adenosine monophosphate (cAMP), and
measures its efflux from cells through unmodulated, endogenously expressed
transport proteins, allowing for thousands of samples to be measured in a short
period of time.
The cAMP signaling pathway has been a focus of cancer research due to its
relationship to multiple intracellular signaling components and, specifically,
programmed cell death, apoptosis. Existing evidence indicates aberrant cAMP
regulation in malignant cells in comparison to normal, healthy cells [47]. It has long
been known that the increased concentration of intracellular cAMP is capable of
triggering cell death in certain cancer cells [73]. Typically, such research has relied
18

upon modulation of the major cAMP-synthesizing enzymes adenylate cyclases (AC)
or phosphodiesterases (PDEs) that hydrolyze cAMP to increase cytosolic cAMP and
reduce cancer cell survival [47, 114]. Until recently, one additional step of the cAMP
signaling pathway that could be targeted for drug discovery has been overlooked:
cAMP efflux by ABC transporters.

The approach described here utilizes high

throughput flow cytometry for measurement of the efflux of a fluorescent cAMP
analog (F-cAMP, Figure 2.1) from leukemic cells. This assay assesses the intrinsic
ability of cells to efflux cAMP through their endogenously expressed transporters
rather than through analysis of the activity of specific protein targets. It thus allows
the measurement of the inherent efflux potential of a cancer cell,

Figure 2.1 Structure of the fluorescent cAMP analog (F-cAMP) used in this assay.
Alexa
Fluor®488
8-(6-aminohexyl)
aminoadenosine
3´,5´-cyclicmonophosphate,
bis(triethylammonium) salt.
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As a proof of this concept, we demonstrate the accumulation and release of FcAMP with flow cytometry (Figure 2.2). We present here the results of a high
throughput screen (HTS) for the identification of ICE from two libraries:

the

SPECTRUM Collection (2320 compounds – 60% drugs, 25% natural products, 15%
bioactive components) and the Prestwick Chemical Library (~1200 previously FDAapproved drugs). The acute myelogenic leukemia (AML) cell line U937 was screened
according to the methods described in this chapter, and the cells were incubated with
compounds overnight (~18 h; Figures 2.3 and 2.4). From this screen, 51 hits were
identified as having F-cAMP fluorescence ≥ 2 standard deviations above the plate
mean negative control values. (Figure 2.4). These hits were validated by testing the
compound F-cAMP efflux inhibition in 8-point dose responses ranging from 60 µM to
9 nM (Figure 2.5A). For this validation, the F-cAMP mean or median fluorescence
intensity (MFI) values were normalized based on F-cAMP fluorescence at time = 0.
The dose-response curves were fit with sigmoidal curves, and those compounds
which exhibited EC50 values < 30 µM and had well-behaved sigmoidal dose response
curves were selected for further validation (Figure 2.5B). This yielded 8 compounds
of interest (artemisinin, parthenolide, patulin, quinalizarin, harmalol, pyrithione zinc,
clioquinol, and cryptotanshinone).

Bioinformatics analysis of the compound

structures allowed for the identification of 3 additional related small molecules:
artesunate, artemether, and dihydroartemisnin. The 11 compounds of interest were
tested in dose response in flow cytometric apoptosis and cell cycle secondary assays
to measure the effects of ICE on U937 cell vitality after overnight incubation (Figure
20

2.6). Additional CellTiter-Glo® viability measurements found that 6 of the hit
compounds

(artesunate,

dihydroartemisinin,

clioquinol,

cryptotanshinone,

parthenolide, and patulin) were selectively inhibitory to leukemia cells at EC50
concentrations much lower than those determined for healthy human primary blood
mononuclear cells (PBMCs; data not shown).

Subsequent testing of the hit

compounds to determine mechanisms of action confirmed that the molecules work
by modulation of the cAMP pathway and induce programmed cell death. Thus, the
utility of the F-cAMP efflux assay approach to identify ICE for leukemia therapeutics
has been validated.
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Figure 2.2 Cell line MK571 optimization and determination of cell F-cAMP efflux ability.
A) Example of MK571 optimization assay results. Data shown were obtained using the acute myeloid
leukemia (AML) cell line U937 loaded with F-cAMP and incubated overnight (~ 16 h) in appropriate
concentrations of positive control MK571. Data was fit with a sigmoidal dose response formula, and
constrained with top = 100 and bottom = 0 to determine the EC50 of inhibition by MK571.
B) Determination of ability of AML cell line MV411 to efflux F-cAMP. Data shown are raw FL-1 MFI
values collected from control and treated samples. C) Normalized data for the assay data shown in
(B). Cell line autofluorescence was subtracted from sample MFI’s and normalized such that F-cAMP
MFI at time 0 = 100%. This data indicates that MV411 cells lose ~8.5% of F-cAMP through passive
leakage (4°C) and ~45% by active efflux (37°C). The positive control with MK571 limited F-cAMP
loss to 13%. Error bars in (B) and (C) indicate the data mean ± standard error of the mean (SEM)
from three independent experiments.
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Figure 2.3 Sample configuration for a 384-well compound mother plate, as described in Note
15.
Solubilized reagents are added to the plate at a minimum volume of 6 µL. Test compounds may be
used in a single-point or dose response manner. This plate incorporates both negative (compound
solvent) and positive (MK-571) controls so that normalized ability to efflux F-cAMP and Z’ values can
be determined for each plate. If reagent availability is limited, fewer wells per plate may be used for
positive controls.

Figure 2.4 Sample data from a 384-well F-cAMP efflux assay plate collected as in step 3.3.9.
Data were analyzed with HyperView software (IntelliCyt, Albuquerque, NM, USA) and time-gated to
define data from each well. A) FSC vs SSC plot with gate around untreated (“live”) cells. B) FL1-H
histogram. C) Time vs FL1-H plot from one 384-well plate. D) A magnified row from the time vs FL1H plot in (C), indicating controls and the potential hit compound clioquinol.
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Figure 2.3 Sample data from hit compound dose-response validation.
A) Magnified time vs FL1-H plot for an F-cAMP efflux 8-point dose response for the hit compound of
interest, clioquinol, including negative and positive controls. B) Graph of normalized response for the
data shown in (A). Sample FL1-H MFI were normalized such that F-cAMP fluorescence at the time of
compound addition = 100%. Data were fit by sigmoidal curves with Hill slope = 1 and top < 250. Graph,
fit, and EC50 determination were done with GraphPad Prism 5.01 software (GraphPad Software, Inc.,
La Jolla, CA, USA).

23

Figure 2.4 Results of ICE hit compounds after overnight incubation on U937 leukemia cell
vitality in flow cytometric secondary assays.
A) Dose-dependent effects of the identified ICE on apoptosis. Bars indicate the percentages of cell
populations which stained double-positive with Annexin V-PE and 7-AAD, indicating that late
apoptotic events had occurred. B) Effects of ICE on U937 cell cycle. The bars indicate the percentages
of the cell population in each phase of the cell cycle, as determined by propidium iodide (PI) DNA
staining. The gating was done on PI histograms as follows: G1/G0: DNA = 2n, S: 2n < DNA < 4n, G2/M:
DNA = 4n, Apoptosis (A): DNA < 2n. Error bars in both graphs indicate the data mean ± SEM from
three independent experiments.
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2.3 Materials
All solutions should be prepared following proper aseptic techniques. Dispose of
waste materials according to appropriate regulations. All fluid component handling
and storage is done in polypropylene tubes: 1.7 mL microcentrifuge, 15 mL conical,
50 mL conical. Cells are grown and incubated in a humidified 37°C, 5% CO2 incubator
unless otherwise specified.
2.3.1 Components for Fluorescent Cyclic AMP Loading
1. 50 mL NF-RPMI: RPMI-1640, 5 mg/L phenol red, 2 mM L-glutamine, 100
units/mL penicillin, 100 μg/mL streptomycin, 10 mM HEPES. No fetal bovine
serum (FBS).
2. 50 mL cRPMI: RPMI-1640, phenol red, 2 mM L-glutamine, 100 units/mL
penicillin, 100 μg/mL streptomycin, 10 mM HEPES, and 10% heat-inactivated
fetal bovine serum (FBS; see Note 1).
3. Fluorescent cAMP analog (F-cAMP), Alexa Fluor®488 8-(6-aminohexyl)
aminoadenosine 3´,5´-cyclicmonophosphate, bis(triethylammonium) salt (see
Figure 2.1 and Note 2).
4. Hypertonic solution: 10% w/v polyethylene glycol (PEG), 500 mM sucrose in
NF-RPMI. 0.1 g poly(ethylene glycol) (PEG) 1,000, 0.17 g sucrose, 0.9 mL NFRPMI. In a 15 mL conical tube, add 0.9 mL NF-RPMI, then weigh and add 0.1 g
PEG and mix thoroughly by vortexing (see Note 3).
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5. In a sterile tissue culture hood, push the solution through a 3-10 mL syringe
fitted with a 0.2 µm nylon membrane filter (Pall Corporation) and transfer into
a sterile 1.7 mL microcentrifuge tube.
6. Hypotonic solution: 40% purified, deionized water, 60% cRPMI. Add 1 mL
sterile water to 1.5 mL cRPMI in microcentrifuge tube. Mix by light vortexing.
Filter-sterilize as in step 2.1.5.
7. Cells known to efflux cAMP, 1-2x107 in a 50 mL conical polypropylene tube
(see Note 4).
8. 1.7 mL microcentrifuge tube.
9. Centrifuge(s) with capacity for 50 mL conical and 1.7 mL microcentrifuge
tubes.
10. T-75 tissue culture flask for F-cAMP loaded cell equilibration.
2.3.2 cAMP Efflux Assay Components
1. 1 mL untreated cells (no F-cAMP loaded) at ≥ 4x105/mL for autofluorescence
testing.
2. F-cAMP loaded cells from step 2.1.
3. Sterile 12-well cell culture plate with lid (or other means of covering for
incubation).
4. 20 mL cRPMI.
5. ≥ 60 µL 30 mM MK571 positive control, solubilized in dimethyl sulfoxide
(DMSO).
6. ≥ 80 µL DMSO
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7. Flow cytometer with 488 nm laser, 530/30 bandpass optical filter, and
multiwell plate auto-sampling capabilities.
8. 15 sample tubes for flow cytometer.

2.3.3 High Throughput Screening Components
1. 1 mL untreated cells (no F-cAMP loaded) at ≥ 4x105/mL for autofluorescence
testing.
2. F-cAMP loaded cells from step 2.1.
3. Multiwell plates, preferably 384-well, for compound mother plates and the
high throughput F-cAMP efflux assay (see Note 5).
4. Compound mother plates: 384 well plates which contain positive and negative
controls, as well as compounds of interest to be tested in the high throughput
F-cAMP efflux assay.
5. ≥ 110 µL 10 mM MK571 positive control per compound mother plate.
6. ≥ 225 µL DMSO negative control per compound mother plate.
7. Proper seals (e.g., DMSO resistant adhesive foil microplate seals) and storage
equipment, such as dessicators and/or -20°C freezer, for the compound
mother plates (see Note 6).
8. Liquid dispensing equipment: this can either be an automated system or
multichannel pipettors capable of delivering 5 µL volumes to wells in 384-well
plates (see Note 7).
9. 100 nL pintool or analogous compound transfer equipment (see Note 8).
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10. 384-well plate lids or seals for the assay plates (see Note 9).
11. Multiwell plate vortexer.
12. Flow cytometer with 488 nm laser, 530/30 bandpass optical filter, and
multiwell plate auto-sampling capabilities.
13. Software which can resolve data from individual wells after high throughput
flow cytometry analysis.

2.4 Methods
2.4.1 Loading F-cAMP into cells
1. Centrifuge cells at 160 x gmax for 10 min and remove supernatant.
2. Wash/remove serum from cell medium: Resuspend cells in 1 mL NF-RPMI
with slow pipetting, add an additional 19 mL NF-RPMI, gently mix, and
centrifuge for 10 min. Discard supernatant.
3. While cells are centrifuging, prepare the F-cAMP loading solution. In a
microcentrifuge tube, add 200 µL hypertonic solution and 10 µL of 5 mM FcAMP (250 µM final).
4. Again resuspend the cells in 1 mL NF-RPMI with slow pipetting and transfer
to 1.7 mL microcentrifuge tube.
5. Centrifuge the cells at ~120 x gmax for 2 min and remove the supernatant.
6. Gently resuspend the cells in the 210 µL of F-cAMP loading solution (see step
3.1.3 above).
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7. Incubate the cells with F-cAMP loading solution at room temperature for 10
min, with gentle mixing by hand or 1-2 sec at ~1,600 rpm every 3 min during
this incubation (see Note 10).
8. Centrifuge the cells ~120 x gmax for 2 min, remove the supernatant, and
resuspend the cells in 1 mL of hypotonic solution.
9. Incubate the cells in hypotonic solution for 2 min at room temperature, with
gentle mixing at 1 min.
10. Centrifuge the cells ~120 x gmax for 2 min, remove the supernatant, and gently
resuspend the cells in 1 mL of cRPMI.
11. Transfer the 1 mL of resuspended cells to a T-75 tissue culture flask containing
24 mL cRPMI and gently mix. If 107 cells were used for the F-cAMP loading,
then this gives a final concentration of 4x105 cells/mL.
12. Place the T-75 flask in the incubator to allow the F-cAMP loaded cells to
recover for 30-120 min (see Note 11).

2.4.2 Optimization of F-cAMP efflux positive control and determining cell F-cAMP
efflux ability
This protocol will allow for optimization of the F-cAMP efflux assay and
conditions. This step should be performed before the high throughput F-cAMP efflux
assay is attempted. Once the positive control and incubation time(s) are determined
for a particular cell line, this step may be skipped.
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1. Add 500 µL cRPMI to each well of a 12-well tissue culture plate, then add 500
µL of F-cAMP loaded cells to all wells and mix by gentle pipetting (final
concentration = 2x105 cells/mL. Save two 1 mL samples of F-cAMP loaded
cells for control purposes, to be used in steps 3.2.5 through 3.2.8.
2. Add DMSO and 30 mM MK571 to the wells (Table 1) for n = 2 for each
concentration tested and mix by gentle pipetting (see Notes 12-13). Do not
exceed a final concentration of 1% DMSO per sample, as this can be toxic to
cells.
3. Incubate the lidded tissue culture plate overnight (16-24 h) under normal cell
culture conditions (see Note 14).
4. Run control samples immediately after the plate is placed in the incubator, to
collect fluorescence data to be used for normalization of the treated samples.

Table 2.1 Volumes of MK571 and DMSO added to each well.
Each well contains 1 mL and F-cAMP loaded cells to give final DMSO concentration = 1%.

Final conc. MK571 (µM)

30 mM MK571 (µL)

DMSO added (µL)

0

--

10.0

10

1.0

9.0

25

2.5

7.5

50

5.0

5.0

75

7.5

2.5

100

10.0

--
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5. Run untreated, non-F-cAMP loaded cells on the flow cytometer, using the 488
nm laser for excitation and collecting fluorescence data with a 530/30
bandpass optical filter. Collect ≥ 3,000 events. Create an FSC vs SSC density
plot and set a “live cell” gate on the major population of the cells. Then, create
an FL-1 channel histogram based on the live cell gate. Data from this untreated
sample will provide the baseline/ autofluorescence of the cell line.
6. Run a 1 mL sample of the F-cAMP loaded cells through the flow cytometer with
the same settings and parameters detailed in step 3.2.5 above. Ensure that
the FL-1 channel histogram does not go off scale; adjust settings so that the
entirety of the histogram is visible (see Note 15). This sample will serve as the
“100% F-cAMP fluorescence” control for time = 0 of the assay.
7. Place the remaining 1 mL sample of F-cAMP loaded cells at 4°C for the duration
of the MK571 optimization plate incubation time.
8. After incubation, run the 4°C-incubated F-cAMP loaded cell sample in the flow
cytometer under the same settings used in step 3.2.5. This will provide a
measurement for the F-cAMP “passive efflux” ability of the cell line (see Note
16).
9. Gently mix the contents of each well in the MK571 optimization plate by
pipetting, collect individual samples, and interrogate with the flow cytometer
(see Note 17). Set a gated event count limit for each sample of ≥ 1,000 events.
10. To process the F-cAMP efflux data, use MFI values from data collected in steps
3.2.5 through 3.2.8.
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11. Subtract the autofluorescence MFI value (step 3.2.5) from the MFIs of all of
the F-cAMP loaded samples, including the F-cAMP fluorescence control
collected at time = 0 (step 3.2.6).
12. Divide the MFIs from each sample by the MFI collected from the 100% F-cAMP
fluorescence/ time = 0 control (step 3.2.6). This will indicate the percentage
of F-cAMP remaining within the cells under each condition.
13. Fit the MK571 dose response data with a variable slope sigmoidal dose
response equation constrained with “bottom” equal to 0 and “top” equal to 100
(fluorescence at initial staining). This will determine the EC50 of MK571 for
cAMP efflux inhibition. Example data from an overnight MK571 optimization
assay with U937 cells is shown in Figure 2.2A.
14. Once an optimal MK571 concentration is determined for a particular cell type,
the assay described here may be used to determine the efflux ability of F-cAMP
loaded samples at other iterations or incubation times. Example data from an
assay to determine the MV411 leukemia cell line cAMP efflux ability is shown
in Figure 2.2B. The MV411 F-cAMP efflux assay data normalized according to
steps 3.2.11 and 3.2.12 is shown in Figure 2.2C.

2.4.3 High throughput F-cAMP efflux assay
The following protocol is designed for a 384-well high throughput assay (see
Note 18). For information on modifications which may be done to conduct the assay
in 96-well plates, see Note 19. If no adjustments were made to the protocol
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completed in Method 3.1 (25 mL F-cAMP loaded cells at 4x105 cells/mL), then this
protocol will allow for the creation of 10, 384-well assay plates.
1. Create a compound mother plate with solubilized compounds at 100x final
assay concentration. Dedicate wells for negative control (compound solvent)
and positive control (MK571; see Notes 20-21 and Fig. 3 for example plate
map). Alternatively, an acoustic dispenser may be used to deliver compounds
directly to assay plates in step 3.3.3, and if so, the creation of separate
compound mother plates is not necessary.
2. Dispense 5 µL cRPMI to all wells of the 384-well assay plates with a liquid
handler or multichannel pipettor.
3. With a 384-well pintool (or other similar liquid transfer equipment), transfer
100 nL from the compound mother plates to the assay plates (see Note 8).
4. Dispense 5 µL F-cAMP loaded cells to the negative and positive control, and
compound-treated wells in the assay plates (see Note 21). If the added cells
were originally at a density of 4x105/mL, then this provides a final cell density
of 2x105/mL, or 2000 cells/ 10 µL final volume well. Save two, 1 mL aliquots
of excess F-cAMP loaded cells for flow cytometer optimization and
fluorescence testing.
5. Seal the assay plates and store upside down in the incubator for desired
incubation time (see Note 9).
6. Conduct cytometer optimization and fluorescence testing according to steps
3.2.5 through 3.2.7.
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7. After assay plate incubation, run the 4°C-incubated F-cAMP loaded cell
“passive efflux” sample as in step 3.2.8.
8. Vortex (2000 rpm) each F-cAMP efflux assay plate 15s before running samples
through the high throughput flow cytometer (see Note 22). Add an FL-1 vs
time density plot to the cytometer collection parameters to allow for well data
separation during analysis.
9. Use high throughput flow cytometry analysis software to identify cells and FL1 MFI from individual wells (see Fig. 4 for example data).
10. To analyze well/compound data, exclude samples with < 50 events. Normalize
data according to steps 3.2.11 and 3.2.12 (see Note 23). Calculate the Z’
values for each plate for quality control purposes. Assay plates which indicate
a Z’ factor of ≥ 0.3 should be considered acceptable [115]. Hit compounds may
be determined per the user’s preference. We identified hits as samples with
MFI values ≥ 2 standard deviations above the plate mean negative control
values.
11. To further validate sample data and decrease the number of false-positive hits,
compounds were assayed in a high-throughput dose response assay. Plates
were set up as in the HTS, with the exception that the plate formats contained
10-well dose responses for each hit compound, at final concentrations ranging
from 30 µM to 4 nM.
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2.5 Notes
1. If the cells used in this assay are typically cultured in another medium, please
substitute that medium for all instances of cRPMI in this protocol.
2. Other fluorescently-conjugated cAMP may be utilized, but fluorophores
conjugated to cAMP at sites which do not mimic the molecule shown in Figure
2.1 have not been tested nor validated for this assay.
3. Dissolving PEG 1000 in NF-RPMI may be somewhat difficult. Continue
vortexing and tilting tube back and forth. If the PEG still does not readily enter
solution, wait a few hours or overnight for the flakes to dissolve. Otherwise,
placing the tube in a 37°C water bath for 5-15 min may help.
4. We have tested F-cAMP loading in leukemia cell lines, at numbers up to 18x106
under the conditions described in this method. For adherent or other cell
types, it would be best to optimize the assay starting at cells and gradually
testing other cell counts and F-cAMP concentrations to suit your needs. If the
assay volumes and/or cell densities that you require are higher than those
described in this protocol, adjust the component volumes and cell numbers
loaded with F-cAMP accordingly (see Note 19).
5. You will need at least 10, 384-well plates for the cAMP assay, and a number of
plates to create compound mother plates. The high-throughput F-cAMP efflux
assay protocol described here is for a small assay volume (10 µL). It would be
best to have small volume flat-welled plates or conical wells for these assay
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plates. In our experience, this assay has worked with both polystyrene and
polypropylene multiwell plates.
The compound mother plates need to have the same well format as the
assay plates (e.g., 384 wells). The compound mother plates should have well
structures optimized for the transfer of small volumes of reagents. We found
that wells with conical bottoms were optimal for our 100 nL compound
transfers by pintool.
6. The compound mother plates may be saved and reused if stored properly. The
plates should be foil-sealed, preferably after being flushed with nitrogen gas
to remove excess oxygen and moisture from the wells. The plates can be
stored at -20°C (typically best for long-term compound storage, avoiding
several freeze-thaws) or in a climate-controlled, low humidity, high nitrogen
desiccator. Plates stored in a desiccator may be stable for up to 3 months,
depending on the properties of individual compounds.
7. Take note of the “dead volume” specifications of your liquid dispensing
equipment. When following the described protocol, ensure that the volumes
of the reagents used are adjusted to meet these minimum requirements before
beginning the high throughput F-cAMP efflux assay.
8. The wells in this assay will have a final volume of 10 µL F-cAMP loaded cells in
culture medium. A compound delivery of 100 nL will ensure that the DMSO
concentration remain below 1%.

If a 100 nL pintool or equivalent is

unavailable, then intermediate compound dilution plates will need to be
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prepared to allow for 1 µL volumes to be transferred to assay wells while
maintaining DMSO at ≤ 1%.
To prepare intermediate compound dilution plates, stock from the
compound mother plates is diluted 1:10 in culture medium.

This is

accomplished in additional 384-well plates, by combining 9 µL of culture
medium with 1 µL of the well contents from the compound mother plates. Mix
well contents thoroughly by pipetting or plate vortexer before making 1 µL
transfers from the intermediate compound dilution plates into the assay plates
(step 3.3.3).
9. Depending on the optimal culturing conditions for the cell line tested, the
assay plates may be incubated with fitted lids or sealed with gas-permeable,
solid polymer, or foil seals. Take into consideration that the assay plates will
contain small volumes (10.1 µL final), and incubation with lids or gaspermeable seals may result in some evaporation of well volumes, especially
on the edges of the assay plates. We found that leukemia cell line responses to
the F-cAMP efflux assay were best when non-permeable seals were used on
the assay plates. Gas permeable plate covers seemed to decrease cell viability,
as evidenced in population shifts on flow cytometer FSC vs SSC density plots
when plates were analyzed after incubation.
10. We have not tested the sensitivity of F-cAMP loaded cells incubated and
equilibrated in full-light conditions. It is best to incubate the cells in the dark
to minimize the potential for ambient light to reduce treated cell MFI’s.
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11. It is possible for the cells to be used in the efflux assay immediately, but
because the plasma membranes have been subjected to stress from the
osmotic lysis of pinocytic vesicles in the F-cAMP loading procedure, it would
be beneficial to allow the membrane integrity to be regained before
proceeding. This step allows the cells to recuperate before testing with
compounds. Different cell lines will recover at different rates. Check the cells
with a light microscope to determine whether the cells appear healthy and
rounded before advancing to the efflux assay.
12. MK571 is a known inhibitor of ABC C-family transporters (also known as
multidrug resistance proteins), and it is often used as a positive control for
cAMP efflux. The concentrations tested here are used to generate a dose
response curve to determine the EC50 of MK571 cAMP efflux inhibition.
Alternative concentrations may also be tested.

With U937 cells, we

determined an MK571 EC50 of ~40 µM, and used a final concentration of 100
µM in our HTS assays to ensure effective cAMP efflux inhibition (Fig. 2A).
13. Because this optimization step does not require many F-cAMP loaded cells,
multiple plates, MK571 concentrations, and incubation times may be tested as
well.
14. The MK571 optimization incubation should be for the anticipated amount of
time in which the HTS assay will be completed. We have conducted this assay
at varying times from 16-48 h. Please note, however, that cells which do not
actively efflux cAMP well, or too short an incubation time may not produce
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data with any significant effects or dose-dependent efflux inhibition by
MK571. Incubation times which are too long (~48 h) could lead to increased
levels of apoptosis, depending on the sensitivity to the cells to high
concentrations of MK571.
15. If the FL-1 channel cytometer settings had to be adjusted in this step, run the
untreated, non-loaded cells (step 3.2.5) again to ensure proper assessment of
the cell line autofluorescence for the assay readings.
16. For some cell lines, incubation at 4°C can cause apoptosis, and this is evident
in shifting of the population on the FSC vs SSC plot. Only use data from events
which fall within the “live cell” gate created with the untreated/
autofluorescence cells.
17. All or partial aliquots of the wells may be collected during this step. If only a
few hundred microliters of each well are sampled, this allows for the
remainder of the plate to continue to be incubated, allowing for aliquots to be
collected at multiple time points.
18. All plate setup and compound handling for HTS can be done in ambient
conditions outside of a tissue culture hood.
19. Considerations for completing the high throughput F-cAMP efflux assay in 96well plates: a) The compound mother plates and assay plates should have the
same well configurations, to ease compound transfer. b) Assays conducted in
96-well plates typically require higher minimum volumes per well for samples
to be collected by high throughput flow cytometry. These minimum volumes
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are contingent on the geometry of the plate wells, of course, but it can be
expected that the wells would require ≥ 50 µL final volumes. c) While the
volume per well can vary from the 10 µL final volume described in this
protocol, it is ideal to maintain final well concentrations of ≤ 1% DMSO and
2x105 cells/mL.
20. In this step, any number of compound mother plates may be created for use
with the 10 assay plates. Therefore, individual compound mother plates may
be used multiple times to increase the sample size tested per compound, or
each assay plate may be tested with different compound mother plates. For
our tests to identify “inhibitors of cAMP efflux”, our compound mother plates
consisted of 6 µL final volume per well. There were 10 mM DMSO-solubilized
compounds in all wells in columns 3-22, the negative control was in columns
1-2, and the positive control was in column 23 of the 384-well plate (Fig. 3).
Alternatively, if compounds of interest are already known, the compound
mother plate can be made to test the compounds in dose response, with
negative controls in columns 1 and 13, and dose series in columns 2-10 and
12-22. The MK571 positive control can be incorporated into the plate as a
dose response series, or as few wells in column 23 at a static concentration.
21. For example, if the compound mother plates were set up as shown in Fig. 3, FcAMP loaded cells would be added to all wells in columns 1-23 of the assay
plates. Because column 24 would not have any compound or cells added, these
wells would serve as “wash” wells.
40

22. In our assay, we used flow cytometers configured with HyperCyt®
autosampling systems (IntelliCyt), with peristaltic pump speeds at 15 rpm,
and aspiration for 1 sec/well (up times between wells could be set from 300500 ms). This allowed for approximately 2 µL (~400 cells) to be sampled from
each well.
23. In some instances, the positive and negative controls data may indicate a
gradient of MFI values dependent on well position on the plate. In such cases,
it would help to normalize F-cAMP efflux for the samples on a per-row basis
(e.g., using only the positive and negative control MFI values from Row H to
normalize the Row H sample MFIs).
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3.1 Abstract
Apoptotic evasion is a hallmark of cancer. We propose that some cancers may
evade cell death by regulating 3’-5’-cyclic adenosine monophosphate (cAMP), which
is associated with pro-apoptotic signaling. We hypothesize that leukemic cells
possess mechanisms that efflux cAMP from the cytoplasm, thus protecting them from
apoptosis. Accordingly, cAMP efflux inhibition should result in: cAMP accumulation,
activation of cAMP-dependent downstream signaling, viability loss, and apoptosis.
We developed a novel assay to assess cAMP efflux and performed screens to identify
inhibitors. In an acute myeloid leukemia (AML) model, several identified compounds
42

reduced cAMP efflux, appropriately modulated pathways that are responsive to cAMP
elevation

(cAMP-responsive

element-binding

protein

phosphorylation,

and

deactivation of Very Late Antigen-4 integrin), and induced mitochondrial
depolarization and caspase activation. Blocking adenylyl cyclase activity was
sufficient to reduce effects of the most potent compounds. These compounds also
decreased cAMP efflux and viability of B-lineage acute lymphoblastic leukemia (BALL) cell lines and primary patient samples, but not of normal primary peripheral
blood mononuclear cells. Our data suggest that cAMP efflux is a functional feature that
could be therapeutically targeted in leukemia. Furthermore, because some of the
identified drugs are currently used for treating other illnesses, this work creates an
opportunity for repurposing.

3.2 Introduction
Apoptosis serves as a natural barrier to cancer development, and targeting this
cancer hallmark represents an indispensable therapeutic strategy [116]. Apoptosis
can be induced via two major pathways, extrinsic and intrinsic, and in acute
myelogenic leukemia (AML) the latter can be directly triggered by elevation of cAMP,
which acts synergistically with first-line antileukemic agents [2]. This creates a
unique situation, where an additional targetable pathway, previously unexploited by
traditional chemotherapeutics, may exist in AML cells [2].
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The effect of intracellular cAMP (icAMP) elevation is tissue/cell specific. In
certain tumors, including pituitary, adrenocortical and thyroid adenomas and
carcinomas, the cAMP/ protein kinase A (PKA) pathway provides signals required for
tumor development and/or cell survival. In leukemias/lymphomas, cAMP elevation
can be pro-apoptotic, whereas in leukocytes/macrophages it is reported to be antiapoptotic (see Tables 1 and 2 in ref. [39] and [83]). Additionally, cAMP can have both
pro- and anti-apoptotic activity within the same cell depending upon experimental
conditions. icAMP compartmentalization may also contribute to the complexity of
signaling [117]. Nonetheless, a significant body of literature suggests that modulating
the cAMP pathway provides a number of promising targets for treating leukemia [53].
AML (IPC-81) and multiple myeloma cells undergo rapid apoptosis after cAMP
elevation [4, 118]. In S49 T-cell lymphoma cells, apoptosis can be induced through a
cAMP/PKA-dependent pathway [3]. Increasing icAMP by using cAMP analogues [73],
adenylyl cyclase (AC) stimulators [119], or phosphodiesterase (PDE) inhibitors [56,
120] has been a focus of cancer therapeutics research [39, 114]. This approach has
been supported by the fact that the concentration of cyclic nucleotides is elevated in
the plasma and urine of individuals with certain leukemias [121, 122], and in some
cases these levels correlate with disease progression [122]. In this report, we
hypothesize that one mechanism for malignant cell apoptotic evasion could be active
efflux of cAMP [114]. Rather than relying on PDEs to degrade icAMP, active cAMP
removal from the cytoplasm can provide a survival advantage. We envision that cAMP
efflux prevents an elevation of icAMP that could trigger up-regulation of the Bcl-2
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interacting mediator of cell death (Bim/BCL2L11) protein [2, 77], or down-regulation
of the myeloid cell leukemia 1 (Mcl-1) protein [4, 10]. Inhibition of cAMP efflux alone
should be sufficient to selectively trigger death in cells that rely on this anti-apoptotic
mechanism for survival. To test this idea, we decided to identify drug-like compounds
that are capable of blocking cAMP efflux.
To identify “inhibitors of cAMP efflux” (ICE), we developed and validated a novel
assay for the detection of cAMP efflux (in press), using a well characterized model for
AML known to efflux cAMP through ABCC4, the multidrug resistance-associated
protein-4 (MRP4) transporter [97].

Next, we screened libraries composed of

biologically active substances and off-patent drugs. We validated the “hits” in
secondary assays that assessed the compound effects on cell signaling, viability and
apoptosis. The ICE were also tested for their effects on cAMP efflux inhibition and
viability in B-lineage acute lymphoblastic leukemia (B-ALL) cells, primary B-ALL
bone marrow patient samples, and healthy human primary blood mononuclear cells
(PBMCs). The most promising compounds showed dose-dependent, selective
inhibition of leukemic cells vs. PBMCs. Our hypothesis was further supported by
measurements of cAMP-dependent activation of downstream effectors after
exposure to ICE compounds. Because several identified ICE are FDA-approved drugs,
our studies provide a potential path for drug repurposing against leukemias.
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3.3 Results
3.3.1 A screen for ICE identifies six potentially active compounds
To identify ICE, we took advantage of a model system where cAMP efflux is well
studied: U937 cells, which can actively extrude cAMP into extracellular media [97]. In
these cells, a rapid increase of cAMP efflux can be triggered through the elevation of
the icAMP concentration using G-alphaS GPCR-specific ligands, blocking PDEdependent cAMP hydrolysis, and by other pharmacological manipulations. The cAMP
efflux is ATP- and MRP inhibitor-dependent, and shRNA knockdown has shown that
the cAMP efflux is mediated by MRP4/ABCC4. Moreover, an increase of icAMP was
sufficient to induce differentiation of U937 and other AML cell lines [97].
To study cAMP efflux, we loaded U937 cells with fluorescently tagged cAMP (FcAMP). MK-571, (MRPs selective inhibitor) [97], was used as a positive control.
Figure 3.1 shows that MK-571 down-modulated cAMP efflux in a dose-dependent
manner, with EC50 ~30 µM. This value was very close to the IC50 previously reported
for MRP4/ABCC4 [123]. Thus, the fluorescent tag (Alexa Fluor®488) did not
significantly affect the ability of cells to efflux cAMP nor of MK-571 to block this
process.
These experiments served as the basis for a screen to identify compounds that
could block cAMP efflux. F-cAMP-loaded U937 cells were screened against
compounds from the Prestwick Chemical Library (~1200 previously FDA-approved
drugs) and the SPECTRUM Collection (2320 compounds – 60% drugs, 25% natural
products, 15% bioactive components). The screen identified 51 hits, which were
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tested in dose-response to validate their activities (data not shown), yielding seven
potentially active ICE compounds: artemisinin, clioquinol, quinalizarin, harmalol,
cryptotanshinone, parthenolide, and patulin. Three additional structurally-related
compounds (dihydroartemisinin, artemether, artesunate) were also included for
evaluation in secondary assays. Based on further validation, only artesunate,
clioquinol, cryptotanshinone, dihydroartemisinin, patulin, and parthenolide were
chosen for extended studies (Table 3.1). The detailed screening data will be
published elsewhere [124].

Figure 3.1 Effect of MK-571 (MRPs selective inhibitor) on efflux of a fluorescently tagged
cAMP (F-cAMP).
A) Structure of the fluorescent cAMP analog. B) U937 cells loaded with F-cAMP were incubated
overnight in the presence of increasing concentrations of MK-571 at 37°C. The EC50 for cAMP efflux
blocking was determined using a variable slope sigmoidal dose response equation with “bottom”
constraint equal to cell autofluorescence and “top” constraint equal to the specific fluorescence. A
representative experiment of three experiments is shown.
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Table 3.1 Hit compounds identified in the screen for inhibition of cAMP efflux.
Hit compound
Structure
Notes
Artesunate
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Dihydroartemisinin
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H
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O

Clioquinol
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H

OH

OH
I

N

Cl

O

Cryptotanshinone
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O

Parthenolide
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Patulin

O

O

OH
O

O

O

In 2007, FDA approved investigational new drug
protocol #76,725 entitled “Intravenous
Artesunate for Treatment of Severe Malaria in
the United States”.
Artesunate is hydrolysed to its active metabolite
dihydroartemisinin. Along with artemisinin
currently used as antimalarial drugs in Asia.
Clioquinol (Iodochlorhydroxyquin) is the FDA
approved antifungal and antiprotozoal drug. A
phase I trial for clioquinol in patients with
hematologic malignancies has been reported
[125].
A major tanshinone isolated from Salvia
miltiorrhiza. It was shown to inhibit cancer cell
proliferation [126].
A sesquiterpene lactone from Tanacetum
parthenium. An orally bioavailable parthenolide
analog selectively eradicates acute myelogenous
leukemia stem and progenitor cells [127].
A mycotoxin produced from Penicillium and
Aspergillus. Patulin-induced apoptosis in human
leukemia cells is mediated through the
mitochondrial pathway [128].
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3.3.2 Correlation between ICE ability to block F-cAMP efflux and viability loss
Next, we compared ICE efficacy for blocking F-cAMP efflux with their ability to
trigger loss of cell viability (Figure 3.2). A strong positive correlation (r2=0.73) has
been observed. The values for all six ICE compounds and MK-571 control ranked in
the same order and were located within 95% confidence interval. Moreover, the slope
of the regression line was equal to 1. This suggests that the relative potency of ICE in
affecting cell viability varies in parallel with the ability to block F-cAMP efflux.

Figure 3.2 Relationship between ICE ability to block F-cAMP efflux and loss of cell viability.
U937 cell were incubated overnight in the presence of increasing concentrations of ICE and MK-571
and cell viability was determined as described in Materials and Methods. Next, the data were fitted
to a sigmoidal dose response equation and the EC50 values for cell viability loss were plotted vs. EC25
determined for F-AMP efflux inhibition. The EC25 was equivalent to a two standard deviation cut-off
that was used for a primary compound screening hit determination criteria. The data were fitted to
a linear regression equation. The 95% confidence interval, a square of Pearson's correlation
coefficient and a slope of the line are shown.

3.3.3 CREB/AFT-1 phosphorylation in response to ICE
Next, to evaluate whether reducing cAMP efflux would result in an elevation of
cytoplasmic cAMP-dependent cell signaling, we studied the effects of ICE on
phosphorylation of cAMP-responsive element-binding protein (CREB; Ser133) and
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activating transcription factor-1 (ATF-1; Ser63), classical cAMP effectors that activate
target genes through cAMP response elements (CRE). This pathway is also directly
implicated in cAMP–induced apoptosis in leukemia [2]. All studied compounds
showed increased binding of anti-CREB (pS133) / ATF-1 (pS63) specific antibodies
as compared to vehicle control (Figure 3.3). For two compounds (clioquinol and
parthenolide), the binding of antibodies was comparable to the adenylate cyclase
stimulator forskolin positive control. Thus, ICE compounds can stimulate CREB/AFT1 phosphorylation.

Figure 3.3 Binding of anti-phospho-CREB/AFT-1-specific antibody in response to ICE.
U937 cells were treated for 1 hour with 20 µM ICE compounds or forskolin (positive control), or
DMSO (vehicle, negative control). Next, cells were fixed, permeabilized and stained with primary
labelled anti-CREB (pSer133) / ATF-1 (pSer63) monoclonal antibody. Histogram overlays from one
representative experiment show negative control events (light grey) and compound-treated events
(dark grey). Bar graph shows MFI ± SEM (standard error of the mean) for four independent
experiments. Statistical significance was determined by one-way ANOVA with repeated measures
using a Dunnett post-test to compare treated samples to DMSO control values (p < 0.05).
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3.3.4 VLA-4 deactivation in response to ICE
Another signaling pathway that in leukocytes can be triggered by the elevation of
cytoplasmic cyclic nucleotides is the conformational deactivation of the Very Late
Antigen-4 (VLA-4, alpha4 beta1 integrin), an adhesion molecule implicated in homing
and retention of early hematopoietic progenitors in the bone marrow. The elevation
of icAMP using G-alphaS GPCR-specific ligands, forskolin and by other
pharmacological manipulations results in rapid dissociation of the VLA-4-specific
ligand-mimicking probe, LDV-FITC [129]. We studied the effect of ICE on VLA-4
deactivation using the same previously characterized model system (Figure 3.4).
Studied compounds triggered rapid dissociation of LDV-FITC in U937 cells preactivated through a non-desensitizing mutant of the FPR1. In several experiments,
the effects of parthenolide and patulin exceeded the effects of the positive control,
forskolin (Figure 3.4). Cryptotanshinone induced rapid and reversible VLA-4
deactivation that looked similar to the effect of a cell-permeable cyclic nucleotide
analog [130]. Thus, ICE compounds were also capable of triggering an integrin deactivation pathway, where the role of elevated cyclic nucleotide concentration is
critical [129, 130].
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Figure 3.4 Dissociation of the VLA-4-specific fluorescent ligand in response to ICE.
U937 cells transfected with a non-desensitizing mutant of FPR1 were maintained in cRPMI at 37°C
while the samples were stirred continuously during data acquisition. Cell suspension was
sequentially treated with LDV-FITC (first arrow), FPR1-specific ligand for cell activation (fMLFF,
second arrow), and ICE compounds or forskolin positive control (40 µM) or DMSO vehicle (third
arrow). The use of the non-desensitizing mutant of FPR1 allows for the maintenance of the high
affinity VLA-4 state during the course of the experiment (control, vehicle). This allows for
monitoring the real-time deactivation kinetics after compound addition. Each line represents MFI ±
SEM of three independent experiments. In each experiment, every experimental point represents
MFI of several hundred events acquired every second. Bars representing SEM are shown for every
10 s time point. Dashed line represents binding of the LDV-FITC prior to cell activation.

3.3.5 Adenylyl cyclase inhibition reduces ICE-induced cell viability loss
Because synthesis is a source for icAMP accumulation, and soluble adenylyl
cyclase (sAC) is directly implicated in the mitochondrial pathway of apoptosis, we
studied how blocking the AC by the selective sAC inhibitor, KH7, influences ICE
effects. Based on the data published by Kumar et al., 2009 [45], we expected that
blocking cAMP production would reduce ICE potency (Figure 3.5A). In fact, we
detected a significant protective effect of KH7 on the cell viability loss induced by the
four most potent ICE compounds (Figure 3.5B). The lack of effect for less potent ICE
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could be due to a lesser effect on viability: KH7 displayed the most prominent effect
in samples where control viability was far below 50%. Thus, inhibition of sAC activity
was sufficient to reduce the effects of the most potent ICE.
Hence, compounds identified in an assay based on blocking cAMP efflux can
reduce cell viability, and stimulate two signaling pathways that are each modulated
by elevation of icAMP, CREB phosphorylation and VLA-4 deactivation. Moreover,
blocking of sAC activity prevented ICE-induced cell viability loss. These data are
consistent with an ICE molecular mechanism involving elevation of icAMP. The
accumulation of icAMP as the result of decreased cAMP efflux in U937 cells was first
demonstrated by Copsel, et al. [97].

53

Figure 3.5 Effect of the selective inhibitor of soluble adenylyl cyclase (KH7) on cell viability
loss induced by ICE.
A) Schematics of KH7 action. By blocking synthesis of cAMP, KH7 is expected to decrease overall
icAMP accumulation and thus, to protect cells from ICE-induced apoptosis. B) U937 cells were
treated overnight with increasing concentrations of ICE in the presence or absence of 6 µM KH7. ICE
concentrations were chosen based on relative ICE potency. Cell viability was assessed using 7-AAD
staining as described in Materials and Methods. Control samples were treated with 6 µM KH7 or
equal volume of vehicle (DMSO). Graph shows percentage of 7-AAD negative events ± SEM of two
independent experiments. Each bar represents mean of five values (n=5). Statistical significance was
determined using unpaired t-test and significant difference is indicated as (p < 0.05) for each pair of
KH7 treated and untreated samples.
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3.3.6 Normal primary peripheral blood mononuclear cells (PBMCs) did not
significantly efflux cAMP
According to our hypothesis, active cAMP efflux represents a novel apoptosis
evasion mechanism that is activated in certain malignant cells, and normal cells
should lack this cAMP efflux ability. To test this proposition, we compared F-cAMP
efflux in U937 cells and normal PBMCs (Figure 3.6). After 24 h incubation, PBMCs
loaded with F-cAMP retained ~80-90 % of the probe fluorescence when incubated at
37°C or at 4°C, whereas U937 cells lost ~80 % of the probe fluorescence only at 37°C.
A significant part of this loss was blocked by incubation with efflux inhibitor MK-571,
indicating active participation of ABCC family transporters. No decrease in the probe
fluorescence was detected at 4oC, suggesting that cell membrane integrity was well
preserved and passive probe leak had not occurred. This result suggests that active
cAMP removal cannot be detected in normal PBMCs in the same time frame as in the
AML model.

Figure 3.6 cAMP efflux activity of U937 cells and human PBMCs.
Cells were loaded with F-cAMP as described in Materials and Methods. F-cAMP retention after
overnight incubation with ICE in samples incubated at 4°C (passive leakage) or 37°C (active
removal), and in the presence of cAMP efflux inhibitor control MK-571, was measured by flow
cytometry. Cell autofluorescence was subtracted, and the data were normalized to the fluorescence
value at initial staining indicated by dashed line. Data shown is MFI ± SEM from one representative
independent experiment conducted in triplicate. Statistical significance was determined by a twotailed Student’s t-test, n.s., non-significant.
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3.3.7 ICE induce apoptosis of U937 cells
The effect of ICE on U937 cell apoptosis after overnight incubation has been
studied using the MultiCyt 4-Plex Apoptosis kit that reports four different apoptosis
endpoints: effector caspases 3 and 7 activation, phosphatidylserine surface
expression, mitochondrial membrane depolarization and cell membrane integrity.
The ICE induced apoptosis in a dose-dependent manner, and the EC50 values for all
four apoptosis endpoints were determined to range from 2-3 µM to several hundred
µM (Figure 3.7). The relative sensitivity of different apoptosis endpoints reflected
different consecutive steps of the intrinsic pathway. Mitochondrial depolarization
and membrane damage were the most sensitive while the effector caspase activation
was the least. Cryptotanshinone showed a very small effect on annexin-V binding and
caspase activation, even at the highest ICE concentrations. These EC50s were excluded
from further analyses (as indicated by NC).
To simplify analysis, the data were color-coded (heat map) according to the
determined EC50 values (Figure 3.7). The most potent compounds (EC50 values 1-10
µM) in the apoptosis assay were: patulin, parthenolide, and dihydroartemisinin
(white color). In addition, the relative ranking was largely independent on the
particular endpoint. Mean EC50s calculated for each compound are shown at the
bottom of a heat map and indicate relative potency of studied ICE. Thus, U937 cells
treated with ICE exhibited a dose-dependent increase in apoptosis.
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Figure 3.7 Effects of ICE on apoptosis of U937 cells.
Cell mitochondrial depolarization, annexin-V binding, caspase 3/7 activation and cell membrane
damage are shown as dose response curves and a heat map. Percentage of U937 cells positive for
four different apoptosis endpoints was determined as described in Materials and Methods. Dose
response curves for each endpoint (n=4) after 24 h incubation with ICE display cell viability (%) ±
SEM. Data were fit using variable slope sigmoidal dose response equation with no constraints. Heat
map shows EC50s ± SEM. NC, not converged.

3.3.8 ICE decrease viability and show cancer cell specificity
Next, we tested the effect of ICE on the viability of U937 cells and B-ALL cell lines
(Table 3.2). On U937 cells, several compounds were more potent than the positive
control MK-571 (Figure 3.8). In general, B-ALL cell lines showed more sensitivity
than the U937 cells to several of the selected compounds. However, B-ALL lines
showed a decreased sensitivity to the two structurally related drugs: artesunate and
dihydroartemisinin. The EC50 values for the ICE with each B-ALL line ranged from low
nanomolar to ~300 µM (Figure 3.8). It can be noted, however, that the compounds,
which consistently decreased viability ranked in the same order across all six B-ALL
lines: patulin, parthenolide, clioquinol, cryptotanshinone.
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To investigate the potential selectivity of the compounds, we compared ICE
effects on cell viability in leukemic and non-malignant cells (PBMCs from healthy
volunteers). The EC50 values indicated that for the most potent of the tested
compounds to be efficacious, PBMCs required a concentration of at least an order of
magnitude higher than was necessary for the leukemic cell lines (Figure 3.8, notice
the darker color-coding for PBMCs). This difference was expected, since normal
PBMCs do not have an established system for cAMP efflux (Figure 3.6), and therefore
should be less sensitive to ICE.

Table 3.2 The hematologic cell lines included in the study, their subtype and genetic
rearrangements [131].
* – Two cell lines were shown to have identical genetic rearrangement and a fusion gene.

Cell line

Subtype

U937
697
Nalm-6
Sup-B15
Reh
RS4;11
MHH-Call 3

AML
B-ALL
B-ALL
B-ALL
B-ALL
B-ALL
B-ALL

Genetic
rearrangement
t(10;11)(p12;q14)
t(1;19)(q23;p13)
t(5;12)(q33;p13)
t(9;22)(q34;q11)
t(12;21)(q13;q22)
t(4;11)(q21;q23)
t(1;19)(q23;p13)

58

Fusion gene
PICALM/MLL10(AF10)
TCF3(E2A)/PBX1*
ETV6/PDGRFB
P190 BCR/ABL1
ETV6(TEL)/RUNX1(AML1)
MLL/MLLT2(AF4)
TCF3(E2A)/PBX1*

Figure 3.8 Effects of ICE on cell viability of U937 cells, the B-ALL cell lines 697, Reh, MHH Call
3, RS4;11, Sup B15, and Nalm 6, and normal human PBMCs.
Dose response curves for each cell type after overnight incubation with ICE display cell viability (%)
± SEM. For U937, n = 8; for PBMCs and B-ALL cells, n = 6. Data were normalized assuming that
negative control (DMSO) was equal to 100% viability. Data were fit using the sigmoidal dose
response equation with constraints: top = 100, bottom = 0, hill slope = -1. Table shows EC50s ± SEM.
NC, not converged.

3.3.9 Leukemic cells have different abilities to efflux cAMP
To further study cAMP efflux in leukemic cells, the B-ALL cell lines were loaded
with F-cAMP, and its efflux from the cells was evaluated. After incubation at 4°C
(passive leakage), the cells lost 20-60% of their fluorescence from the initial F-cAMP
loading. Incubation at 37°C (active efflux) resulted in F-cAMP removal that ranged
from ~60% to ~90%, with no apparent relationship between 4°C and 37°C samples
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(Figure 3.9A). For example, Nalm-6 and 697 cells showed dissimilar passive leakage,
but both cell lines exhibited similar active F-cAMP removal abilities.
The cell lines also exhibited varied sensitivity to MK-571, a control for
transporter-dependent efflux. We found a strong relationship between levels of FcAMP remaining in cells at 37°C, both alone and in the presence of MK-571. Based on
this parameter, cell lines could be stratified into three groups, which indicated
correlations between ability to actively efflux cAMP and MK-571 inhibition of cAMP
removal. Group 1: Sup-B15 and MHH-Call3 removed ~60% of the F-cAMP by active
efflux, which was blocked completely by MK-571. Group 2: Reh and RS4;11 cells
removed 75-80% of the F-cAMP by active efflux, and ~30-40% with MK-571. Group
3: 697 and Nalm-6 cells removed > 90% of the F-cAMP by active efflux, and 60-70%
with MK-571 (Figure 3.9B). Thus, the cell lines that effluxed F-cAMP poorly were
better inhibited by MK-571, and those that were efficient in the removal of F-cAMP
were less inhibited by MK-571. This suggests that for cell lines in Groups 2 and 3, an
additional MK-571-insensitive mechanism participated in the removal of F-cAMP.
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Figure 3.9 Retention of F-cAMP in hematopoietic cell lines.
A) F-cAMP leakage from B-lineage ALL cell lines after overnight incubation at 4°C, or 37°C, and in
the presence of the positive control MK-571. Lower values correspond to higher efflux. Data shown
are the mean ± SEM from three independent experiments. Initial F-cAMP loading is indicated by a
dashed line. B) The correlation between F-cAMP fluorescence remaining in cells incubated at 37°C
alone and in the presence of MK-571. See text for details.

3.3.10 The primary cAMP transporter, MRP4/ABCC4, is differentially expressed by
leukemic cell lines
cAMP is primarily released by cells via the ABCC4 (MRP4) and ABCC5 (MRP5)
transporters [90]. The affinity of ABCC4 for cAMP is ~10-fold greater than that of
ABCC5 (km values of 44.5 µM and 379 µM, respectively) [90, 132]. Therefore, we
hypothesized that the presence of ABCC4 on leukemic cells would correlate with their
ability to efflux F-cAMP. ABCC4 phenotypes were determined for the B-ALL cell lines,
and the number of ABCC4-specific binding sites ranged from ~100 on MHH-Call3 to
~104 on RS4;11 cells (Figure 3.10). However, no apparent correlation between
ABCC4 expression and F-cAMP efflux were detected (compare Figure 3.9 and Figure
3.10). This suggests that other transporters and/or mechanisms may play additional
roles in leukemic cell removal of cAMP.
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Figure 3.10 Determination of ATP-binding cassette transporter ABCC4-specific binding sites
on B-ALL cell lines.
Raw histograms of IgG isotype controls (grey) and ABCC4-specific antibody (dark grey) binding to
each cell line. Specific binding sites calculated using Quantum™ Simply Cellular® anti-human IgG
calibration beads stained with primary anti-ABCC4-specific and secondary fluorescent antibody.
Calibration beads allowed mean fluorescence intensity (MFI) values to be converted into nonspecific binding sites. Binding site values for IgG primary antibody-bound isotype control cells were
subtracted from the ABCC4 non-specific binding site data to calculate the number of ABCC4-specific
binding sites per cell. Estimated site numbers are indicated on each panel. A representative
experiment of two experiments is shown.

3.3.11 ICE decrease primary ALL patient sample viability
To further establish the effectiveness of ICE in reducing cancer cell viability,
primary cells from six B-ALL patients (Table 3.3) were tested ex vivo. The results
showed dose-dependent decreases in patient sample viability after exposure to the
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compounds (Figure 3.11). To verify the relative ranking of ICE, the mean EC50 values
for each compound were plotted against the mean EC50 values determined for all BALL cell lines. The result indicated a strong correlation for most patient samples
(Figure 3.11B). This result suggests that the data obtained using cell lines adequately
reflect the relative compound potency detected in patient samples, and therefore, cell
lines can be used to test ICE derivatives in future medicinal chemistry applications.
Moreover, the overall shape of the dose-response curves obtained for different
patient samples revealed an interesting pattern: the shape of the curves was more
patient-specific rather than compound-specific. For example, in the samples from
patients no. 1 and no. 5, we observed a significant increase in cell viability vs. vehicle
treated sample at lower concentrations of dihydroartemisinin, clioquinol or
parthenolide (see points above the dashed line, Figure 3.11A). This behavior was
also evident in viability data from B-ALL cell lines (Figure 3.8). These results are
consistent with the report that small or transient increases in icAMP can be antiapoptotic and therefore, can support cell survival [2, 39]. Under identical conditions,
the same compounds elicited no such effect in the samples obtained from patients no.
2 or no. 4. Another difference can be observed when the slopes of the dose-response
curves are analyzed. It appears that in some patient samples, the slopes are steeper
than in others. These data suggest that certain traits of a particular patient sample
play a significant role in the response to different ICE compounds. It might be useful
to correlate genotypic and phenotypic profiles of patient samples with these dose-
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response curve parameters. However, this will require further studies with larger
numbers of patient samples with diverse genotypic and phenotypic profiles.

Table 3.3 Genotypic and phenotypic profile of B-ALL patient samples.
* – have MLL-AF4 rearrangement
Abbreviations: ALL: acute lymphoblastic leukemia; WBC: white blood cell; FISH: fluorescent in situ
hybridization; STD: standard risk; VHR: very high risk
Patient

Age

Gender WBC

124-12

4

F

2.9

238-13*

18

M

629.2

329-13*

26

F

53.1

017-14

22

M

39.5

280-13

2

M

116-13

7

F

Ploidy

Phenotype Risk Cytogenetics/FISH
STD

diploid

CD34+
CD19+
CD22dim
CD10+
CD19+
CD22+
CD10+
CD19+
CD22+

22.0

0.92
hypoploid

4.0

diploid

CD10+
CD19+
CD34+
CD10+
CD19+
CD34+

46,XX,del(9)(p13),der(19)t(1;19)(q23;p13.3)
[10]/46,idem,add(5)(p13),add(9)(p21),del(10)
(q23)[2]/46,idem,
t(1;13)(p13;q14)[3]/46,XX[5]
VHR 46,XY,t(4;11)(q21;q23)[cp6]/49,XY,+X,+1,
t(4;11)(q21;q23),+21[5]/46,X,-Y,
t(4;11)(q21;q23),+mar[3]
VHR 46,XY,t(4;11)(q21;q23)[cp6]/49,XY,+X,+1,
t(4;11)(q21;q23),+21[5]/46,X,-Y,
t(4;11)(q21;q23),+mar[3]
VHR 45,XY,-7,t(9;22)(q34;q11.2)[16]/46,XY[4]
complement with translocation t(9;22) and
monosomy 7 in sixteen of twenty cells
analyzed;
BCR/ABL1 transcript ratio: 0.37. Ratios>0.1
STD 46,XY[4]
STD
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46,XX

Figure 3.11 Effects of ICE on cell viability of primary ALL patient samples.
A) Compound dose response curves for each patient sample tested in duplicate. Data were normalized
assuming that negative control (DMSO) was equal to 100% viability. Data were fit using the sigmoidal
dose response equation with constraints: top = 100, bottom = 0, hill slope = -1. Table shows EC50s ±
SEM. NC, not converged. B) Correlation between mean compound EC50 values obtained from B-ALL cell
line data (Fig. 8) and mean EC50 values from primary B-ALL patient samples. The coefficient of
determination (r2) was calculated from the Pearson correlation coefficient.

3.4 Discussion
For many years, researchers have been eager to develop methods to robustly
modulate icAMP in cancer cells, and all known steps of the cAMP-related signaling
pathway have been targeted [53]. Only recently, researchers have realized that icAMP
can be also modulated by cyclic nucleotide efflux transporters. The finding that
blocking cAMP efflux or down-regulation of efflux transporters can trigger cAMP
elevation and downstream signaling [97] has opened new avenues for developing a
novel class of anticancer therapeutics via inhibitors of cAMP efflux. Analysis of the
proteins capable of cyclic nucleotide efflux also suggests notable possibilities.
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The cAMP transporter ABCC4 has increased expression in blood cancer cells as
compared to normal hematopoietic cells [133], and its expression decreases
significantly upon cell differentiation [96].

ABC transporters are likewise

upregulated in stem-like cells, which may suggest that these cells require active
removal of cAMP or other structurally-related compounds in order to remain in a
pluripotent state, and that the metabolic specificity of these cells requires active
transport of certain metabolites [134]. These cancer stem cells are also associated
with higher resistance to typical cancer therapeutics [135]. However, our results for
ABCC4-expression did not define any clear correlations between cAMP efflux and
ABCC4 expression in the cell lines. It is possible that other transporters capable of
cAMP efflux (ABCC5 or ABCC11 [132, 136]) are present, or that there is a difference
in the efflux capacity of different transporters. This may indicate that the ability to
inhibit cAMP transport is substrate- or condition-dependent.
Of the active compounds identified in our screen for ICE, the majority were
sesquiterpene lactones: parthenolide is derived from the feverfew (Tanacetum
parthenium) plant; artemisinin and dihydroartemisinin are from Artemisia annua;
and artesunate and artemether are semi-synthetic artemisinin derivatives.
Cryptotanshinone is also plant-derived (Salvia miotiorrhiza), whereas clioquinol is an
antimicrobial hydroxyquinolone derivative, and patulin is an antibiotic mycotoxin
produced by Aspergillus and Penicillium. These compounds have been reported to
exhibit anticancer activity in a number of model systems (Table 3.4), and the
reported anticancer effects of these compounds were often similar to those seen in
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our assays (Table 3.5). However, none of the compounds has previously been
reported to modulate cyclic nucleotide efflux.

Table 3.4 Previously reported anticancer activity of the compounds identified as ICE.

Compound
Patulin

Tested cancer types
kidney [137], oral squamous cell carcinoma [138], glioblastoma
[139], colon [140-142], colorectal [143], hematological [128, 144],
liver [145]
Parthenolide
Melanoma [146, 147], cervical [148, 149], hematological [127,
150, 151], breast [152]
Artesunate
Ovarian [153], cervical [154], Kaposi’s sarcoma [155], squamous
carcinoma [156], breast [157, 158], liver [159], pancreatic [160,
161], hematological [162-166], colorectal [165, 167],
neuroblastoma [168], lung [165, 169], osteosarcoma [170]
Dihydroartemisinin ovarian [153, 171], breast [172], liver [172, 173], melanoma
[174], pancreatic [175-179], lung [180-182], cervical [154],
hematological [183-188], prostate [189], glioma [190],
osteosarcoma [191]
Clioquinol
hematological [125, 192-194], breast [195, 196], cervical [197],
prostate [198-200]
Cryptotanshinone hematological [201, 202], prostate [126, 203, 204], breast [126,
205], melanoma [206, 207], lung [207], rhabodomyosarcoma
[126]

Artemisinin, dihydroartemisinin, artesunate and artemether are currently used
worldwide for the treatment of malaria. Artemether is a component of the drug
Coartem manufactured by Novartis and approved by the US Food and Drug
Administration in 2009. Several ongoing clinical trials of artemisinin derivatives to
treat hepatocellular carcinoma, breast cancer, cervical intraepithelial neoplasia, as
well as a trial evaluating “biological activity of oral clioquinol in patients with
relapsed or refractory hematological malignancy” initiated by Dr. Mark Minden from
Ontario Cancer Institute Princess Margaret Hospital in Canada, can be found on
clinicaltrials.gov. Therefore, these drugs have the highest potential to be repurposed
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into current treatment regimens. Poor water-solubility and bioavailability of
parthenolide prompted medical chemistry efforts to improve these characteristics
[208]. However, since these drugs were identified from two relatively small libraries
totaling ~3500 compounds, we envision that larger efforts to identify compounds
capable of blocking cAMP efflux may lead to better drugs. This is especially important
because of the unique signaling role of cAMP in apoptosis.
Table 3.5 Previously reported molecular/ signaling mechanisms related to anticancer activity
of the compounds identified as ICE.
Abbreviations: VEGF: vascular endothelial growth factor; NF-κB: nuclear factor kappa-B; AP-1:
activator protein 1; MAPK: mitogen-activated protein kinase; ERK: extracellular signal-regulated
kinases; STAT: signal transducer and activator of transcription; ROS: reactive oxygen species; PI3K:
phosphatidylinositol-4,5-bisphosphate 3-kinase; Akt: protein kinase B; mTOR: mammalian target of
rapamycin; eIF-4E: eukarytotic initiation factor 4E; UPR: unfolded protein response

Compound

Cell cycle
arrest

Anticancer effects

Parthenolide

G1 [147, 209],
S [210]

↓VEGF expression &
metastasis [147, 211, 212];
↑p53 activation [127];
↓cyclin D1 [147, 209]

G1 [176],
Dihydroartemisinin G2 [173, 187,
191]

Artesunate

G1 [156, 216],
S [167],
G2 [165, 170]

Cryptotanshinone

G1 [206],
G2 [206]

Clioquinol

G1 [196]

Patulin

G1 [219],
G2 [143]

↓VEGF expression &
angiogenesis [185, 187, 188];
↓cyclin B, CDC25 [173]
↓metastasis/ migration [166,
169];
↓VEGF expression/
angiogenesis [156, 162, 166];
↓cyclins B & D1, Cdks 2, 4, 6
[156];
↑p21, p27 [156]
↓cyclin D1, Bcl-2 [126, 201,
202];
↑p53, Chk1, Chk2 [206]

Potential mechanism(s) of
action
↓NF-κB & AP-1 activation [127,
147, 211, 213, 214];
↓MAPK/ERK signaling [213, 214];
↓STAT signaling[215];
↑ROS[127, 151, 215]
↓NF-κB activation [176, 191];
↓MAPK/ERK, PI3K/Akt signaling
[183, 189]; ↑ROS [172, 181, 190]
↓NFκB & AP-1 activation [169,
217, 218];
↓nitric oxide, cAMP-mediated,
Wnt/β-catenin, PI3K/Akt signaling
[167, 217, 218];
↑ROS [156, 158, 164]

↓mTOR, STAT3 signaling [202,
203];
↓eIF-4E [126]
↓NF-κB activation [194, 198];
↓cyclin D1 [196];
ionophore/chelator activity [192,
↑p21, p27, p53 [192]
194, 198];
proteasome inhibition [193, 195]
↓ERK1/2 activation [138, 220]; ↑ROS, DNA damage [143, 145,
↑UPR [138, 220];
219, 220, 222];
↑intracellular [Ca2+][221]
↓glutathione [220, 222]
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As a messenger, cAMP plays significant regulatory roles within cells. Multiple
signaling mechanisms critical for leukemogenesis can be down-modulated by cAMP.
At least two cAMP/PKA-related pathways can be involved in the induction of cAMPdependent apoptosis in cancer cells: 1) the mitochondrial-mediated (intrinsic)
pathway, and 2) modulation of the NF-κB signaling pathway (Figure 3.12). The proapoptotic intrinsic mechanism promoted by cAMP depends upon PKA [77], which can
phosphorylate CREB, and results in transcription of the apoptotic activator
Bim/BCL2L11 [2]. cAMP modulation of NF-κB can affect transcription of pro-survival
genes [15]. Our data suggest that inhibition of cAMP transport by ICE was able to elicit
many of these effects.
Targeting cancer through a “pathway-dependent approach” that consists of
different means of elevating cAMP is considered a viable option for novel therapeutic
development [53]. It appears that every potential step of the pathway, including cAMP
synthesis, degradation, and downstream signaling, has been taken into consideration
to stimulate icAMP accumulation [53, 223, 224]. Classically, cyclic nucleotide analogs
or other cAMP-elevating agents have been used to treat hematological malignancies
by slowing cell growth and differentiating cancer cells [114].

However, while

modestly effective, these compounds exhibit toxicity in non-cancerous tissues [69, 71,
225]. Our data suggest that targeting cAMP efflux with small molecules could be an
efficient way to raise icAMP in certain types of cancer, and this could potentially result
in the development of a new class of pathway-specific therapeutics. Because
increased cAMP efflux is not a typical trait of healthy cells, the identified ICE exhibited
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specificity toward leukemic cells. The relatively efficient targeting of cAMP transport
in cancers would directly depend on cell- or patient-specific characteristics and efflux
ability. We anticipate that identification of drugs that inhibit this transport could
allow for selective targeting of cancers that capitalize on cAMP pathway modulation
for survival, and this merits further investigation into the effects of ICE on multiple
ABC transporters. The fact that the machinery responsible for apoptotic evasion by
cAMP efflux can also potentially support the removal of structurally related
chemotherapy drugs (e.g., ara-C), and thus may contribute to multidrug resistance
[226-228], makes this work unusually promising.
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Figure 3.12 Mechanisms for cAMP-dependent regulation of cell death.
cAMP is produced by various pools of soluble and membrane-bound adenylyl cyclases (sAC and AC).
Blocking cAMP efflux with ICE 1) triggers several signaling endpoints that are related to the
modulation of pro-apoptotic and cell survival pathways. Here, we detected phosphorylation of
CREB/ATF-1 2), mitochondrial depolarization 3), effector caspases 3 and 7 activation 4), and
apoptosis 5) in the form of annexin-V binding and cell membrane damage. Blocking adenylyl cyclase
activity using selective inhibitor of soluble adenylyl cyclase (KH7) was sufficient to reduce effects of
most potent compounds. Various molecular mechanisms are implicated in effects of cAMP on
apoptosis induction. In AML cells pro-apoptotic protein Bim/BCL2L11 expression is up-regulated
via CRE/CREB in a cAMP-dependent manner [2]. Induction of Bim represents a crucial event in the
cAMP-induced apoptosis in murine T-cell lymphoma and human acute leukemia [3]. cAMP is also
shown to inhibit MCL-1 protein transcription in human MM cells [4] or human B-precursor cells
[10]. Relocalization of the cytosolic sAC pool toward mitochondria leads to PKA activation and
phosphorylation of the pro-apoptotic protein Bax that activates mitochondrial apoptotic pathway
[13]. Also, cAMP is implicated in a regulation of NF-κB action [15], which is a potential target in AML
[16].
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3.5 Materials and methods
3.5.1 Ethics
All blood samples from healthy volunteers were obtained with written, informed
consent per local institutional research guidelines according to the University of New
Mexico Human Research Protections Office protocol 11-225. Bone marrow samples
acquired from pediatric B-ALL patients were taken upon written, informed consent
according to the University of New Mexico Human Research Protections Office
protocol 05-435.

3.5.2 Cells and reagents
Alexa Fluor®488 8-(6-aminohexyl) aminoadenosine 3´,5´-cyclicmonophosphate,
bis(triethylammonium) salt (F-cAMP) (Life Technologies, cat. A35775). The VLA-4specific probe 4-((N’-2-methylphenyl)ureido)-phenylacetyl-L-leucyl-L-aspartyl-Lvalyl-L-prolyl-L-alanyl-L-alanyl-L-lysine-FITC

(LDV-FITC)

was

synthesized

at

AIBioTech. The selective inhibitor of soluble adenylyl cyclase, KH7, was purchased
from Cayman Chemical Company (cat. 330676-02-3). All other reagents and hit
compounds for secondary assays were from Sigma-Aldrich.
Cell lines, purchased from ATCC and DSMZ, were cultured in RPMI-1640 medium
supplemented with 2 mM L-glutamine, 100 U/ml penicillin-streptomycin and 10%
heat-inactivated fetal bovine serum (FBS; 20% for MHH-Call3), hereafter referred to
as cRPMI, and incubated in a humidified atmosphere with 5% CO2 at 37°C.
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3.5.3 PBMCs
Healthy PBMCs were obtained from volunteers. Mononuclear cells were purified
using Mono-Poly resolving medium (MP Biomedicals, cat. 091698049) according to
manufacturer’s instructions. PBMCs were resuspended in cRPMI and kept on ice prior
to use.

3.5.4 Primary ALL patient samples
Bone marrow samples were acquired at diagnosis from pediatric B-ALL patients.
Mononuclear cells were enriched by centrifugation in Ficoll-Paque (GE Healthcare,
cat. 17-1440-02) and aliquoted for storage in liquid nitrogen until use. Samples were
thawed in a 37°C water bath, resuspended in 20% FBS cRPMI, and centrifuged to
remove freezing medium. Cells were resuspended in conditioned medium (DMEM,
10% FBS, 50 U/ml penicillin-streptomycin, 2 mM L-glutamine) from HS-5 stromal cell
cultures.

3.5.5 cAMP efflux assay
Cells were loaded with F-cAMP as described [229].

Briefly, cells were

resuspended in a hypertonic solution containing 10% polyethylene glycol 1000, 0.5
M sucrose, and 250 µM F-cAMP in cRPMI without FBS, incubated 10 min at room
temperature, washed, and then resuspended in hypotonic solution (60% cRPMI, 40%
sterile water) for 2 min at room temperature to complete F-cAMP loading. Cells were
resuspended in cRPMI and equilibrated for 2 h under normal culture conditions.
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For testing cAMP efflux, an aliquot of loaded cells was kept at 4°C to serve as
control, and the remaining cells were incubated in the presence of vehicle or
compounds overnight. Samples were evaluated using Accuri C6 or BD FACScan flow
cytometers (Becton Dickinson (BD)).

3.5.6 High throughput screening (HTS)
Liquid handling was accomplished with a Biomek FX Multichannel system
(Beckman-Coulter, Fullerton, CA, USA) and/or Biotek Multiflo system (Winooski, VT,
USA). F-cAMP-loaded U937 cells (2000/well) were seeded into 384-well
polypropylene plates (Greiner Bio-One 784201, Monroe, NC, USA). Cells were treated
with compounds (10 µM final concentration) from the Prestwick Chemical Library
(Illkirch, France) or SPECTRUM Collection (MicroSource, Gaylordsville, CT, USA)
delivered by pintool (V&P Scientific, San Diego, CA), at a final DMSO concentration of
1%. Plates were foil-sealed with AlumaSeal 384™ (Excel Scientific, Victorville, CA,
USA), and incubated inverted overnight. Sample plates were analyzed by CyAn flow
cytometers (Beckman-Coulter) configured with HyperCyt high-throughput autosampler systems (IntelliCyt, Albuquerque, NM, USA) using 488 nm excitation to
assess FL-1 (530/40) MFI levels.
Data were analyzed with HyperView software (IntelliCyt) and time-gated to
determine data from each well. Wells with ≥ 50 events were evaluated for FL-1 MFI
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values. Samples with MFI values ≥ 2 standard deviations above the plate mean
negative control values were considered “hit” compounds.

3.5.7 Compound validation
To validate sample data and decrease the number of false-positive hits,
compounds were assayed in a high-throughput dose response assay. Plates were set
up as in the HTS, with the exception that the plate formats contained 10-well dose
responses for each hit compound, at final concentrations ranging from 30 µM to 4 nM.
For B-ALL cell lines, tests of hit compound inhibition of cAMP efflux were
conducted as in the HTS, with compounds in 10-well dose responses ranging from
100 µM – 1.53 nM, at cell densities of 5000/well.
The dose response data were normalized for percent response based on sample
FL-1 MFI values in comparison to untreated F-cAMP-loaded cells kept at 4°C
overnight or at time = 0, and were fitted by GraphPad Prism 5 software (GraphPad
Software, La Jolla, CA, USA) for sigmoidal dose response with constrained hill slope =
1. Compounds with S-shaped dose response curves and EC50 values less than 3 μM
were selected for secondary assays.

3.5.8 Detection of CREB/AFT-1 phosphorylation in response to ICE
Cells were suspended at 106 cells/ml in cRPMI and incubated for 1 hour at 37°C
with 20 µM ICE compounds or forskolin (positive control). Negative control samples
were treated with DMSO at equal volume. Cells were fixed with 20x volume of pre75

warmed 1x solution BD PhosflowTM Lyse/Fix Buffer (cat. 558049), incubated at 37°C
for 10 minutes, permeabilized with BD PhosflowTM Perm buffer II (cat. 558052), and
incubated on ice for 30 minutes. Permeabilized cells were then washed and stained
with BD Phosflow™ Alexa Fluor® 488 Mouse Anti-CREB (pS133) / ATF-1 (pS63)
clone J151-21 (cat. 558435) according to the manufacturer’s instructions.

3.5.9 Kinetic analysis of VLA-4 deactivation
Kinetic analysis of the binding and dissociation of the LDV-FITC probe was
described previously [230]. Briefly, flow cytometric data were acquired at 37°C while
the samples were stirred continuously with a stir bar (Bel-Art Products). First, U937
cells transfected with a non-desensitizing mutant of the Formyl Peptide Receptor
FPR1 [231] were analyzed for 30–120 s to establish a baseline. The FPR1 mutant
triggers VLA-4 activation, which persists for hundreds of seconds, allowing for
integrin deactivation to be detected. Next, the LDV-FITC was added and acquisition
was re-established. For cell activation, the high affinity FPR–specific agonist (Nformyl-L-methionyl-L-leucyl-L-phenylalanyl-L-phenylalanine, fMLFF) was added at a
saturating concentration (100 nM), and acquisition was re-established. Finally, 40 µM
of ICE, forskolin (positive control) or vehicle (negative control) were added.
Acquisition was re-established, and data were acquired continuously for up to 1024
s.
The concentration of the LDV-FITC probe used in deactivation experiments (4
nM) was below the dissociation constant (Kd) for its binding to resting VLA-4 (low
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affinity state, Kd ~12 nM), and above the Kd for physiologically activated VLA-4 (high
affinity state, Kd ~1–2 nM). Therefore, the transition from low to high affinity state
led to increased binding of the probe. This was detected as an increase in the median
fluorescence intensity (MFI). VLA-4 deactivation led to the dissociation of the probe
and decreased MFI [129].

3.5.10 Viability
Cell viability was determined with the CellTiter-Glo® Luminescent Cell Viability
Assay (Promega). Greiner 655083 had 100 µL cRPMI +/- 4x104 cells/well, and dose
response curves of compounds ranged from 100 µM to 1.53 nM (1% DMSO). Wells
with DMSO-only served as negative controls. Samples were incubated overnight, and
the assay was completed according to the manufacturer’s protocol. Plates were
analyzed using a Victor3V™ 1420 Multilabel Counter (Perkin Elmer).
For primary ALL patient samples, media consisted of 50% cRPMI, 50%
conditioned DMEM from HS-5 stromal cell cultures and compounds. Cell densities
ranged from 28,000-68,000 cells/well, and plates were foil-sealed prior to
incubation.

3.5.11 Determination of cell viability by 7-AAD exclusion
Cells treated with ICE and control samples were incubated with 1 µg/ml of 7-AAD
for 20-60 minutes at 4°C on a rotator in the dark, and analyzed by flow cytometry
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according to manufacturer instructions. Gates were set on 7-AAD negative and
positive events based on histograms. Percent of 7-AAD negative events is shown.

3.5.12 Apoptosis
Apoptosis was determined using MultiCyt® 4-Plex Apoptosis Screening Kit
(IntelliCyt, cat. 90053). The kit provides four different apoptosis endpoints that
include effector caspases 3 and 7 activation, phosphatidylserine surface expression,
mitochondrial membrane depolarization and cell membrane integrity. The activation
of caspases is detected using NucView™ 488 Caspase3/7-specific substrate that
exhibits increase in fluorescence upon cleavage by activated enzyme. Surface
phosphatidylserine is detected by the binding of labelled annexin-V. Another
fluorescent dye accumulates in intact mitochondria and upon mitochondrial
membrane depolarization it leaks into the cytoplasm and exhibits a decrease in
fluorescence. Cell membrane damage is detected by the uptake of a proprietary DNA
intercalating agent analogous to 7-aminoactinomycin D.
384-well plates (Greiner 784201), pre-loaded with 5 µL cRPMI were stamped
using a pintool with 100 nL of DMSO-solubilized compounds from the 100-fold
concentrated stock solution. Next, 5 µL U937 cells (2 x 106/ml in cRPMI) were added
to wells and mixed, and plates were foil-sealed. Compounds (Table 3.1) were tested
in dose response at final concentrations ranging from 15.2 nM to 100 µM (1% DMSO
final). Vehicle (DMSO) was used as a negative control. After 24 h incubation under
culture conditions, the IntelliCyt MultiCyt 4-Plex Apoptosis Screening Kit was used
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according to manufacturer’s protocol. The data were acquired using iQue Screener
Platform (IntelliCyt). Singlet cell populations were analyzed for individual measures
of apoptosis, and gates were set based on control histograms.

3.5.13 Quantitation of ABCC4
ABCC4 transporters in fixed B-ALL cell lines were enumerated by flow cytometry
using: primary mouse anti-human ABCC4 or IgG1 negative isotype-matched control
(Abcam®, Cambridge, MA, USA), FITC-conjugated AffiniPure F(ab’)2 of goat antimouse IgG secondary antibody (Jackson Laboratories, West Grove, PA, USA), and
Quantum™ Simply Cellular® anti-human IgG calibration beads (Bangs Laboratories,
Fishers, IN, USA) according to manufacturers’ protocols. Post-labeling, all samples
were analyzed for FL-1 MFI. The calibration beads were used to generate a linear
regression, which associated MFI to the antibody-binding capacity of the beads. This
regression was used to calculate the number of antibody binding sites (ABS) per cell
sample. For each cell type, the calculated ABS for isotype control samples were
subtracted from ABS of the ABCC4 samples to determine specific binding sites.

3.5.14 Data analysis
The kinetic data were converted to MFI versus time using FCSQuery software
developed by Dr. Bruce Edwards (University of New Mexico). Analysis of apoptosis
was done using ForeCyt software (IntelliCyt). Curve fits and statistics were done
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using GraphPad Prism software version 5.01 (GraphPad Software), as described in
figure captions.

3.6 Acknowledgments
We would like to thank Dr. Bruce Edwards (University of New Mexico) for
providing FCSQuery and HyperView software and Dr. Anna Waller for thoughtful
input and discussions.

3.7 Disclosure of potential conflicts of interest
Larry A. Sklar is a co-inventor of HyperCyt, a high throughput flow cytometry
platform used for drug identification utilized in the current manuscript, and is a cofounder of IntelliCyt, a company that manufactures HyperCyt. Other authors declare
no conflicts of interest.

3.8 Grant support
This work was supported by The Oxnard Foundation (to A.C. and L.A.S.),
University of New Mexico Clinical & Translational Science Center Pilot Award
1UL1RR031977 (to A.C.), and New Mexico Cancer Nanotechnology Training Center
grant R25CA153825 (to D.R.P).

80

CHAPTER 4: High throughput flow cytometry identifies small
molecule inhibitors for drug repurposing in T-ALL

Dominique R. Perez1,2,4, Christian K. Nickl3,4, Anna Waller1,2,4, Cristina DelgadoMartin5, Travis Woods1,2,4, Nitesh D. Sharma3,4, Michelle L Hermiston5, Mignon L. Loh5,
Stephen P. Hunger6, Stuart S. Winter7, Alexandre Chigaev1,2,4, Bruce Edwards1,2,4,
Larry A. Sklar1,2,4,#, Ksenia Matlawska-Wasowska3,4,#

Department of Pathology, 2 Center for Molecular Discovery, 3 Department of
Pediatrics, Division of Pediatric Research, Health Sciences Center, University of New
Mexico, Albuquerque, NM, USA
4 University of New Mexico Comprehensive Cancer Center, Albuquerque, NM, USA
5 Department of Pediatrics, University of California, San Francisco, Benioff Children’s
Hospital, San Francisco, CA, USA
6 Department of Pediatrics and the Center for Childhood Cancer Research, Children’s
Hospital of Philadelphia and the Perelman School of Medicine at the University of
Pennsylvania, Philadelphia, Pennsylvania, USA
7 Children’s Minnesota Research Institute, Children’s Minnesota, Minneapolis,
Minnesota, USA
1

#

These authors contributed equally to this work
SLAS Discovery. 2018 Aug 23 (7):732-741.
doi: 10.1177/2472555218774248. PMID: 29746793.

81

4.1 Abstract
Kinase inhibitors have dramatically increased patient survival in a multitude of
cancers, including hematological malignancies. However, kinase inhibitors have not
yet been integrated into current clinical trials for patients with T-cell lineage acute
lymphoblastic leukemia (T-ALL). In this study, we used a high throughput flow
cytometry (HTFC) approach to test a collection of small molecule inhibitors including
26 FDA-approved tyrosine kinase inhibitors in a panel of T-ALL cell lines and patient
derived xenografts. Because hypoxia is known to cause resistance to chemotherapy,
we developed a synthetic niche that mimics the low oxygen levels found in leukemic
bone marrow to evaluate the effects of hypoxia on the tested inhibitors. Drug
sensitivity screening was performed using the Agilent BioCel automated liquid
handling system integrated with the HyperCyt HT flow cytometry platform, and the
uptake of propidium iodide was used as an indication of cell viability. The HTFC doseresponse testing identified several compounds that were efficacious in both normal
and hypoxic conditions. This study shows that some clinically approved kinase
inhibitors target T-ALL in the hypoxic niche of the bone marrow.

4.2 Introduction
T-cell lineage acute lymphoblastic leukemia (T-ALL) is an aggressive
hematopoietic malignancy, which arises in the thymus from malignantly transformed
T-cell progenitors [232]. It comprises ~15% of newly diagnosed children and young
adults with ALL. Currently, patients with T-ALL require intensified therapies, for
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which risk-adjusted treatments are primarily determined by minimal residual
disease (MRD) response [233]. Importantly, patients with high-risk T-ALL do not
benefit from further therapy intensification and often experience additional adverse
events. Although cure rates have shown dramatic improvement over time, poor
outcomes are still observed in patients who failed induction or relapsed after
conventional chemotherapy. Affected patients are typically adolescents or young
adults for whom a second remission is often very short. Therefore, the development
of novel treatment programs for pediatric T-ALL is essential. Novel therapies could
cure patients for whom cure has been elusive, or could provide bridging therapies to
eradicate persistent MRD and facilitate stem cell transplantation.
Tyrosine kinase inhibitors (TKIs) have revolutionized modern pharmacology,
leading to increased survival in a multitude of solid tumors, as well as precursor Bcell ALL (B-ALL) and chronic myelogenous leukemia (CML) with BCR-ABL1 fusion
[234]. While B-ALL and CML have become an intensive area of study for kinasedirected therapies, TKIs have not yet been integrated into current therapies for
patients with T-ALL. To date, a few studies have investigated the efficacy of kinase
pathway inhibition in T-ALL aberrantly overexpressing FLT3, JAK-STAT or mTOR, etc.
[235-237]. However, the development of targeted therapies is challenged by the high
degree of heterogeneity in T-ALL, in which most cytogenetic or molecular driver
mutations occur at very low frequencies [232].
Genome wide studies have played a prominent role in drug response profiling
[236] but the repertoire of specific biomarkers for targeted therapies remains limited
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in T-ALL. Notably, kinase signaling pathways are critically involved in all aspects of
cellular function. In cancer cells, they drive aberrant signaling, regulating cell
proliferation, cell survival and chemoresistance. Dysregulation of tyrosine kinase and
other kinase signaling pathways is commonly seen in T-ALL, providing an
opportunity for therapeutic intervention [238]. Such pathways might be targeted
with FDA-approved small molecule inhibitors which are available for drug
repurposing, and the development of novel targeted therapies. Because kinase
inhibitors have relatively safe adverse event profiles, they have generally been able
to safely integrated into dose-intensified therapies in leukemia treatment regimens
[234]. We hypothesized that T-ALL may be sensitive to treatment with clinically
approved kinase inhibitors. Therefore, we tested a library of FDA-approved inhibitors
to identify the most potent drug candidates with antitumor activity against T-ALL.
One critical factor that influences cancer cell sensitivity to drug treatment is the
microenvironment, with an emphasis on hypoxia [239, 240]. Many promising drug
candidates with demonstrated antitumor potential in in vitro assays paradoxically fail
in pre-clinical trials in vivo because the microenvironment niche serves as a site for
resistance to chemotherapy. On the other hand, some inhibitors show increased
antitumor activity towards hypoxic cells, suggesting that conventional drug
sensitivity testing under normoxic conditions may result in overlooking promising
drug candidates [239].
Recent works suggest Src activation as an important mechanism by which cancer
cells maintain chemoresistance under hypoxia to promote cell survival, progression,
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and metastasis of a variety of human cancers [240]. In T-ALL, the hypoxic bone
marrow niche is commonly infiltrated with rapidly proliferating T-cell lymphoblasts.
A growing body of evidence indicates that the hypoxia present in the bone marrow
microenvironment alters the activity of multiple clinically approved TKIs
contributing to drug resistance [240]. Therefore, novel approaches that will identify
drug

candidates

that

effectively

target

leukemic

cells

in

the

hypoxic

microenvironment are warranted.
We utilized the unique drug screening capabilities of the University of New
Mexico Center for Molecular Discovery [241] to identify small molecule kinase
inhibitors for drug repurposing in T-ALL. In addition to T-ALL cell lines, we
performed drug sensitivity profiling using T-ALL primary samples and patient
derived xenografts, which were maintained as monoculture in serum-rich media. We
established a high throughput flow cytometry synthetic niche which mimics the low
oxygen levels found in leukemic human bone marrow to assess leukemic cells for
sensitivity against clinically approved inhibitors. We successfully identified inhibitors
that were efficacious in normoxia as well as niche-mimicking conditions and which
have not been used in modern T-ALL regimens. Our HTFC screening platform
provides a rapid and convenient tool for the implementation of new therapeutic
options and drug repositioning opportunities for suspension target cells such as
leukemic blasts.
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4.3 Material and Methods
4.3.1 Reagents
All reagents were purchased from Thermo Fisher Scientific (Waltham, MA)
unless specified otherwise.

4.3.2 T-ALL cell lines
Human T-ALL cell lines (Loucy, ALL-SIL, Jurkat, CCRF-CEM) were purchased from
DSZM-German Collection of Microorganisms and Cell cultures. CUTLL1 cell line was
a generous gift from Dr. Ferrando at the Columbia University. The cells were cultured
in RPMI-1640 medium supplemented with 10% FBS, 2mM L-glutamine and 100 U/ml
penicillin G in a 5% CO2 incubator at 37°C.

4.3.3 T-ALL patient samples and patient derived xenografts (PDX)
Cryopreserved primary samples were obtained from patients enrolled in
Children’s Oncology Group T-ALL trial AALL0434 and/or the University of New
Mexico Health Sciences Center. All patients or their parent(s)/guardian(s) provided
written, informed consent for future research in accordance with the Declaration of
Helsinki and local institutional human research guidelines. The Institutional Animal
Care and Use Committee approved the animal studies. Characteristics of patient
derived xenografts (PDX) are listed in Appendix B, Table S4.1. PDX were established
by injecting 1-2 x 106 cells via tail vein into non-obese diabetic/severe combined
immunodeficiency NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ mice. Leukemia engraftment was
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assessed by flow cytometry analyses of peripheral blood with fluorescent labeled
anti-human APC-CD45+ and anti-mouse BV21-CD45+ antibody (BD Biosciences, San
Jose, CA). Leukemic cells were purified via centrifugation in Ficoll-Paque/Percoll
density gradient (GE Healthcare, Piscataway, NJ). The cells were preserved with
freezing medium (90% FBS, 10% DMSO) and stored in liquid nitrogen. PDX samples
were used at low passage up to 3 to limit the effect of mouse positive selection on PDX
divergence from the original tumor sample. The cells were thawed and rested for ~4
hours at 37°C in complete RPMI-1460 medium supplemented with 2mM L-glutamine,
10% FBS, 10% human AB serum (Sigma-Aldrich, St. Louis, MI), 50 ng/ml SCF
(Peprotech, Rocky Hill, NJ), 20 ng/ml Flt3L (Peprotech), 10 ng/ml IL7 (Peprotech),
and 116 ng/ml insulin (Sigma-Aldrich).

4.3.4 Compounds
We investigated several drug classes, including: TKIs (n = 26), cyclin dependent
kinase inhibitors (n = 2; alvocidib and palbociclib), Hedgehog signaling inhibitor (n =
1; vismodegib) and proteasome inhibitors (n = 2; bortezomib and carfilzomib), all
purchased from LC Laboratories (Woburn, MA) (Appendix B, Table S4.2). The
compounds were solubilized in DMSO (250 µM for alvocidib, bortezomib and
carfilzomib; 20 mM for vandetanib, 25 mM for all others) and stored frozen at -80°C.
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4.3.5 High Throughput Flow Cytometry Viability Testing
An Echo® 555 Liquid Handler (Labcyte, San Jose, CA) was used both to create
intermediate source plates and to add inhibitors to assay plates. The HTFC assays
were conducted in 384-well Greiner Bio-One 784201 polypropylene plates (Monroe,
NC). The thirty-one drugs were added to the plates to generate 10-point dose
responses, with assay final DMSO concentration at <1%. Each compound was tested
at clinically relevant concentration range (0.005–100 µM except for bortezomib and
carflizomib that were tested at 0.05–1000 nM) (Appendix B, Table S4.1). The cells
were resuspended in fresh media and 15 µL was added to wells with a Biotek Multiflo
system (Winooski, VT). The cell lines were tested at 5000 cells per well, and the
primary samples were tested at 4500-6000 cells per well. The assay plates were
incubated in a humidified atmosphere at 37°C and 5% CO2. The hypoxic incubation,
1% O2, was achieved in a Cytomat™ 24 C 10 (ThermoFisher, Waltham, MA). The assay
plates were covered with polystyrene lids for the first 24 h of incubation and sealed
with a PlateLoc Thermal Microplate Sealer (Agilent, Santa Clara, CA) for the
remainder of the incubation. Plates from normoxic conditions were flushed with
ambient air for 1.2 sec prior to sealing, and those from hypoxic conditions were
flushed with 100% N2. Three replicate experiments were performed for the cell lines,
which were incubated for 72 hr. Due to the limited availability of primary samples,
those experiments were done in single replicates, but with multiple plates to allow
for 48 and 72 h incubations. On average, eight 384-well plates (3072 wells) were
analyzed per day. With continuous round-the-clock automation, we have the
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potential to analyze ~ 100 x 384 or 1536 well plates per day, but our throughput was
based on the availability of cells and primary samples.
The cell viability assay was performed as previously described [11]. Briefly, 5 µL
of propidium iodide (PI; Sigma-Aldrich, St. Louis, MO) was added to all wells of the
assay plates to a final concentration of 0.75 µg/mL. The plates were then incubated
on rotators at 4°C for 20-45 min. The HTFC data were collected with a HyperCyt®
platform (IntelliCyt, Albuquerque, NM) configured to an Accuri C6 Plus flow
cytometer (BD Biosciences, Franklin Lakes, NJ). The data were analyzed with
HyperView software (IntelliCyt). The samples were gated on forward and side scatter
to isolate the cell populations, and a binary gate was used on the histograms for
fluorescence in the FL-3 channel to distinguish PI positive and negative populations.

4.3.6 Data analysis
The data were normalized to the mean viability from negative control wells =
100% viability for inhibitor-treated samples. GraphPad Prism 7 software (La Jolla,
CA) was used to plot and fit the data. Half-maximal effective concentration (EC50)
values were calculated based on least squares fit of the data to a four-parameter
sigmoidal dose response curve. EC50 values are only reported for compounds that
yielded a maximum response values of 20% or greater. For EC50 values calculated to
be beyond the concentration range tested and for those samples which yielded
maximal responses < 20% ,they are reported as “>100 µM”. The hypoxia cytotoxicity
ratio (HCR) was determined for each drug and cell line as EC50normoxia/EC50hypoxia. For
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each cell line and compound, the HCR from independent experiments were compared
with a two-tailed paired t-test.

4.4 Results and Discussion
4.4.1 Drug sensitivity screening in T-ALL cell lines
To determine the sensitivity of T-ALL cells to tyrosine kinase pathway inhibition
in T-ALL, we compiled a library of 26 FDA-approved TKIs with clinically proven
efficacy against multiple tyrosine kinases including, PDGFR, VEGFR, EGFR, ALK, etc.
(Appendix B, Table S4.2). Due to growing interest in kinases that regulate cell cycle,
we also added two cyclin dependent kinase inhibitors: alvocidib, targeting
CDK7/CDK9 (under clinical development), and the FDA-approved CDK4/6 inhibitor,
palbociclib. Our drug panel also included vismodegib, a Hedgehog pathway inhibitor,
which was recently reported as a novel therapeutic option for T-ALL [242]. Because
bortezomib, a reversible inhibitor of 26S proteasome has been introduced into
clinical trials in relapsed/refractory T-ALL (NCT02112916), we used bortezomib as
a reference and also added a second generation, non-reversible proteasome inhibitor,
carfilzomib, to our screening library.
Drug sensitivity screening of five T-ALL cell lines revealed a differential response
to the compounds tested under normoxia conditions (Figure 4.1). Despite the
heterogeneity of the inhibitor responses, all the cell lines demonstrated high
sensitivity to six kinase inhibitors: afatinib, axitinib, crizotinib, ponatinib and
sunitinib, which induced cytotoxic responses of EC50 ≤10 µM and alvocidib (EC50 ≤1
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µM) after 72 h incubation (Figure 4.1A,C; Appendix B, Table S4.3). Interestingly,
alvocidib was the most efficacious among all the tested kinase inhibitors, with
demonstrated cytotoxic activity at EC50 ≤1 µM across all the cell lines. In addition, the
proteasome inhibitors bortezomib and carfilzomib were also effective against all TALL cells at nanomolar concentration range (EC50 ≤1 µM). Another six inhibitors
(bosutinib, cabozantinib, ceritinib, dasatinib, erlotinib and lapatinib) were efficacious
in at least three out of five cell lines tested (EC50 ≤10 µM) (Figure 4.1A; Appendix B,
Table S4.3). The remaining compounds were less potent (EC50 >10 µM), showing
selectivity against a single T-ALL cell line (e.g., vandetanib, EC50 = 3.4 µM in Loucy
cells) or did not induce a significant response in the tested cells.
To further delineate the cytotoxic activity of kinase inhibitors, we determined the
maximum response of each drug at the highest tested dose (100 µM for each inhibitor
except for alvocidib, bortezomib and carfilzomib, for which the highest tested dose
was 1 µM). As seen in Figure 4.1B, most of the tested agents effectively eradicated
leukemic cells at the highest tested concentration, indicating that their cytotoxic
activity increases substantially as the maximum tested dose was approached.
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Figure 4.1 Drug response profiles of the T-ALL cell lines.
A) Heatmap indicating the responses of five T-ALL cell lines to 31 small molecule inhibitors after 72
h incubation under normoxic conditions. The columns indicate the T-ALL cell lines and the rows
indicate the tested drugs. The color bar reflects the log10 transformed EC50 values obtained for three
independent experiments. The darkest red indicates the most sensitivity (lowest EC50 values) of the
cell lines to the tested inhibitors. EC50 values are only reported for compounds that yielded a
maximum response values of 20% or greater. For those samples which yielded maximal responses <
20% and/or had EC50 values greater than 100µM, we report those EC50 values as “>100 µM” (light
grey). B) Maximum responses of each T-ALL cell line to the small molecule inhibitors at the highest
tested dose, which was 100 µM for each drug except for *alvocidib, *bortezomib and *carfilzomib, for
which the highest tested dose was 1 µM. The heatmap shows the percentage of dead cells, where
darkest red indicates 100% propidium iodide positive cells. C) Representative high throughput dose
response curves of T-ALL cell lines to tyrosine kinase inhibitors. The cells were treated with a series
of drug concentrations (0.005 - 100 µM for afatinib, crizotinib and ponatinib; 0.05 – 1000 nM for
alvocidib) and incubated for 72 hr, followed by cell viability analyses by flow cytometry using
propidium iodide. The data represent the average of three separate experiments. Error bars denote
SEM.
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Since first described by Coustan-Smith et al., patients with early T-cell precursor
phenotype (ETP-ALL) have received much attention for their increased risk for
relapse [243]. In our study, Loucy cells, which show a transcriptional program related
to ETP-ALL, were highly sensitive to the tested drugs similar to the other four more
differentiated T-ALL cell lines (Figure 4.1; Appendix B, Table S4.3). Our results
identify attractive kinase inhibitor candidates and suggest that kinase inhibitors
might be promising targeted therapies, and are worthy of further exploration as
potential treatment options in T-ALL.

4.4.2 Hypoxia cytotoxity ratio (HCR) in T-ALL cell lines
To test whether hypoxia modulates the activity of the tested compounds, we
performed drug sensitivity profiling in T-ALL cell lines under hypoxia (1% O2). The
results were integrated with the data obtained for the cells incubated in normoxic
conditions (20% O2) as described above. The hypoxia cytotoxicity rate (HCR) for the
T-ALL cell lines (n = 5) treated with inhibitors for 72 h are presented in Figures 4.24.3 and Appendix B, Figure S4.1. Here we demonstrate that hypoxia can induce
differential responses in T-ALL cells exposed to clinically approved kinase inhibitors.
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Figure 4.2 Hypoxia Cytotoxicity Ratios (HCR) for five T-ALL cell lines treated with 31 small
molecule inhibitors.
T-ALL cell lines were incubated with the tested inhibitors for 72 h under normoxia (20% O 2) and
hypoxia (1% O2), respectively. The HCR values were calculated as EC 50normoxia/EC50hypoxia values
obtained from three independent experiments. The detailed HCR values are reported in Appendix
B, Figure S4.1. The straight line represents HCR = 1, indicating equitoxic responses of the cells under
hypoxia and normoxia. The area above the line indicates sensitivity under hypoxia (HCR > 1), while
the area under the line (HCR < 1) indicates resistance under hypoxia.
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Figure 4.3 Representative patterns of T-ALL sensitivity to kinase inhibitors in oxygen
deprived environment.
A, B) resistance under hypoxia (HCR < 1). C) sensitivity under hypoxia (HCR > 1). D) equally sensitive
under hypoxia and normoxia (HCR = 1). T-ALL cell lines were incubated with the tested drugs under
hypoxic or normoxic conditions for 72 hr. Cell survival was determined using propidium iodide
staining and HTFC. Each value represents the mean of three independent experiments. Error bars
denote SEM.

Unexpectedly, most of the tested inhibitors were generally equipotent under hypoxic
and normoxic conditions (HCR = 1; arbitrarily set to 0.8-1.2). However, specific
patterns of drug response indicative of increased sensitivity under hypoxia (HCR
>1.2) or decreased sensitivity under hypoxia (HCR <0.8) were also observed (Figures
4.2-4.3; Appendix B, Figure S4.1). Interestingly, imatinib was preferentially more
efficacious under hypoxia in all the tested cell lines (HCR 1.33 - 1.63). Sensitivity to
ruxolitinib and sunitinib was also elevated under hypoxic conditions in at least three
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out of five T-ALL cell lines. Nevertheless, several of the tested compounds including,
afatinib and crizotinib, were more active in normoxia (three cell lines or more),
suggesting decreased sensitivity under hypoxia (Figures 4.2-4.3; Appendix B,
Figure S4.1). We have not observed any specific pattern of response among the
tested drugs and cell lines since all three patterns of drug response could be observed
in many cases. For example, axitinib was less potent under hypoxia in CUTLL1 (HCR
= 0.46), Loucy (HCR = 0.62) cells, but its antitumor activity was increased under
hypoxia in CCRF-CEM (HCR = 2.11) and Jurkat (HCR = 1.30) cells (Figure 4.2,
Appendix B, Figure S4.1). Our EC50 results indicate that despite distinct HCR values
for individual drugs, the majority of the kinase inhibitors were equally sensitive or
marginally less active under hypoxia conditions in the tested T-ALL cell lines. This
was consistent with the observation of reduced cell survival at the maximum tested
dose under hypoxia (Appendix B, Figure S4.2). The results of our study indicate that
hypoxic T-ALL cells are highly responsive to kinase inhibitors and should be further
investigated in the context of hypoxia sensitive therapies in T-ALL. Further studies
will be required to determine the effects of other tumor microenvironment factors
such as adhesion molecules or extracellular matrix components on drug sensitivity in
leukemia. Our results underscore the potential importance of hypoxia testing in drug
profiling studies and provide compelling evidence for the application of HTFC to
search for hypoxia selective drug candidates.
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4.4.3 Drug sensitivity screening in T-ALL primary samples and PDX
With evidence that kinase inhibitors are effective against T-ALL cell lines, we next
utilized our platform to evaluate drug sensitivity in T-ALL primary samples (n = 2)
and patient derived-xenografts (n = 5). Primary tissue is often considered a limiting
factor in high throughput studies, which require a high number of cells. In this study,
we utilized PDX models of T-ALL, which were shown to better preserve both the
genomic integrity and the tumor heterogeneity observed in patients [244]. Therefore,
PDX models are proposed as an attractive alternative strategy for drug profiling
studies when sufficient primary tissue is not available. We tested a small set of T-ALL
samples for which phenotypic and genomic data were available (Appendix B, Table
S4.1). Patient and PDX samples were subjected to high-throughput flow cytometry
screening for sensitivity to 31 small molecule inhibitors under conditions described
in Material and Methods. Untreated cells demonstrated excellent cell viability in
serum-rich monoculture, which varied between 70-95% up to 72 h incubation
(Appendix B, Table S4.4), which was comparable to the viability of the T-ALL cell
lines.
We observed that the sensitivity of T-ALL cells to kinase inhibitors was
heterogeneous but also sample-dependent (Figure 4.4). Primary cells and PDX
models were less sensitive to kinase signaling inhibition compared to the cell lines
(Figures 4.1, 4.4). This is consistent with previous studies showing that primary
samples or relevant PDX are more resistant, and often respond differently, to
investigational agents in comparison to cell lines [6, 245]. T-ALLs with ETP phenotype
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and/or harboring MLLT10 and/or KMT2A gene rearrangements are slowly
proliferating leukemias, which often present stem-like features. PDX obtained from
such patients were included in our sample set (Appendix B, Table S4.1). Cell
stemness and a low proliferation rate may affect cellular responses to drugs whose
cytotoxic activity relies on the proliferative activity of the leukemic cells. Such
differences in cell proliferative activity may also affect engraftment kinetics [244]. In
our study, PASGJG, which was insensitive to the tested inhibitors, engrafted more
slowly than PATZZM or PASNXS, which were more sensitive to the tested agents (data
not shown). Secondly, we observed that the primary specimens (12-089 and 15-093)
had an overall better response to kinase inhibitors compared to PDX (Figure 4.4B).
This interesting observation needs to be further explored, considering the relatively
small sample size in our study. Recent data indicate that PDX maintain oncogenic
translocations and preserve ~75% of the genomic lesions initially identified in
patients [244]. However, PDX undergo mouse-specific tumor evolution, which is
comparable to that of cell lines, but still may affect drug response [246].
Among the PDX samples, PATRAP and PATZZM were more sensitive to the tested
drugs than PASNXS (Figure 4.4). PASGJG and PASSPP were resistant to all the tested
inhibitors, suggesting that some T-ALL samples demonstrate high resistance to
kinase signaling inhibition, which can be associated with kinome reprograming
and/or adaptive bypass response leading to drug resistance [247]. This may also be
related to the genetic and molecular features of the tested cells. Some of our PDX
models were developed from samples that harbor genomic lesions e.g. KMT2A gene
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rearrangements, which are associated with high-risk and refractory disease
(Appendix B, Table S4.1) [232, 248].

Figure 4.4 Response of T-ALL primary samples (n = 2) and patient derived xenografts (n = 5)
to small molecule inhibitors (n = 31).
A) The heatmap represents the mean EC50 values obtained for the samples treated with the drugs for
48 h under normoxic conditions. The columns indicate T-ALL samples and the rows indicate the
tested drugs. The darkest red indicates the most sensitivity (lowest EC 50 values) of the tested samples
to the tested inhibitors. EC 50 values are only reported for compounds that yielded a maximum
response values of 20% or greater. For those samples which yielded maximal responses < 20%
and/or had EC50 values greater than 100 µM, we report those EC50 values as “100 µM” (light grey).
B) The maximum responses of each T-ALL sample to the tested inhibitors at the highest tested dose,
100 µM, with exception of *alvocidib, *bortezomib and *carfilzomib, for which the highest tested dose
was 1 µM. The heatmap indicates the levels of percentage of dead cells, where darkest red indicates
100% PI-positive cells. C) Representative high throughput dose response curves of T-ALL samples
(primary samples, 12-089 and 15-093; patient derived xenografts, PATRAP, PATZZM) treated with
the tested inhibitors. The cells were treated in dose responses (afatinib and sunitinib, 0.005 - 100
µM; carfilzomib, 0.05 – 1000 nM) for 48 hr, followed by cell viability analyses by flow cytometry using
PI.
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Interestingly, several samples demonstrated decreased sensitivity at 72 h
compared to 48 hr, which might be related to the heterogeneous and clonal
architecture of the tested samples, and/or induction of spontaneous cell death,
and/or induction of quiescence in some cell subpopulations of T-ALL (Figure 4.4;
Appendix B, Figure S4.3). Sensitivity to afatinib and sunitinib (EC50 ≤10 μM) was
detected in five out of seven tested T-ALL samples (~70% samples) after 48 h
incubation (Figure 4.4, Appendix B, Table S4.5). Bortezomib, which is currently
being tested in the COG AALL1231 clinical trial (NCT02112916), had no activity in the
tested cells (the highest concentration tested was 1μM), compared to carfilzomib, the
second generation proteasome inhibitor that was highly efficacious (EC50 ≤1 μM) in
the T-ALL patient samples and PDX (five out of seven samples) (Figure 4.4A,C,
Appendix B, Table S4.4). In addition, ponatinib and crizotinib were efficacious
against at least three out of seven samples (~42%), with the lowest EC50 values
observed for PASNXS (ponatinib, EC50 = 1.92 µM; crizotinib, EC50 = 0.69 µM) (Figure
4.4A; Appendix B, Table S4.5). Strikingly, selumetinib was uniquely selective
against PASNXS (EC50 = 2.70 µM) while dasatinib was preferentially effective in
PATRAP (EC50 = 2.43 µM) (Figure 4.4; Appendix B, Table S4.5A). The analyses of
the maximum responses of the tested inhibitors at the highest concentration tested
further revealed the high heterogeneity of the drug responses (Figure 4.4B).
Although the patient and PDX samples were overall less sensitive to the tested drugs
compared to the cell lines, similar trends of drug response were observed (Figures
4.1B, 4.4B). With a few exceptions (e.g. axitinib, erlotinib), the inhibitors which were
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found to be the most potent against T-ALL cell lines, induced a decrease in T-ALL cell
survival at the highest tested concentration across the majority of the samples (e.g.
afatinib, ponatinib, sunitinib). In addition, we investigated the sensitivity of normal
peripheral blood mononuclear cells to the tested inhibitors. We found that the most
potent inhibitors were also cytotoxic towards normal cells, indicating that they were
not specific to leukemic cells (Appendix B, Figure S4.5).
Our observation that several T-ALL samples were generally more susceptible to
multiple kinase inhibitors (Figure 4.4) strongly supports the rationale for targeting
the deregulated kinome in T-ALL. However, it is worth noting that most of the tested
samples were highly selective towards one or a few specific inhibitors, suggesting
that high-throughput drug screening may rapidly detect unique sensitivities of
individual patient cells to the tested drugs [236]. Our data underscore the roles of
personalized medicine in the development of modern therapies in T-ALL.
Recently, two independent reports implicated dasatinib as a novel targeted
therapy in a subset of T-ALL [244, 245]. While dasatinib was effective against our
tested T-ALL cell lines, only one T-ALL sample was preferentially sensitive to this
inhibitor in our study (Figures 4.1 and 4.4). Interestingly, there were other
promising inhibitors that demonstrated greater activity against T-ALL cells than
dasatinib, and are worthy of further investigation (Figures 4.1, 4.4). One interesting
observation in this study was sensitivity to cyclin dependent kinase inhibition.
Alvocidib (CDK7/CDK9 inhibitor), which is currently under development as a
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combination therapy for AML (NCT01349972, NCT02520011)[249], was efficacious
against T-ALL cell lines and some patient samples (Figures 4.1, 4.4).
The results of our study also indicate that T-ALL cells show good response to
several TKIs, which target multiple kinases including PDGFR, VEGFR (ponatinib,
sunitinib, axitinib), EGFR (afatinib), ALK (ceritinib, crizotinib) (Figures 4.1, 4.4).
Although preliminary, these findings provide a foundation for future studies on
targeting the T-ALL kinome by FDA-approved multi-target inhibitors. It will be
critical to test active agents in murine models of T-ALL, either genetically engineered
or injected with PDX.
Overall, our analyses show that T-ALL samples were less sensitive than the cell
lines. Importantly, our approach includes culturing T-ALL primary samples and PDX
at 10% FBS and 10% human AB serum concentration. Serum may sequester drugs via
their binding to serum proteins and therefore limit their cytotoxic response.
Furthermore, the growth factors present in the culture medium may accelerate prosurvival signaling as opposed to serum-free culturing systems, which may affect cell
metabolism and eventually sensitize the cells to the tested agents. Taking this into
account, it would be critical to establish the minimum levels of serum facilitating drug
response profiling without compromising cell viability in our monoculture systems.
We successfully utilized a conditioned medium from stromal cells to maintain the
viability of B-ALL cells in our previous reports [6]. Frismantas et al. [244] have
recently reported serum free co-cultures of PDX and/or primary cells on hTERTimmortalized mesenchymal stroma cells as a novel strategy to facilitate the survival
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of ALL cells, including T-ALL. The authors postulated that stromal co-cultures are
better predictors of drug response in the context of in vivo validation studies. Still,
they were able to demonstrate a significant correlation between both serum-free coculture and serum-supplemented monoculture systems.
The results of this study demonstrate that a flow cytometry-based PI screen can
be effectively used in HTFC to identify small molecule inhibitors as a targetable
therapy in T-ALL. Common plate reader-based viability assays, such as MTT and
CellTiter Glo, require cell lysis, and thus provide only one metric from a treated
sample. In contrast, a flow cytometry approach with PI allows for rich information to
be collected from a treated sample in addition to simple viability assessments. Flow
cytometry enables particle count and analysis of a sample on a cell-by-cell basis, and
hence, drug effects within a heterogeneous population may be determined
(Appendix B, Figure S4.4). The PI assay used here provided phenotyptic analysis of
the TKI-treated T-ALL cells. Our data suggest that primary patient samples can be
screened within 72 hours and yield results that may inform personalized therapies
with the potential to compare drug activity on PBMC (Appendix B, Figure S4.5) and
patient samples (Figure 4.4) to circulating drug levels (Appendix B, Table S4.2)
(See, for example, the potential of sunitinib to provide a therapeutic window between
PBMC and patient sample with an achievable dose). Thus, our approach provides a
reproducible tool for functional screening and novel therapeutics.
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5.1 Abstract
Classical therapeutic regimens are subject to toxicity, low efficacy, and/or the
development of drug resistance. Thus, the discovery of synergistic drug combinations
would permit treatment with lower, tolerable dosages of each agent and restored
sensitivity. We describe the development and use of the SynScreen software
application, which allows for visual and mathematical determinations of compound
concentrations that produce super-additive effects. This software uses non-linear
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regression fits of dose-responses to determine synergism by the Bliss independence
and Loewe additivity analysis models. We demonstrate the utility of SynScreen with
data analysis from in vitro HTFC combination screens with repurposed drugs and
multliplexed synergy analysis of multiple biologic parameters in parallel. The
applicability of SynScreen was confirmed by testing open-source data sets used in
published drug combination literature. A key benefit of SynScreen for highthroughput drug combination screening is that observed measurements are
graphically depicted in comparison to a three-dimensional surface that represents
the theoretical responses at which Bliss additivity would occur. These images and
summary tables for the calculated drug interactions are automatically exported. This
allows for substantial data sets to be visually assessed, expediting the quick
identification of efficacious drug combinations, thereby facilitating the design of
confirmatory studies and clinical trials.

5.2 Introduction
Drug discovery research is progressively moving toward the identification of
combinations which interact synergistically by both targeted and unbiased screening
approaches. There are multiple motivations for pursuing these efforts. The
predominant paradigm is that drug combinations could decrease the incidence of
refractory and resistant disease responses to treatment. Off-patent and generic drugs
may be repurposed for use in combinations to elicit responses more favorable than
their use individually. Recent studies have illustrated the advantages of multi106

targeted drug combinations that do not have synergistic interactions [250]. However,
synergistic drug interactions could potentially reduce the dosages and duration of
treatment required for therapeutics with adverse side effects. Furthermore, some
hypothesize that the nature of targeted drug interactions may provide an indication
of potential crosstalk between biological pathways [251, 252]. The experimental
designs for drug combination studies are fairly straightforward. In these strategies,
drugs are tested with concentrations in fixed or non-fixed ratios, and the latter
approach may be expanded into matrix or factorial arrays. The analysis of drug
combinations used simultaneously or sequentially may provide contradicting
outcomes, the results of which could provide insight into the mechanistic nature of
the drug interactions.
Drug interactions with respect to synergy are generally determined by the
following methods: Highest Single Agent (also referred to as Gaddum non-interaction
effect)[253], Bliss independence model [254], and Loewe additivity model [255], an
application of which is the median effect analysis developed by Chou-Talalay [256].
Additionally, combination data may be compared to single agent dose-responses by
isobolograms, combination thresholding, curve shift analyses, or by zero-interaction
potency [257, 258]. There are both benefits and disadvantages for each model, and
therefore it is practical to use multiple analyses to reliably determine synergism. For
in-depth descriptions of these models, their advantages and constraints, please see
the review by Foucquier and Guedj [257].
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While technology has allowed for HTFC screening of vast, multiple drug
combination testing, there are few resources that facilitate the assessment of high
throughput (HT) results, thus creating a bottleneck for the validation of drug
interaction data toward preclinical studies. There is currently a myriad of free
(Combenefit [259], CompuSyn [260], MixLow [261]) and commercial (CalcuSyn,
Chalice™, Genendata Screener®) software available for drug combination analysis.
Please refer to Table 1 in Di Veroli, et al. [259] Fortunately, most such applications
provide analyses by multiple means. However, one limitation of evaluating HT drug
combination data is due to the means by which the data are displayed, typically in
tables or two-dimensional graphs [262, 263]. The visualizations of such drug
combination analyses are unintuitive, and require thoughtful assessment prior to the
determination of specific compounds and concentrations that will be pursued in
confirmatory assays. This is especially problematic for drug combinations tested in
matrices, wherein some of the breadth of the results can be lost with two-dimensional
representations. Consequently, response surface approaches have proven useful to
display results of matrix combination testing [258]. Nonetheless, many of these
common methods require that the user view single agent or predicted noninteraction responses separately from observed drug interaction data.
Here, we introduce a novel application for drug combination analysis that is
especially

utile

for

the

implementation

of

HTFC

data,

SynScreen

(https://github.com/bestwards/FlowProg). An unlimited amount of normalized
assay data from single or multiple screening runs can be imported and analyzed by
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multiple drug interaction models. The results are plotted in real-time and provide
three-dimensional simultaneous visualizations of both observed single and
combination drug responses in comparison to a response surface that corresponds to
a theoretical threshold of additivity. These graphics are automatically exported, and
can be collated to allow for the quick assessment of synergy, thus expediting the
process of triaging hit drug combinations for further confirmatory assays.

5.3 Materials and Methods
5.3.1 Development of the SynScreen application
SynScreen was implemented as a graphical user interface (GUI) package to be
used within MATLAB software (Mathworks, Natick, MA). A copy of the software will
be available from the authors on request.

5.

5.3.1.1 Data normalization and curve fitting

Two models were used to evaluate the possibility that a combination of two
compounds resulted in a response that was additive, greater than additive
(synergistic) or less than additive (antagonistic). Both models rely upon nonlinear
curve fits to dose-response data produced by single compounds.
First, response data were normalized to controls such that the negative control
produced the minimum response (e.g., 0% cytotoxicity in presence of DMSOcontaining diluent alone) and the positive control represented the expected maximal
response (e.g., 100% cytotoxicity):
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normalized fa = (DRUGXfa - ncntrlfa) / (pcntrlfa - ncntrlfa)

in which DRUGXfa, ncntrlfa and pcntrlfa are the fractional responses observed in the
wells containing test compound, negative controls and positive controls, respectively.
Note that SynScreen assumes that the data will be normalized such that responses
will increase with increasing compound concentration. If compounds are expected to
inhibit the assay response then:

normalized fa = 1 - [(DRUGXfa - ncntrlfa) / (pcntrlfa - ncntrlfa)]

Normalized responses < 0 were recoded as 0 prior to curve fitting.

Curves were fitted with MATLAB software using non-linear least squares regression
in a sigmoidal dose-response model, the four parameter logistic equation, in which
the top, bottom and slope of the fitted curve were allowed to vary.

6.

5.3.1.2 Bliss Independence model calculations

The Bliss Independence model assumes that the effects of compounds are
probabilistic processes in which the activity of each compound is independent of the
other, but each contributes to a common result. The additive effects of two
compounds are thus predicted by the equation:
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Blissfa = DRUG1fa + DRUG2fa - DRUG1fa * DRUG2fa

in which DRUG1fa and DRUG2fa are the normalized fractional responses produced by
compounds 1 and 2 acting as single agents (determined from curve fit equations) and
Blissfa is the observed fractional response resulting from the two in combination.
MATLAB software was used to create a three-dimensional surface representing the
response predicted for each combination as if it was additive according to the Bliss
Independence model. Responses to individual combinations projecting above the
surface were considered greater than additive (potential synergy) and below the
surface less than additive (potential antagonism). A global combination response
parameter, the Bliss Beta coefficient, was also calculated as the slope of a linear least
squares fit to the predicted (x-axis) vs. observed (y-axis) responses for all
combinations.

Data normalized as described above (response increasing with

increasing compound concentration) will result in a Beta coefficient > 1 indicative of
synergy, < 1 indicative of antagonism and equal to 1 indicative of additive effects.
Curve fit statistics were also used to estimate a 95% confidence interval for the Bliss
Beta coefficient.

7.

5.3.1.3 Loewe Additivity model

The Loewe Additivity model assumes the dose equivalence principle in which, for
a given response produced by a dose of compound 1, there is a dose of compound 2
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that can produce the equivalent response. The model predicts the following
relationship if the effects of two compounds are additive:

DRUG1uM / DRUG1uMfa + DRUG2uM / DRUG2uMfa = 1

in which DRUG1uM and DRUG2uM are the actual doses (uM) of compounds 1 and 2
used in combination, and DRUG1uMfa and DRUG2uMfa are the doses of compounds
1 and 2, when applied as single agents, that are required to attain the response
produced by the combination. The latter two dose parameters are calculated using
coefficients from the single agent dose-response curve fits. The sum of the two dose
ratios is referred to as the combination index (CI). A CI < 1 is indicative of synergy
and CI > 1 of antagonism. A CI = 1 is considered additive.
The Loewe Additivity model is best applied to compounds that produce doseresponse curves with parallel slopes and equal individual response maxima.
However, it is often the case that there will be a regime of combinations in which the
response produced by the combination cannot be reproduced by the compounds
when applied as single agents (e.g., when response maxima of either or both of the
compounds are limiting). In such a case, a CI cannot be calculated and is designated
as out of range (OOR). SynScreen displays the CI, as well as components of the CI
calculation in the results table including doses used (DRUG1uM, DRUG2uM), single
agent doses required to produce the observed combination response (DRUG1uMfa,
DRUG2uMfa), and the dose ratio of each compound (DRUG1uMratio =
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DRUG1uM/DRUG1uMfa, DRUG2uMratio = DRUG2uM/DRUG2uMfa) (Appendix C,
Table 5.1). If any of these elements involves a value of DRUGXfa that is out of range
it is given the OOR designation.

5.3.2 HTFC Assays and Data Collection
Unless otherwise noted, compounds and reagents were purchased from SigmaAldrich (St. Louis, MO). The leukemia cell lines U937 and RS4;11 were acquired from
ATCC (Manassas, VA). These cell lines were cultured in RPMI-1640 medium
supplemented with 2 mM L-glutamine, 100 U/mL penicillin-streptomycin and 10%
heat-inactivated fetal bovine serum and incubated in a humidified atmosphere with
5% CO2 at 37°C. Freshly-washed cells were resuspended in medium at 5x105 cells/mL
and used in 10 µL 384-well assays (final cell density = 5000/well). The HTFC
cytotoxicity screen consisted of twenty-five drug combinations, composed of five
previously-identified repurposed drugs [6] paired with five known chemotherapeutic
agents, tested in 64-well matrix arrays. The apoptosis assay consisted of drug pairs
tested in 9-point 1:1 and 1:2 fixed ratio dose responses. The drugs were added with
the Echo® 555 Liquid Handler (Labcyte, San Jose, CA) into 384-well plates (Greiner
Bio-One 784201, Monroe, NC) to a final DMSO concentration of 1%. To prevent excess
evaporation and to optimize conditions, the assay plates were flushed with ambient
air and sealed with a PlateLoc Thermal Microplate Sealer (Agilent, Santa Clara, CA)
prior to incubation. The cytotoxicity plates were incubated for 48 h, and the apoptosis
plates were incubated 2-24 h. The propidium iodide (PI) cell viability assay was
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performed as previously described [11], and the MultiCyt Apoptosis Kit (IntelliCyt,
Albuquerque, NM) was used according to the manufacturer’s protocol. HTFC data
were collected with a HyperCyt® platform (IntelliCyt) configured to an Accuri C6 Plus
flow cytometer (BD Biosciences, Franklin Lakes, NJ). The .fcs data were resolved and
annotated with HyperView software (IntelliCyt).

5.3.3 Preparation of Data for SynScreen Analysis
The preparation of data files for import into SynScreen is similar to methods used
by most HTFC laboratories. After an HTFC assay, the data are exported in Flow
Cytometry Standard (FCS) format and analyzed on the basis of air gap-dependent
interruptions in the temporal flow of cells to identify the wells from which the cells
were sampled [264]. Once the data are annotated for the contents and concentrations
in each well, the observed response values are then normalized in comparison to
responses recorded from cells in control wells. We generally normalize our data such
that the mean %viability of cells in wells containing diluent alone (e.g., DMSO) for
each assay plate = 100% viability for the compound-treated samples. The normalized
data are organized in a Microsoft Excel spreadsheet containing four columns that
describe the nature of the drugs and concentrations tested: 1) agent/combo IDs, 2)
concentrations tested for DRUG1, 3) concentrations tested for DRUG2, and 4)
response (see Appendix C, Figure S5.1). The spreadsheets were then imported into
SynScreen and the data were analyzed as described below.
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5.3.4 SynScreen Software Determination of Drug-Drug Interactions in HTFC Data
SynScreen analysis begins with entering the range of data within the spreadsheet
file that is then imported into the software (Appendix C, Figure S5.1). The single
agent data are automatically fit by nonlinear regression and analyzed, although the
user should manually evaluate the dose-response curves to exclude outliers and
ensure goodness of fits (Figure 5.1A). The dose-responses from single agents are
visualized individually, and metrics for the data (total points), fit (r2 value, slope, top,
bottom), and EC50 are determined by the software and the tables are automatically
exported (Appendix C, Table S5.2). Outliers may be selected and excluded from
further analysis and the data output can be updated by the “UpdateSingles” button.
The minFahit (%) box allows for a minimum response threshold to be set for the
determination of synergy “hits” from the combination data, e.g., only data points in
which 20% or more of cells respond to the drug combination are considered for the
summaries of synergistic hits.
For each drug combination, a three-dimensional surface is generated based on
the Bliss prediction of additivity from the single agent dose-responses (left panels of
Figure 5.1B,C). Observed data for a combination are plotted, and either the average
from repeated measures or all points from each run may be displayed. The threedimensional graphs may be rotated within the application interface to allow for better
viewing of the observed data. This is especially helpful for the visualization of data
with efficacies below the Bliss surface. Moreover, SynScreen mathematically
determines a global combination response parameter, the Bliss Beta coefficient,
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calculated as the slope of a linear least squares fit to the predicted (x-axis) vs.
observed (y-axis) responses for all combinations (right panels of Figure 5.1B,C). A
Bliss Beta coefficient > 1 is indicative of synergy, < 1 indicative of antagonism and
equal to 1 (black line in Figure 5.1B,C) indicative of additive effects. Curve fit
statistics were also used to estimate a 95% confidence interval for the Bliss Beta
coefficient (right panels of Figure 5.1B,C). Data points for single drugs and drug
combinations can be reversibly excluded from the analysis in real time to evaluate,
for example, effects of removing statistical outliers.
The analyzed data are automatically saved and exported by SynScreen. The
images for each combination’s three-dimensional response data and Bliss/ noninteraction threshold evaluations are exported as individual files. A summary .docx
file is generated that contains statistics for all screened drug combinations contained
in the imported data file, providing a basic overview of the number of synergistic data
points determined by Bliss independence and combination index analyses
(Appendix C, Table S5.3). This table provides an overview of all combinations
analyzed in a data set, and facilitates the identification and ranking of drug pairs and
their resultant interactions from a screen. Furthermore, for each drug combination,
SynScreen tabulates metrics for all potentially synergistic data points, and it
annotates: 1) the method(s) by which synergism was determined (Bliss and/or
combination index); 2) the doses of each agent which interacted synergistically; 3)
the differences between the observed effects and theoretical values for Bliss
additivity; 4) the ratio of the concentration used in a combination relative to the single
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agent concentration that elicited the same response; and 5) indications of
combinations for which the Loewe Additivity model CI is not applicable due to
combination responses out of range (OOR) relative to single agent dose-response
curve fits (see Methods, Table 5.1, Appendix C, Table S5.4). For each drug pair,
SynScreen automatically creates .docx files containing the data response graph and a
table with the aforementioned metrics for each data point tested, as well as .jpg files
of the three-dimensional and Bliss threshold plots.
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Figure 5.1 SynScreen facilitates the assessment of drug combination effects from an HTFC
screen.
U937 acute myeloid leukemia cells were screened in 384-well plates with 5 repurposed drugs [6]
paired with 5 known chemotherapeutics in 64-well arrays, totaling 25 drug pairs. After 48 h
incubation, cell viability was assessed with an HTFC propidium iodide (PI) assay [11]. The .fcs data
were analyzed with HyperView software and normalized %PI-positive data from four independent
experiments were imported into SynScreen. Shown is an example of one drug pair tested, clioquinol
(CQL) and cytarabine (AraC). A) The measured responses and nonlinear regression fits for the
individual drugs. Outliers were excluded to improve the fit of the curves where applicable (“x”
symbols). B) Graphs of the drug combination responses, showing the results from n = 4 experiments
with single replicates each. Left, the multicolor surface represents the theoretical responses at
which Bliss additivity would occur based on the dose-response curves in (A). The red dots indicate
the replicates of the observed experimental data. The z-axes range from 0-100% PI-positive
responses (cytotoxicity). The x and y axes are plotted as log µM. The multicolor surfaces represent
the theoretical responses at which Bliss additivity would occur. Most results visible above the
surface are determined to be potentially synergistic. Right panel, plots of responses predicted based
on the Bliss Independence model versus responses observed in the presence of each drug
combination. The Bliss Beta coefficient was estimated as the slope of the line (green) of best fit to
the relationship between predicted and observed responses. A 95% confidence interval for the
coefficient is indicate in parentheses. C) The mean observed responses from (B) are plotted. The
visualizations from (B) and (C) provide insight into the reproducibility of data from multiple
screens.
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Table 5.1 Synergistic effects of the repurposed compound, clioquinol, with a conventional
cytotoxic drug, cytarabine.
Shown are the hit synergistic data points from the data in Figure 5.1. See Appendix C, Table S5.1 for
an explanation of the reported metrics. CQL, clioquinol, AraC, cytarabine.
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5.3.5 Validation of Synscreen and Application to Other Screening Platforms.
Normalized dose-response and combination data were obtained from the drug
combination study published by Borisy, et al. [1]. There, compounds were tested in
10 x 10 matrices in 384-well plates and analyzed for inhibition of cell proliferation.
For integration into SynScreen, the data were organized into a Microsoft Excel
spreadsheet with columns (see above; Appendix C, Figure S5.1).

5.4 Results and Discussion
5.4.1 Validation of SynScreen Analysis for HTFC Assays
We previously identified a set of repurposed drugs with activity against leukemia
cells [6]. To progress the research forward, we elected to test these drugs pairwise
with known leukemia therapeutics. Hence, we adapted a HTFC viability assay [11] to
quantify the effects of the 25 drug pairs tested in 64-well matrix arrays. The
normalized data from four independent experiments were combined and imported
into SynScreen for analysis. Data from one drug combination, clioquinol and
cytarabine, are shown in Figure 5.1. The dose-response data for the individual drugs
were fit by nonlinear regression, and outliers were removed to improve the fits
(Figure 5.1A). Furthermore, the reproducibility of the data from multiple biological
replicates was evaluated by the proximity of observed responses to one another
(Figure 5.1B) or by visualization of the means from all replicates (Figure 5.1C).
Synergy was evident for most paired concentrations below the maximal single agent
concentrations, in the effect ranges 10-90%. Table 1 describes the synergistic data
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points from this drug combination. A summary of the combination synergy statistics
from the full screen can be seen in Appendix C, Table S5.3. All the combinations
tested indicated hits for synergy, and twelve drug pairs scored with Bliss Beta > 1.
Furthermore, over half the tested drug combinations produced CI values < 0.1. These
metrics served to guide the compositions that should be further investigated. To
further validate our findings, we processed the HTFC data from the drug pair with
Combenefit [259] software. Those analyses determined similar concentration regions
as synergistic that were identified with SynScreen. The discrepancies between
software results are likely due to fact that the Combenefit software demonstrated
poor goodness of fit for the dose responses of the individual agents. Combenefit did
not allow for extended dose response data, including replicates, for the single agents
to be imported for analysis. For a comparison of SynScreen to Combenefit and
CompuSyn applications see the discussion in SynScreen Facilitates Drug Combination
Analysis.
The utility of SynScreen for the analysis for multiplex HTFC drug combination
assays was also tested with data from an assay wherein drug pairs were tested in
fixed concentration ratio dose-responses to identify the outset and order of cell death
responses induced by the compound interaction. SynScreen analysis was able to
determine synergism between the repurposed agents cryptotanshinone and
vardenafil within the four apoptosis endpoints collected by flow cytometry data
(Figure 5.2). Hence, the use of SynScreen for the evaluation of drug combinations
tested via HTFC by multiple assay approaches (fixed ratio, matrix, and multiplex) was
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validated. The results allowed for an effective visual assessment of the tested
combinations and the identification of efficacious drug pairs and concentrations. This
feat would not have been easily accomplished through analysis by other software
applications, which would have required considerable reformatting of HTFC data
prior to analyses. While we report here the use of SynScreen for phenotypic flow
cytometry assays, the analysis capabilities should be applicable for functional assays
as well.

5.4.2 Application of SynScreen Analysis to Other Screening Platforms
The utility of the SynScreen application was further evaluated by analyzing a
published set of drug combination data wherein synergistic interactions were
identified. Data published from a screen for antiproliferative drug combinations by
Borisy, et al. [1] were imported into SynScreen and analyzed to determine synergistic
interactions. We additionally analyzed the data set with Combenefit [259]. The
original publication identified 63 responses over Bliss additivism, whereas SynScreen
identified 56 points and Combenefit identified 59 points. The sum of the differences
between the responses and the predicted thresholds determined by Borisy, et al. [1]
was 801, and the totals from SynScreen were 522 and 577, respectively. The results
of the analyses are shown in Appendix C, Figure S5.2. These variations in data
between applications are most likely due to the fact that some of the observed
response data (percent inhibition) were negative values, and SynScreen converts
negative response values to zero prior to analyses. Although SynScreen analysis did
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not produce results identical to those published, it identified the same drug
combination regions in which responses exceeded Bliss additivity (compare Figure
5.3 here to Figure 4 in the original study [1]). Nonetheless, SynScreen analysis
recapitulated the findings of established drug combination data, confirming its
general applicability for the determination of synergistic drug interactions.

Figure 5.2 An example of SynScreen analysis of multiplex HTFC drug combination data.
RS4;11 cells were screened in 384-well plates with the drug pair cryptotanshinone + vardenafil
tested in duplicate with 1:1 and 1:2 fixed ratios and incubated for multiple time points before
conducting the MultiCyt® 4-Plex Apoptosis assay. The .fcs data were analyzed with HyperView
software. The multicolor surfaces represent the theoretical effects at which Bliss additivity would
occur. The red dots indicate the observed experimental data. The assay determined changes in the
apoptotic endpoints mitochondrial depolarization (loss of Δψ m), annexin-V binding to
phosphytidylserine expression on the cell membrane (PS surface expression), caspase 3/7
activation, and cell membrane damage (loss of cell viability) to provide an indication of the order
and timing of cell death events induced by the drug combination. The z-axes range from 0-100%
positive responses for each endpoint. Data points visible above the three-dimensional surface
approximate the degree of synergy evident for each concentration pair.
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Figure 5.3 Validation of SynScreen analysis of drug combination effects and the
determination of synergy.
Single agent and drug combination data from a published drug combination data set from Borisy, et
al. [1] were imported into SynScreen for analysis. The resulting graph and software-derived metrics
recapitulate the results for synergistic data points that were reported by the original authors. A)
Graphical illustration of observed inhibition responses in comparison to theoretical additivity. The
x and y axes are plotted as log µM. The multicolor surface represents the theoretical responses at
which Bliss additivity would occur. The red dots indicate the observed experimental data. Most
results visible above the surface were determined to be synergistic (see Appendix C, Table S5.4).
B) A plot of drug combination observed versus predicted responses based on single agent doseresponses. The Bliss independence model used to determine a threshold for synergy for the range
of response values. The symbols represent the observed response values in comparison to the
predicted additive outcome which would produce the same response.
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5.4.3 SynScreen Facilitates Drug Combination Analysis
A considerable benefit of HTFC is the ability to concurrently assess multiple
parameters. Therefore, it is vital that software applications for HTFC data analysis be
compatible with data from a variety of assay types and formats. Unfortunately, few
adequate applications are amenable for HTFC drug combination data, which must be
processed to isolate specific population(s) and responses for each parameter
measured. The annotated data are typically tabulated in list formats which are not
readily suitable for drug combination software packages specifying that data be
arrayed in matrices [259], with responses from each drug positioned in rows and
columns. The need to reorganize HTFC drug combination data to use such
applications would limit the throughput of data generated from HTFC experiments.
Additionally, some drug combination analysis programs stipulate that only data from
fixed concentration ratios be entered [261]. This restricts the breadth of data that can
be collected from robust methods such as HTFC. Furthermore, results from drug
combination analyses are often presented in two-dimensional diagrams, such as
heatmaps, dose-response x,y graphs for each concentration ratio tested, or tables of
synergy statistics [1, 262], and therefore quick interpretation of the data may not be
straightforward.
Using the open-source combination analysis software Combenefit [259] and
CompuSyn [260], we analyzed a selection of our HTFC data from a cytotoxicity assay.
The use of both applications required extensive reformatting of the HTFC data.
CompuSyn has no limits on the numbers of data points entered for each drug and
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combination, but requires that the response data be converted into fractional form 01 before each data point was entered into the software manually. CompuSyn uses
linear fits in the median effect plots for individual dose responses, which are not
amenable to data with various slopes without the deletion of several data points.
Conversely to SynScreen, where normalized data from negative controls are set to the
minimum response (e.g., 0%), Combenefit requires that normalized negative control
values equal the maximum response (e.g., 100%). The application also necessitates
that data be positioned in matrices, and is an ideal application for use with plate
reader-based data. Because HTFC data often exists in columns and data from specific
drug combinations do not necessarily appear sequentially, it took a considerable
effort to reconfigure the data into such matrices. Furthermore, the data from each
combination and replicate had to be saved into separate .xls files prior to import into
Combenefit. Because synergy analyses rely heavily upon comparison of combination
vs single agent data, we collected robust dose responses (more doses and smaller
dilution factors) for single agents, in replicate, in our screen. We were unable to enter
the replicate data or values from the extended dose response ranges of the single
agents in our data, as the Combenefit software constrains data from individual drugs
to match the tested concentrations used in combinations. Neither CompuSyn nor
Combenefit allowed for real-time editing of data through their interfaces.
The utility of SynScreen overcomes some of the aforementioned limitations
encountered by some drug combination analysis software packages. There is no
limitation on the quantity of data imported for analysis, and data from multiple
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replicates can be incorporated into a single analysis. Furthermore, HTFC data are
compatible with a columnar output configuration that can be directly loaded into
Excel (or CSV) files to facilitate SynScreen analysis. To expedite data processing, the
application interface was developed to enable all aspects of drug combination
analyses to be visualized in real-time. Because synergism can only reliably be
determined by comparison of combination responses to those of each compound
alone, it is imperative that researchers use dependable dose-response curves for
single agent responses. Therefore, SynScreen automatically displays single agent
dose-responses and nonlinear regression curve fits so that aberrant data points can
be excluded to improve the fit of the data (Figure 5.1A). The application produces
visualizations of the data in three dimensions to allow for simultaneous assessment
of the combination responses in relation to the individual drug responses and the
theoretical threshold of additive interactions (Figure 5.1B, C). The combination data
are analyzed by the Bliss independence and Loewe additivity combination index
models to validate data points that produce synergy. These metrics, as well as
graphical representations of the data, are automatically output into common file
formats, and can easily be adapted for further data processing and prioritization.

5.4.4 Limitations of the SynScreen Software Application
Like many drug combination analysis applications, SynScreen is currently
designed for the analysis of drug pair interactions. The annotated drug
concentrations are required to be in micromolar units. Likewise, the imported
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normalized response data should be recorded in values from 0-100% (or 0-1 in
fractional form) in which the normalized response increases with drug concentration.
Due to this normalization, single agent dose-responses must be tested with enough
data points to provide robust curves. The software does allow for data with
normalized responses of less than 0% to be present in the source file, although these
values are automatically set to equal zero, and thus some dose-responses may appear
with reduced efficacy ranges. Moreover, the artificial weighting of all negative values
to zero may mask noise in these data. One additional limitation of both SynScreen and
other commonly-used drug combination analysis platforms that determine synergy
by classical models is that they do not readily incorporate the influence of potential
adverse effects between drugs, and thus the identification of synergistic interactions
may not reflect realistic therapeutic windows [265]. However, it should be noted that
incorporating these effects also requires extensive testing and validation of reference
samples. For the purposes of HT screening, the pragmatic approach would be to
identify potential hit drug combinations and ranges, and parse these with
confirmatory secondary assays.

5.4.5 SynScreen is an Optimal Application for HTFC Drug Combination Analysis
Here, we have described the development of a novel application for drug
combination analysis that is especially utile for HTFC screening data. SynScreen is
particularly useful for HTFC drug combination studies because it is amenable to facile
analysis of data sets of almost unlimited size. The properties of the drug
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concentration ratios tested and the quantity of tested wells are unrestricted,
permitting that there are sufficient data from the single compounds to produce
reliable dose-response curves and fits. A minimum response threshold can be set to
filter hits with specific activities. The application generates summary tables that
provide an overview of the imported dose-response combination data. These serve
to simplify the collation of multiple experimental runs and conditions for comparison
analyses. Furthermore, the capacity to import files with screening data from multiple
runs allows for a qualitative assessment of reproducibility of assays (Figure 5.1).
Additionally, the drug combination graphs generated by SynScreen also provide a
visual approximation of the regions where synergistic drug interactions have
occurred. Most data points visible above the surface of the theoretical additivity
threshold are mathematically identified as synergistic by Bliss and/or combination
index models. Hence, HTFC drug combination data may be rapidly evaluated, thus
expediting the triage process for screening campaigns.
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6.1 Abstract
Acute myeloid leukemia (AML) and B-cell lineage acute lymphoblastic leukemia
(B-ALL) are debilitating malignancies that affect elderly and pediatric populations,
respectively. Predictably, the poor rates of survival are partially due to refractory and
resistant responses to current treatment regimens. Therefore, the development of
novel therapeutics for administration in combination with existing drugs is vital to
improve patient outcomes. A promising target toward this advancement is the second
messenger 3’,5’-cyclic adenosine monophosphate (cAMP), as the expression of
pathway-related proteins and downstream effectors is abnormal in many cancers.
Previously, we proposed that malignant cells evade apoptosis and promote survival
by active efflux of cAMP. To target this process, we identified several repurposed
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drugs termed inhibitors of cAMP efflux (ICE). When used alone, ICE were capable of
triggering cell death, thus targeting leukemia through a novel mechanism. Drug
resistance in acute leukemias is often attributed to increased activity and expression
of ATP-binding cassette transporters. Remarkably, the same transporters are also
associated with cAMP efflux. Because numerous first-line leukemia drugs are known
to be substrates of cAMP transporters, we hypothesized that the ICE compounds
could increase sensitivity to leukemia chemotherapeutic agents (LCA). We tested
AML and B-ALL cell lines, as well as primary B-ALL patient samples, with pairwise
ICE+LCA combinations to identify their potential synergistic effects in reducing
viability and proliferation. While sensitivities varied across cell lines, most
combinations produced some degree of synergy, indicating a beneficial effect of ICE
with LCAs. ICE combinations with cytarabine, methotrexate, or topotecan
consistently indicated the most synergism. Future studies will explore mechanisms
of action to determine whether the synergistic effects produced by ICE/LCA
combinations are due to transporter inhibition and/or modulation of multiple
cellular pathways. Because ICE are clinically actionable repurposed drugs, this
provides the possibility for additional testing of these drugs in combination with
chemotherapeutics in in vivo xenograft models.

6.2 Introduction
Leukemias rank amongst the top 10 cancers in the United States, in terms of both
morbidity and mortality. Acute myeloid leukemia (AML) primarily affects the elderly,
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and has an abysmal five-year survival rate of only 28.3% [8]. B-cell lineage acute
lymphoblastic leukemia (B-ALL) is now >85% curable [19, 30]. While the lineage of
the two acute leukemias may differ, both diseases involve the unregulated
proliferation of immature blood cells, blasts. Due to this fact, there is significant
overlap in the treatment regimens for both malignancies. Typically, induction and
consolidation leukemia chemotherapeutic agents (LCA) for AML consist of a
combination of cytarabine (AraC) with an anthracycline [31]. B-ALL is first treated
with a combination of a glucocorticoid, anthracycline, vincristine, and asparaginase
[19]. Maintenance therapy for B-ALL generally employs methotrexate and nucleotide
analogs, such as mercaptopurine [19].
Despite improvements in treatment regimens over the last few decades, the long
term responses from leukemia chemotherapies are poor, primarily due to the
development of resistance [30, 266]. Leukemia multidrug resistance (MDR) can be
attributed to many mechanisms, primarily the overexpression and activity of ATPbinding cassette (ABC) transporters [102, 103, 226] that can actively remove LCA
from cells, reducing their ability to take effect. As such, one potential means to reduce
MDR is to inhibit ABC transporters and thus increase cell retention of cytotoxic
agents. Consequently, the development of novel therapeutics for use in combination
with existing drugs is vital to improve patient outcomes.
Based on its role in physiological processes that modulate cell death and survival,
cyclic AMP (cAMP) represents a promising target in cancer. The expression of cAMP
pathway-related proteins is abnormal in many malignancies, including leukemias [61,
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62, 65, 78, 82, 267]. Moreover, elevation of intracellular cAMP has been shown to
reduce the viability of malignant hematopoietic cells [2, 3, 74, 75, 118]. In our previous
work, we hypothesized that one mechanism that may be utilized by acute leukemia
cells to evade cell death is by the efflux of cAMP through the ABC transporters ABCC4,
ABCC5, and ABCC11 [6]. To target this process, we identified several repurposed
drugs termed inhibitors of cAMP efflux (ICE). When used alone, ICE were capable of
selectively reducing leukemia cell viability, and our data suggested that these effects
were largely independent of leukemia genotype [6].
Due to their nucleotide-like structures, many LCA are substrates of cAMP
transporters [102, 103, 133, 268-271]. Not surprisingly, the expression levels of
ABCC4, ABCC5, and ABCC11 have been reported to be prognostic for clinical
responses [102, 103, 226, 269]. On this basis, we propose to test ICE+LCA
combinations for synergism against leukemia cells. We postulate that ICE can reduce
LCA efflux, thus enhancing their cytotoxic effects. Synergistic interactions could
reduce the concentrations of individual agents needed for efficacy. This is especially
attractive because many LCA lack specificity for malignant cells and can be damaging
to normal tissues. In support of our hypothesis, several studies have shown that
cAMP-modulating agents can reverse resistance and/or enhance the effects of LCA
[226, 272-274]. In preparation for these studies, we developed high throughput flow
cytometry (HTFC) approaches for testing and analyzing drug combinations in
leukemia cell lines and primary samples [275, 276].
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The objective of this work was to assess and optimize ICE combinations to move
toward clinical translation. We hypothesized that cAMP efflux mechanisms are
related to drug resistance, and therefore that ICE should improve leukemia cell
sensitivity to first-line leukemia therapeutics. We established the utility of ICE used
in conjunction with LCA that are known substrates of cAMP transporters. In order to
validate cAMP efflux as both a prognostic trait and a favorable target for acute
leukemia therapeutics, we attempted to determine potential relationships between
retention of a fluorescent cAMP analog (F-cAMP) and drug sensitivity. Our findings
provide a basis for the development of a new class of agents, ICE, that when combined
with current leukemia treatment modalities, could enhance the killing of malignant
hematologic cells.

6.3 Results
6.3.1 HTFC assays were designed to test ICE+LCA combinations
We designed HTFC assays comprising drug pairs from ICE and LCA to determine
whether interactions between the two classes of drugs would potentially elicit
synergistic inhibition of leukemic cell viability. We proceeded with the four ICE that
had the most translational potential, as well as MK-571 as a positive control. We
tested LCAs that are both commonly used in leukemia chemotherapeutic protocols,
as well as having been found to be substrates of the cAMP efflux transporters. Table
6.1 summarizes the drugs tested for these combination studies.
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Table 6.1 Compounds used in drug combination assays.
*Indicate drugs that we identified as ICE in ref [6], but are not clinically actionable enough to pursue
in drug combination assays. ‡ This drug was used only with AML cell lines.

ICE
(Inhibitor of
cAMP Efflux)

COMPOUND

NOTES

Artesunate (ART)

Sesquiterpene lactone from Artemisia annua; FDAapproved antimalarial
FDA-approved antimicrobial
A tanshinone isolated from Salvia miltiorrhiza
Sesquiterpene lactone; Active metabolite of
artesunate
Positive control for cAMP efflux inhibition;
blocks multiple ABC-C family transporters
Sesquiterpene
lactone
from
Tanacetum
parthenium
Mycotoxin produced by Penicillium and Aspergillus
Substrate of ABCC5, ABCC11 [268]
Substrate of ABCC4, ABCC5 [269]

Clioquinol (CQL)
Cryptotanshinone (CTS)
Dihydroartemisinin
(DHA)
MK-571 (571)
Parthenolide (PTH)*

LCA
(Leukemia
Chemotherapeutic
Agent

Patulin (PLN)*
5-fluorouracil (5FU)
6-mercaptopurine
(6MP)‡
Cytarabine (AraC)
Methotrexate (MTX)
Topotecan (TPT)

Substrate of ABCB1 [103], ABCCC10 [270], ABCC11
[102]
Substrate of ABCC4 [133]
Substrate of ABCC4 [271]

Due to the potential complex interactions that may occur between drugs used in
tandem, it is important that appropriate concentration ratios are tested to encompass
conditions wherein interactions might occur. With this in mind, we elected to test
ICE+LCA combinations in matrices comprised of 48 different drug concentration
ratios, along with 8-point dose responses for individual drugs (Figure 6.1). Because
the responses of individual agents are critical for analyses of drug interactions, our
HTFC assays also included extended dose response curves that were separate from
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the matrices. The compound concentrations tested were based on previous
characterization of drug efficacies [6, 275].

Figure 6.1 Diagram of the 64-well ICE+LCA combination matrix.
Each ICE+LCA pair comprised of a matrix that included 8 identical 7-point dose response curves
consisting of drugs diluted in 1:4 ratios. ICE dose response curves were generated horizontally, and
LCA were generated vertically. The single agent dose response curves for ICE and LCA were located
on the top and left of the matrix, respectively.

6.3.2 AML cell lines show enhanced sensitivity to ICE+LCA combinations
To test our hypothesis that ICE can increase sensitivity to LCAs, we analyzed
combinations on AML cell line viability and determined whether such mixtures
exhibit synergy. Here, we chose to test U937 cells, as we had previously extensively
determined ICE effects on this cell line [6]. We also used MV-411 and KG-1a cell lines,
as they represent mature and immature AML phenotypes, respectively [277, 278].
Table 6.2 describes the AML cell lines chosen for this study, as well as their
characteristics.
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Table 6.2 The AML cell lines used in these studies and their characteristics.
AF = ALL1-fused gene from chromosome n; CALM = clathrin assembly lymphoid myeloid; FGFR1 =
fibroblast growth factor receptor 1; FLT3-ITD = fms like tyrosine kinase 3 internal tandem duplication;
MLL = mixed lineage leukemia; OP2 = oncogene partner 2; M, male.
FAB
Cell line
Subtype
Source
Fusion protein
Other Characteristics
+
KG-1a
M0
M age 59
FGFR1OP2–FGFR1
CD34 ;stem cell phenotype;
U937

M5

M age 37

CALM-AF10

differentiation resistant
Facile differentiation

MV4-11

M5

M age 10

MLL-AF4

FLT3-ITD

We treated the AML cell lines with ICE+LCA combinations for 24 and 48 h and
then determined cell viability with a propidium iodide (PI) assay. These time points
were chosen based on the fact that ICE have been able to reduce cell viability within
24 h at similar concentrations [6]. We analyzed the viability data with SynScreen
software, which both facilitates the analysis of drug combination data, and also
provides simple 3D visualizations of data to allow for quick assessment of each drug
pair [275]. We identified several drug combinations that synergistically reduced AML
cell line viability. In Figure 6.2, we show data from the combination of artesunate and
methotrexate, both to demonstrate the evidence of this synergism, as well as to
provide an example of how to best interpret SynScreen data. We were able to
compare the data from all the drug combinations tested to assess potential patterns.
Figure 6.3 shows the data from 4 replicate experiments of U937 cells treated with
ICE+LCA combinations for 48 hours. The data on the right exhibit more observed
instances of synergism, coinciding with ICE combinations with AraC, methotrexate,
or topotecan which exhibit potent activity against AML cells as single agents. These
drugs have also been shown to have multiple mechanisms of action, so it is plausible
that these ICE+LCA combinations may be affecting pathways beyond cAMP and cell
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proliferation. The data from 24 h incubation was not striking and may reflect latency
on killing (Appendix D). Table 6.3 provides a summary of the data for the three AML
cell lines, indicating the total number of ICE+LCA combination data points that were
determined to be synergistic according to the Bliss model of independence [254].
While the combination index model [256] is considered to be one of the most
comprehensive methods to use for drug interaction analysis, it is inappropriate to use
when the responses of drugs used in combination exceed the responses achievable
by one drug alone.

Figure 6.2 Representative drug interaction analysis of ICE+LCA combination effects on U937
cell viability.
Shown are the results from n = 4 experiments. The multicolor surface represents the theoretical
responses at which Bliss additivity would occur based on the single agent dose–response curves of
artesunate (ART; left axis) and methotrexate (MTX; right). The red dots indicate the replicates of the
observed experimental data. The z-axis ranges from 0% to 100% PI-positive responses
(cytotoxicity). The x and y axes are plotted as log μM. Most results visible above the surface are
determined to be potentially synergistic based on the Bliss model of independence.
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Figure 6.3 ICE+LCA combination effects on U937 cells after 48 h.
Shown are the results from n = 4 experiments. ICE compound dose response curves are plotted on
the left axes, and LCA are on the right. The red dots indicate the replicates of the observed
experimental data. The z-axis ranges from 0% to 100% PI-positive responses.
Table 6.3 Summary of synergistic data points from ICE+LCA combination viability assays in
AML cell lines.
Shown are the total number of data points that were identified by SynScreen software to be
synergistic by the Bliss model of drug interaction analysis. Incubation times are indicated on the left.
Cell lines are listed on the bottom. The LCA are listed horizontally, and ICE are listed vertically. The
data from 4 replicate experiments was analyzed together. The maximum number of synergistic data
points is 196 per condition. Darker colors on the heatmap indicate more identified synergistic data
points.
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6.3.3 B-ALL cell lines exhibit sensitivity to some ICE+LCA combinations
Because our work is focused on elucidating the potential utility of using ICE for
treatment of acute leukemias, we proceeded to test ICE+LCA combinations on B-ALL
cell lines (Table 6.4). Here, we chose to use three cell lines that exhibited different
capacities for F-cAMP efflux, and inhibition by the positive control MK-571: Nalm 6,
Sup B15, and Reh (see Figure 3.9B in Chapter 3). In contrast to the work done with
AML cell lines, the B-ALL cell lines were unable to thrive under the same incubation
conditions. Hence, we adapted our methods to allow these B-ALL cell lines to have
access to circulating air during the incubation period. Furthermore, as we moved
forward to optimize our HTFC combination assays, we opted to eliminate the LCA 6mercaptopurine from our drug panel for efficiency, since it elicited similar results to
5-fluorouracil in the AML studies. For this stage of the work, we also wanted to
expand the breadth of information that could be obtained from ICE+LCA
combinations, and included proliferation as another factor for drug sensitivity.
Table 6.4 The B-ALL cell lines used in these studies and their characteristics.

We predicted that since Nalm 6 has the highest cAMP efflux ability, and the lowest
ability for efflux to be inhibited by MK-571, that the viability of this cell line would be
the most resistant to ICE+LCA combinations. Surprisingly, Nalm 6 cells exhibited the
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most ICE+LCA synergistic effects. Sup B15 cells, which previously exhibited the
lowest F-cAMP efflux capacity of our tested B-ALL cell lines [6], were the least
sensitive to ICE+LCA combinations (Figure 6.4).

Figure 6.4 Representative drug interaction analysis of ICE+LCA combination effects on B-ALL
cell viability.
Data shown are from 72 h incubation. A-C), interaction data from the combination of MK-571 (left)
with 5-fluoruracil (right). D-F) interaction data from the combination of cryptotanshinone (left) with
5-fluorouracil (right). G-I) interaction data from the combination of clioquinol (left) with topotecan
(right). A, D, G, Nalm 6; B, E, H; Sup B15, C, F, I, Reh cells. The z-axis ranges from 0% to 100% SYTOX
green-positive responses
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The B-ALL cell line behavior was further unexpected by exhibiting different
sensitivities to ICE+LCA combinations in comparison to the AML cell lines. In our
previous work [6], while the EC50 values for single drugs tested on AML and B-ALL
cell lines varied, the efficacious drugs ranked in the same order. In our ICE+LCA
combination studies here, we found that combinations that included 5-fluorouracil
produced strong synergism in the B-ALL cell lines, whereas these drug interactions
were modest in the AML cell lines. Furthermore, we determined that combinations
with our identified ICE elicited similar effects as the positive control, MK-571 (Figure
6.4, A-F; Appendix D). Nonetheless, akin to the AML cell line data, ICE+LCA
combinations involving AraC, methotrexate, or topotecan produced synergy in the
context of B-ALL cell line viability (Figure 6.4, G-I). We also observed that synergism
was stronger in B-ALL cells incubated 72 h in comparison to those treated for 48 h.
We summarize the ICE+LCA combination synergistic points in Table 6.5. As
previously mentioned, we also sought to determine how ICE+LCA combinations
might affect cell proliferation. This metric was assessed because one primary goal of
cancer treatment is to limit cell growth, and clinicians are interested in treatments
that are cytostatic just as much as they are interested in therapies that are cytotoxic.
While the proliferation results were not as profound as that from the viability studies,
some ICE+LCA combinations did synergistically limit cell replication. Of note, the
combination of topotecan with clioquinol demonstrated several concentration ratios
that prevented proliferation (Figure 6.5). It should also be noted that for the majority
of drug combinations, most synergistic inhibitions of B-ALL cell line proliferation
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occurred with Sup B15 cells incubated 48 h and Nalm 6 cells treated 72 h (Appendix
D). Table 6.6 provides a summary of the number of synergistic data points identified
from the B-ALL cell line proliferation assays.

Table 6.5 Summary of synergistic data points from ICE+LCA combination viability assays in BALL cell lines.
Shown are the total number of data points that were identified by SynScreen software to be synergistic
by the Bliss model of drug interaction analysis. Incubation times are indicated on the left. Cell lines are
listed on the bottom. The LCA are listed horizontally, and ICE are listed vertically. The data from 3
replicate experiments was analyzed together. The maximum number of synergistic data points is 147
per condition. Darker colors on the heatmap indicate more identified synergistic data points.
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Figure 6.5 ICE+LCA combination effects on B-ALL cell line proliferation.
Shown are the results from n = 3 experiments. Clioquinol (ICE) dose response curves are plotted on
the left axes, and topotecan (LCA) are on the right. A) data collected from the B-ALL cell lines after
48 h incubation. B) data collected from the B-ALL cell lines after 72 h incubation. The red dots
indicate the replicates of the observed experimental data. The z-axis ranges from 0% to 100%
fluorescence retention of the proliferation stain.
Table 6.6 Summary of synergistic data points from ICE+LCA combination proliferation assays
in B-ALL cell lines.
Shown are the total number of data points that were identified by SynScreen software to be
synergistic by the Bliss model of drug interaction analysis. Incubation times are indicated on the left.
Cell lines are listed on the bottom. The LCA are listed horizontally, and ICE are listed vertically. The
data from 3 replicate experiments was analyzed together. The maximum number of synergistic data
points is 147 per condition. Darker colors on the heatmap indicate more identified synergistic data
points.
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6.3.4 Primary B-ALL samples have limited sensitivity to ICE, LCA, or ICE+LCA
combinations
To test the realistic potential of ICE+LCA combinations to be effective against
acute leukemias, we sought to determine drug interactions against primary B-ALL
samples ex vivo. For these samples, we assessed combination effects on cell viability.
Due to the fragile nature of primary samples, we were reluctant to load these cells
with a proliferation marker. In order to potentially support our hypothesis by relating
cAMP efflux ability to drug sensitivity, we also measured primary B-ALL sample
retention of a fluorescent cAMP analog, F-cAMP.
We tested primary B-ALL samples that were obtained at the time of diagnosis and
cryogenically banked. Matched vials were previously assessed with for mRNA
expression. From the genes that were analyzed, eleven related to the cAMP pathway,
including three adenylyl cyclases (ADCY6, 7, 9), two phosphodiesterases (PDE7A,
PDE4D), RAPGEF3 (EPAC1), PRKAR1A (protein kinase A-1α), cAMP efflux
transporters ABCC1 and ABCC5, NTPDase1 (CD39) and ecto-5’-nucleotidase (CD73).
The normalized data from twenty-three primary B-ALL samples were log2transformed followed by unsupervised hierarchical clustering gene cluster analysis
based on expression of the aforementioned genes. The samples formed two distinct
clusters. We selected four representative samples from Cluster 1, and five samples
from Cluster 2 for analysis in F-cAMP retention and ICE+LCA viability assays (Figure
6.6 and Table 6.7).
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Figure 6.6 Representative drug interaction analysis of ICE+LCA combination effects on U937
cell viability.
Shown are the 23 banked B-ALL primary samples (top) that were previously analyzed and clustered
based on their expression of genes related to the cAMP pathway (right). The heatmap is log 2 scale,
with red indicating increased expression and green indicating reduced expression. The two
identified clusters are indicated in yellow. The primary samples that were selected for our studies
are highlighted with peach boxes.
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Table 6.7 Characteristics of the tested primary B-ALL cell lines.
WBC, white blood count (representative of blasts in the bone marrow). MRD, minimal residual
disease evident in bone marrow (BM) 29 days after diagnosis and induction therapy.

We were only able to determine the primary B-ALL samples’ ability to retain FcAMP because there were no differences between the negative control and MK-571treated condition. We later determined that this lack of distinction was most likely
due to the inclusion of 0.5% amphotericin B in the culture media, an oversight on our
part. Because amphotericin B can affect cation transport, it is likely that this molecule
may have affected the integrities of the cell membranes or transporters. Table 6.8
presents the retention of F-cAMP after incubation. Most samples lost over half of the
loaded F-cAMP after about 20 hours. Patient sample 15-007 exhibited a high
percentage of retention, although these data could be confounded by the fact that the
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sample had low viability. Primary samples 15-078 and 17-191 had the next highest
F-cAMP retention values, > 60%, and had similar diagnostic characteristics, in that
both patients were young and exhibited no MRD after 29 days of treatment. However,
samples 17-191 had little change, whereas 15-078 had decreased expression of most
cAMP-related genes (Tables 6.7 and 6.8, Figure 6.6). Samples 17-102-P2, 16-265,
and 14-307 exhibited the lowest F-cAMP retention values, about 30%, but were
representative of different gene clusters, and thus had disparate expression of cAMPrelated genes. These samples also represented patients with drastically different
ages, DNA ploidy, and karyotypes. Therefore, it is difficult to associate any one trait
with F-cAMP retention ability. Future studies will need to optimize the F-cAMP efflux
assay without amphotericin B in order to resolve whether F-cAMP efflux ability, and
its potential inhibition by MK-571, are associated with any specific patient sample
traits.

Table 6.8 Summary of primary B-ALL sample F-cAMP retention and viability.
Shown are the primary B-ALL samples selected for our studies and the cAMP gene cluster
from which they were identified. The incubation time and % retention of F-cAMP are
indicated. Also provided are the average % viability of the negative controls (DMSO-only) that
were used for data normalization.
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While it has been often reported that the drug sensitivities determined for cell
lines in vitro are similar to those observed for primary samples ex vivo, our ICE+LCA
combination data do not necessarily fall within that paradigm. Whereas the drug
combinations elicited multiple synergistic interactions in the B-ALL cell lines, the
responses of the primary B-ALL samples were poor. The primary samples were not
only resistant to the ICE+LCA combinations, but to the drugs as single agents as well.
Note the difference in the single agent dose responses at the edges of the graphs in
Figure 6.7. Nonetheless, the primary B-ALL samples did exhibit a variety of
responses. Surprisingly, the two samples that exhibited the lowest F-cAMP retention,
17-102-P2 and 16-265, appeared to be the most sensitive to ICE+LCA combinations,
and synergistic interactions therein. However, sample 14-307, which exhibited
similar F-cAMP retention, but also represented poor diagnostic traits (older age, high
initial WBC), was poorly responsive to treatment. Remarkably, the two primary
samples that displayed MRD after treatment, a significant marker of poor prognosis,
15-007 and 16-145 (Table 6.7), showed dose-dependent responses to the ICE
compound clioquinol (CQL) that resulted in nearly total loss of cell viability (Figure
6.7).

150

Figure 6.7 Comparison of ICE+LCA combination effects on B-ALL cell line and primary sample
viability.
Shown are data from B-ALL cells treated with the combination of clioquinol (left) and cytarabine
(right) for 72 h. The graphs from B-ALL cell lines (top row) are representative of three replicate
experiments. The graphs from primary B-ALL samples represent a single experimental replicate. The
z axis ranges from 0% to 100% SYTOX green-positive responses (cytotoxicity)

Given the heterogeneity of the sample characteristics, cAMP-related gene
expression, and ability to retain F-cAMP, these variations were expected. A summary
of the total synergistic ICE+LCA interactions that were identified for the primary BALL samples is provided in Table 6.9 and the graphs for these data are in Appendix
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D. These data underscore both the fact that the responses of individual patients are
unique, and additionally support the premise that personalized medicine approaches,
such as those developed in these studies, are necessary to maximize the potency of a
treatment regimen [279].
Table
6.9
Summary
of
synergistic data points from
ICE+LCA combination viability
assays in primary B-ALL
samples.
Shown are the total number of
data points that were identified
by SynScreen software to be
synergistic by the Bliss model of
drug
interaction
analysis.
Incubation times are indicated on
the bottom. Patient sample
identifiers are listed on the left.
The LCA are listed horizontally,
and ICE are listed vertically. The
maximum number of synergistic
data points is 49 per condition.
Darker colors on the heatmap
indicate
more
identified
synergistic data points.
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6.4 Discussion
We previously identified several compounds capable of reducing the efflux of a
fluorescent cAMP analog from drug repurposing libraries, which we termed
inhibitors of cAMP efflux (ICE). We validated the fact that ICE appropriately
modulated downstream cAMP pathway activity [6] in acute leukemia cells, and
hypothesized that these molecules might be capable of reducing the activity of the
cyclic nucleotide effluxing transporters ABCC4, ABCC5, and ABCC11. Due to the fact
that many leukemia chemotherapeutic agents (LCA) are nucleotide analogs, the
expression of ABCC4, ABCC5, and ABCC11 is associated with drug resistance [102,
103, 226, 269]. Considering that the expression of these transporters is related to
prognosis, we hypothesized that the combination of ICE with LCA may interact
synergistically. Since both ICE and LCA are capable of independently inducing
apoptosis, the combination of the two classes of agents should increase the efficacy of
reducing leukemia cell viability. As such, we determined the effects of ICE+LCA
combinations on AML and B-ALL cell lines and primary B-ALL samples.
We identified several drug pairs that resulted in synergism at several
concentration ratios. Generally, combinations that included the LCA AraC,
methotrexate, or topotecan exhibited the most potency. The effects of ICE+LCA
combinations were more effective in reducing acute leukemia cell viability, although
some drug pairs were able to also decrease proliferation. It is plausible that the
incubation times in which proliferation was assessed, 48 and 72 h, were not long
enough to allow for several cell divisions. However, for most of our proliferation data,
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the ICE+LCA combinations were less potent than what was observed for the agents
used alone. Two possibilities may account for these observations. First, because we
determined that the ICE+LCA drug pairs were able to synergistically reduce cell
viability at the same time points, perhaps too few viable cells remained to
significantly influence proliferation. Second, it has been noted that under conditions
of cellular stress, modest elevation in intracellular cAMP can stimulate cell growth
[83, 85]. Further studies would be needed to elucidate the effects of specific ICE+LCA
combinations on cell replication mechanisms.
We observed that the sensitivity of AML cell lines was related to phenotype. The
stem-like cell line KG-1a was fairly resistant to ICE+LCA combinations, whereas MV411 cells, representing a more mature phenotype, were more sensitive to the tested
drug pairs (Table 6.3). Other researchers have indicated that less-differentiated
hematopoietic cells have higher expression of ABC transporters [96]. In our past
work, we found that cells that had higher F-cAMP efflux ability were not as sensitive
to efflux inhibition by our positive control MK-571 [6] (Figure 3.9). Hence, it is
plausible that the KG-1a cells were resistant to the effects of ICE, LCA, and
combinations since these cells likely express a multitude of transporters that are not
as easily affected by our tested drugs. However, in striking contrast to our
observations with AML cell lines, our results from B-ALL cell lines indicate that the
cell line that we previously identified as having high F-cAMP efflux activity, Nalm 6,
was most sensitive to ICE+LCA combinations (Figure 6.4 and Table 6.4). These
results are in contrast to Shabestari, et al., wherein the combination of cAMP154

elevating agents with the anthracycline doxorubicin reduced Nalm 6 cell apoptosis
[87]. It should be also be noted that Nalm 6 cells had the lowest overall viability at the
measured time points, indicating that these cells generally had the lowest capacity for
survival under our experimental conditions. Our data for Sup B15 cells, which have
lower F-cAMP efflux activity, were the least sensitive to the tested compounds. The
differences in our data for AML and B-ALL cell lines may be attributed to lineage
specific mechanisms, or to potential differences in intracellular signaling and
metabolism. We observed that B-ALL cells required free air exchange during
incubation, while AML cells had higher viability if the plates were sealed with ambient
air. Therefore, the differences in oxygen sensitivity of these two hematopoietic
lineages may be a result of different metabolic dependencies [280].
The data from this work also demonstrated that the primary B-ALL samples were
much less sensitive to the tested compounds, to the extent that some conditions did
not even induce dose dependent responses (Appendix D). We obtained similar
results in a previous study wherein we tested tyrosine kinase inhibitors on primary
T-cell lineage ALL cells [276]. Because primary cells have been developed in a
complex microenvironment, enriched in pro-survival chemokines, it makes sense
that these cells have likely employed different survival mechanisms than cell lines.
One potential limitation of our experimental approach may be the fact that we
incubated the primary cells in media containing serum. While some researchers have
used similar approaches [281], others have focused on the use of serum-free culturing
conditions [244]. The ability to appropriately mimic the leukemia microenvironment
155

for the development of personalized medicine approaches will be difficult to resolve,
and much more work needs to be done to determine the optimal conditions (serum,
oxygen content, growth factors) to culture primary samples.
While the data from the current study were promising, it should be noted that the
development of drug combinations for translation to treatment regimens is complex.
Here, we tested drug pairs administered to leukemia cells concomitantly. Others have
reported that some drug combinations are more efficacious when the individual
drugs are used sequentially [282]. Lee, et al. noted that erlotinib administered for 24
h prior to the addition of doxorubicin significantly reduced triple negative breast
cancer cell viability more than when the drugs were used simultaneously [283]. Given
that ICE potentially reduce the transport of LCA out of cells, it is possible that
incubation of leukemia cells with ICE prior to the addition of LCA might produce
stronger apoptotic effects.
We should also note that our approach was simplistic in the sense that we limited
our combinations to pairs. This approach was used both to facilitate the mathematical
determinations of drug interactions, but also to limit the potential mechanistic
variables that could be involved in the cell responses. However, our work shows that
we are on the right track, as recent work by Drenberg, et al. determined that
combinations of artesunate or dihydroartemisinin with cytarabine synergistically
reduced AML burden in three murine in vivo models [284]. Realistically, current
cancer treatment paradigms involve the use of multiple chemotherapeutics, and
future work would need to be done to test ICE in combination with these drug
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cocktails to determine both efficacy and potential contraindications. Because efflux
transporters are expressed in many organs, we should also be wary of the potential
of any compounds targeting these proteins to cause damage to these tissues. Belinsky,
et al. showed that the administration of the nucleotide analog PMEA to ABCC4
knockout mice induced damage to the bone marrow, spleen, thymus, and intestine
[285]. Another study showed that single nucleotide polymorphisms that rendered the
transporters ABCB1, ABCC1, or ABCG2 non-functional caused AML patients to
develop hepatic, lung, and cardiac toxicities after treatment with induction
chemotherapy [286]. The testing of ICE+LCA combinations in vivo could help identify
these potential issues. Nonetheless, because the transporters that may be responsible
for apoptotic evasion by cAMP efflux can also potentially support the removal of
structurally related chemotherapy drugs, and thus may contribute to multidrug
resistance [226-228, 268], this work may lead to the development of new treatment
regimens with increased efficacy against acute leukemia cells.

6.5 Materials and Methods
6.5.1 Reagents and compounds
The positive control for F-cAMP efflux, MK-571, was purchased from Cayman
Chemical (Ann Arbor, MI). The remaining ICE and LCA compounds were purchased
from Sigma-Aldrich (St. Louis, MO). All ICE and LCA compounds were dissolved in
DMSO. Other reagents were purchased from Thermo Fisher Scientific (Waltham, MA)
unless specified otherwise.
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6.5.2 Cell lines
The human AML (U937, MV-411, KG-1a) and B-ALL (Nalm 6, Sup B15, Reh), and
stromal (HS-5) cell lines were acquired from ATCC (Manassas, VA). These cell lines
were cultured in complete RPMI (cRPMI; RPMI-1640 medium supplemented with 2
mM L-glutamine, 100 U/mL penicillin-streptomycin and 10% heat-inactivated fetal
bovine serum; VWR, Radnor, PA) and incubated in a humidified atmosphere with 5%
CO2 at 37°C. However, it should be noted that the B-ALL and stromal cell line culture
cRPMI media additionally contained 1% amphotericin B (cRPMI+B; Sigma-Aldrich).
Conditioned media from HS-5 stromal cells were collected after 3-4 days of
growth, with cells at 70-90% confluency. The conditioned media were centrifuged 5
min at 400 rcf to remove cellular debris. The supernatant was collected and frozen
until use.

6.5.3 B-ALL patient samples
Primary B-ALL bone marrow samples were acquired at diagnosis from pediatric
patients with written, informed consent (HRPO-05-435). All patients or their
parent(s)/guardian(s) provided written, informed consent for future research in
accordance with the Declaration of Helsinki and local institutional guidelines.
Leukemia blasts were enriched by Ficoll-Paque centrifugation and the RNA was
extracted using Direct-zol RNA Kit (Zymo Research). RNA libraries were sequenced
on P1v2 chips using the Ion Proton™ System (Thermo Fisher Scientific). Sequencing
and data processing was completed by the Analytical and Translational Genomics
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Shared Resource at the University of New Mexico Comprehensive Cancer Center as
described before [287]. The normalized data were log2-transformed followed by
unsupervised hierarchical clustering. Java Tree View was used to create the heatmaps
[288].
Only cryopreserved patient samples that had a combined total of at least 20
million cells were used for our studies. The primary cryopreserved cells were thawed,
centrifuged at 1300 rpm, and rested for ~2 h in a 5% CO2 incubator at 37 °C in cRPMI
without penicillin or streptomycin. Prior to use, for assays, the rested primary cells
were centrifuged at 400 rcf, and resuspended in 27 mL cRPMI+B.

6.5.4 HTFC drug combination setup
All HTFC assays were conducted in 384-well plates (Greiner Bio-One 784201,
Monroe, NC). Media were added to all wells with a BioTek MultiFlo (Winooski, VT)
liquid dispenser, 5 µL for sample wells and 10 µL for wash wells. For cell lines, the
media was that used for tissue culture. For primary B-ALL samples, the conditioned
media from HS-5 cells was used for this step. The compounds were then added with
the Echo® 555 Acoustic Liquid Handler (Labcyte, San Jose, CA) into to a final DMSO
concentration of 1%. Freshly washed cells were resuspended in media (cell lines: 106
cells/mL; primary cells: 0.7-1 x 106 cells/mL, based on the above description). Then,
5 µL of cells were added to sample wells, resulting in a final density of 5000 cells/well
for cell lines, and 3500-5000 cells/well for primary B-ALL samples). According to our
previous methods[6, 275], the AML cell line assay plates were flushed with ambient
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air and sealed with a PlateLoc Thermal Microplate Sealer (Agilent, Santa Clara, CA)
prior to incubation. The B-ALL cell lines and primary samples were sealed with
Breathe-Easy® sealing membranes according to the manufacturer’s protocol
(Diversified Biotech, Dedham, MA), and covered with polystyrene plate lids prior to
incubation. The AML cell lines were incubated with ICE+LCA combinations for 24 and
48 h, whereas B-ALL cell lines and primary samples were incubated for 48 and 72 h.

6.5.5 HTFC viability assays
6.5.5.1 Propidium iodide (PI) viability assay
The propidium iodide (PI) assay to determine cell viability was performed as
previously described [11, 276]. Briefly, PI (Sigma-Aldrich, St. Louis, MO) was added to
all wells of the assay plates with a BioTek MultiFlo to a final concentration of 1 µg/mL.
The plates were then incubated on rotators at 4°C for 20-45 min.

6.5.5.2 SYTOX green viability assay
The SYTOX green nucleic acid stain (Thermo Fisher Scientific) was used to
determine B-ALL cell viability. The dye was diluted with Dulbecco's phosphatebuffered saline (DPBS) to a working concentration of 1.5 µM. The Echo® 555 Acoustic
Liquid Handler was used to dispense 20 nL of this solution into assay plates, resulting
in a final concentration of 3 nM. The plates were incubated on rotators at 4°C for 1540 min to prevent potential efflux of the dye at room temperature.
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6.5.5.3 Viability data collection and analysis
The HTFC viability data were collected and analyzed as previously described
[275, 276]. The assay plates were vortexed on an Eppendorf MixMate® (Hauppauge,
NY) at 2000 rpm for 15-30 sec prior to flow cytometry. The data were collected with
a HyperCyt® platform (IntelliCyt, Albuquerque, NM) configured to an Accuri C6 Plus
flow cytometer (BD Biosciences, Franklin Lakes, NJ). The data were exported in Flow
Cytometry Standard (FCS) format and analyzed based on events collected from
individual wells [264]. The data were analyzed with ForeCyt® software (IntelliCyt).
The samples were gated on forward and side scatter to isolate the cell populations,
and a binary gate was used on the fluorescence histograms (PI, FL-3; SYTOX green,
FL-1) to distinguish negative (viable) and positive (non-viable) populations.
The data were annotated for the contents and concentrations in each well, and
the observed response values were normalized in comparison to responses recorded
from cells in control wells. Generally, the mean %viability of cells in negative control
wells (containing diluent alone, e.g., DMSO) for each assay plate = 100% viability for
the compound-treated samples. The negative control data from individual assay
plates was used for normalization, with outliers excluded. The normalized data were
then imported into SynScreen software (Bruce Edwards, Albuquerque, NM) and
analyzed for drug combination effects as described previously [275].
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6.5.6 HTFC proliferation assay
The MulitCyt FL-4 cell proliferation kit (IntelliCyt) was used to assess B-ALL cell
line proliferation. The cells were loaded according to the manufacturer’s protocol,
with 5 µL of dye used to stain 25.2 million cells. After loading, the cells were rested
for at least 30 min prior to being added to the assay plates. Small aliquots of unstained
and stained cells were analyzed with Accuri C6 Plus flow cytometers to determine the
FL-4 channel autofluorescence and initial proliferation dye fluorescence intensity in
the cells (t = 0).
For HTFC proliferation assay data analysis, the median fluorescence intensity
(MFI) from unstained cells was subtracted from the t = 0 MFI value, generating the Δt
= 0 MFI value used for normalization. The FL-4 MFI values were obtained for each
sample well in the assay. The data were normalized to determine the %retention of
the FL-4 fluor. %retention = (sample FL-4 MFI – autofluorescence MFI) / Δt = 0.
Higher %retention values are indicative of reduced proliferation. These %retention
values were imported into SynScreen software and analyzed for drug interactions.

6.5.7 Primary cell F-cAMP assay
The F-cAMP assay that we previously reported [6, 101, 124] was adapted to load
small batches of primary B-ALL cells with the analog. TheF-cAMP was purchased from
BIOLOG Life Science Institute (cat. no. F002, via AXXORA, LLC, Farmingdale, NY).
DPBS was used to dissolve the probe, resulting in a 500 µM F-cAMP solution. From
the prepared B-ALL samples described above, 1 mL was harvested, centrifuged at 300
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rcf for 3 min, and resuspended in NF-RPMI (cRPMI without FBS), then washed once
more. The cells were then suspended in the F-cAMP loading solution, consisting of
100 µL hypertonic solution (10% w/v polyethylene glycol (PEG), 500 mM sucrose in
NF-RPMI) with 10 µL of 500 µM F-cAMP. The samples were incubated in F-cAMP
loading solution for 10 min at room temperature, then centrifuged. The samples were
resuspended in 500 µL hypotonic solution (40% purified, deionized water, 60%
cRPMI) and incubated for 2 min at room temperature. The cells were again
centrifuged, then resuspended in 1 mL cRPMI. In a 12-well plate (Corning® Costar®
TC-treated, 3513, Corning, NY), 500 µL of HS-5 conditioned medium was added to
three wells. Unstained primary cells (500 µL) were added to one well, and 500 µL of
F-cAMP-loaded primary cells were added to the remaining two wells. One F-cAMPloaded well was treated with 2.5 µL 20 mM MK-571 (50 µM final), while the remaining
two wells were treated with 2.5 µL DMSO alone. 300 µL was collected from each well
to determine initial fluorescence intensities. The remaining samples were incubated
under tissue culture conditions for 20-24 h.
The fluorescence intensities for F-cAMP (FL-1) were obtained via flow cytometric
analysis of 10,000 cells. The samples were gated on forward and side scatter to
identify live cells. These gates were kept consistent for both time 0 (t0) and after
incubation. To determine F-cAMP retention, the FL-1 MFI values were first baselinecorrected: A, (t0 F-cAMP loaded MFI – t0 autofluorescence MFI) = t0*; B, (incubated
F-cAMP loaded – incubated autofluorescence MFI) = incubated*. % F-cAMP retention
= t0* / incubated*.
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7.1 Abstract
Clioquinol, one of the first mass-produced drugs, was considered safe and
efficacious for many years. It was used as an antifungal and an antiprotozoal drug
until it was linked to an outbreak of subacute myelo-optic neuropathy (SMON), a
debilitating disease almost exclusively confined to Japan. Today, new information
regarding clioquinol targets and its mechanism of action, as well as genetic variation
(SNPs) in efflux transporters in the Japanese population, provide a unique
interpretation of the existing phenomena. Further understanding of clioquinol’s role
in the inhibition of cAMP efflux and promoting apoptosis might offer promise for the
treatment of cancer and/or neurodegenerative diseases. Here, we highlight recent
developments in the field and discuss possible connections, hypotheses and
perspectives in clioquinol-related research.
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7.2 Introduction
Clioquinol (5-chloro-7-iodo-quinolin-8-ol) (Figure 7.1) was first developed in
1899 as a topical antiseptic. It was subsequently repurposed to treat traveler’s
diarrhea, as well as certain fungal and protozoal infections of the gastrointestinal
tract [289]. For many years, it was considered safe, and in the 1930s clioquinol
became available over-the-counter in Europe, the US and Asia.

Figure 7.1 Chemical structures of
substrates of ABCC4, ABCC5 and
ABCC11,
and
other
related
compounds.
Clioquinol
(5-choloro-7-iodo-8quinolinol), PBT2 (5,7-dichloro-2((dimethylamino)
methyl)
8quinolinol) and 8-hydroxyquinoline are
ionophore/chelator
drugs.
6Mercaptopurine, 6-thioguanine, 5fluorouracil,
Ara-C
(cytosine
arabinoside), pemetrexed and 6thioguanine nucleotides are cancer and
immunosuppressor
drugs
and
substrates of ABCC4 and ABCC11
transporters. cAMP and cGMP are
natural ABCC4, ABCC5 and ABCC11
substrates.
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7.3 Subacute myelo-optic neuropathy: clioquinol’s fall from grace
While versatile and used worldwide, clioquinol became associated with a
mysterious illness primarily confined to Japan. Between 1958-1970, Japanese
physicians observed a number of cases that, at first, were characterized by mild
abdominal pain and/or diarrhea [290]. These symptoms were often followed by a
myelitis-like illness that exhibited an array of neuropathological changes consisting
of “pseudosystemic degeneration involving the peripheral nerves, post-lateral
columns of the spinal cord and retrobulbar optic nerves” [290]. The new illness was
designated as subacute myelo-optic neuropathy or SMON, with unknown etiology. It
affected thousands of people who were blinded, paralyzed or confined to wheelchairs
for the rest of their lives [289]. 10,000 diagnoses were made and nearly 5 % of cases
were fatal [291]. Multiple hypotheses on the etiology of SMON were considered:
intoxication by industrial waste or pesticides; a metabolic disorder or vitamin
deficiency, and involvement of viral or bacterial infections [290], none of which were
confirmed by subsequent studies. SMON patients presented with a green “fur” on
their tongues, and green-pigmented urine and feces. Surprisingly, this green pigment
was identified as the Fe (III) chelate of clioquinol [290]. Moreover, the number of
SMON monthly cases closely correlated with the number of clioquinol tablets
consumed, and only patients that took clioquinol exhibited symptoms of the disease
[290]. This necessitated a ban of clioquinol sales in September 1970. As a result, the
monthly SMON incidence went from ~ 150 in July to 1 in October [290]. However, one
mystery that remained was that SMON was primarily endemic to Japan.
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Internationally, the 1969 sales of clioquinol per capita in 15 studied countries were
higher than in Japan, yet there were no reports of SMON [291]. Some researchers
speculated that familial (genetic) factors could account for the higher incidence of
SMON in Japanese clioquinol users [290].

7.4 Clioquinol makes a comeback against neurodegenerative diseases
One of clioquinol’s first-identified mechanisms of action relates to its ability to
interact with metals. The idea that the accumulation of the “wrong” metals in the
human brain can cause Alzheimer’s disease (AD) dates back to the late 1970s [292].
In a more recent study, researchers found a significant decrease in serum manganese
level in AD subjects vs. healthy individuals but concluded that neither lead nor
manganese levels represented biomarkers in the studied cohort [293]. Another study
found that the copper content was increased in AD platelets. The patient stratification
using MMSE score (see glossary, section 7.12) revealed a larger copper increase in the
group with more significant impairment. They detected a 1700% copper increase in
severe cognitive impaired patients and only a 112% increase in the mild-to-moderate
cognitively impaired group. As a result, platelet copper was envisioned as a potential
diagnostic biomarker for AD [294]. Specific roles for rubidium and potassium in AD
were also proposed, since both metal ions are decreased across all intracellular
compartments in the AD brain [295]. Nevertheless, these and other data motivated
studies to assess metals as markers in AD pathogenesis.
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In an effort to develop a novel therapeutic options for AD, Ashley Bush and
collaborators reported results from a drug repurposing screen aimed at identifying
efficient metal chelators among existing antibiotics and anti-inflammatory drugs
[296]. In 2001, clioquinol was reported to dissolve β-amyloid deposits in postmortem
human tissues [297]. In a mouse AD model, clioquinol was also reported to inhibit
plaque formation [296]. Subsequently, Dr. Bush’s group introduced the novel concept
of metallostasis, a dysfunction of metal trafficking in the brain, where metals are
redistributed into inappropriate compartments [298]. This hypothesis, originating
from early clioquinol-related findings, is based upon a triad of transition metals: Fe,
Cu and Zn [299-301]. Today, several groups are attempting to improve clioquinolbased structures (Figure 7.1) [302, 303]. Clioquinol and its next generation metal
chelator derivative, PBT2 (5,7-dichloro-2-((dimethylamino)methyl) 8-quinolinol;
Figure 7.1), have shown “cognitive and plasma biomarker effect[s]” for 36 patients
in a Phase II clinical trial in AD. However, a subsequent Phase II/III trial was
terminated because of a toxic impurity, an unwanted by-product of the drug synthesis
(see

http://www.alzforum.org/therapeutics/clioquinol).

The

following

trials

showed satisfactory safety and tolerability of PBT2 in AD and Huntington's disease
patients, with the conclusion that larger and longer future trials will be required to
establish any potential therapeutic benefits [303, 304]. Hence, future “large-scale
phase 3 trials of [metal based therapeutic approaches] are warranted” [305]. More
recent reports indicate that clioquinol was also capable of preventing the loss of
substantia nigra cells in the Parkinsonian human A53T transgenic mouse model, as
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the accumulation of nigral iron (Fe) in aggregates containing α-synuclein represents
an important feature of Parkinson’s disease pathogenesis [306]. The effect of
clioquinol upon cognitive and motor function in this mouse model was attributed to
its ability to prevent a Fe-synuclein interaction as a moderate-affinity metal chelator
[307].
Nonetheless, the mechanism of clioquinol’s action, at first thought to be related
to Cu/Zn or other metal chelating properties, is still debated and considered
important [289]. Alternative theories have suggested that the accumulation of
aggregated proteins in neurodegenerative diseases like AD could be attributed to
defective clearance of misfolded or aggregated proteins in astrocytes and neurons.
Autophagy, a cellular degradation process that targets unnecessary cytosolic proteins
to the lysosomal compartment, seemed a plausible candidate for the pathogenesis of
AD. In fact, it was found that clioquinol induces autophagy [308], or that it can reverse
arrested autophagy [309]. At micromolar concentrations, clioquinol up-regulated
phosphatidylethanolamine conjugated to the protein LC3-I, a marker of autophagy.
The microtubule-associated protein 1A/1B-light chain 3 (LC3) cytosolic form is
referenced as LC3-I, and the phosphatidylethanolamine conjugate as LC3-II [310].
This effect appears to be related to the ionophore properties of clioquinol rather than
its zinc chelation properties, as an alternative zinc chelator was shown to reduce LC3II accumulation. Moreover, the addition of zinc increased the accumulation of LC3-II,
confirming the role of zinc in the induction of autophagy [308]. While “arrested
autophagy” could contribute to AD [309], data relating clioquinol and autophagy are
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limited. Because targeting the autophagic pathway is envisioned as a promising
approach in cancer therapy [311], it is not surprising that clioquinol is under study in
cancer-related fields.
Nonetheless, several reports indicate that autophagy induction by clioquinol is
model-dependent. For example, in human hepatoma cells, clioquinol induced neither
autophagy nor apoptosis, although it triggered cell cycle arrest in the S-phase. This
effect was accompanied by down-modulation of cell cycle proteins, including Cdk2
and cyclins D1 and A2, as well as up-regulation of p21 and p27 [312]. As transition
metals are unlikely to be unique targets of clioquinol, other potential clioquinol
targets were later identified. ABC transporters represent one class of potential
targets.

7.5 Clioquinol may be a rising star against cancer too
Due to multiple reported cellular effects, clioquinol has also been studied for use
against cancer, where modulating membrane transport is of interest. Originally, ATP
binding cassette (ABC) transporters (see glossary, section 7.12) attracted attention
because of their abilities to efflux the nucleoside-like drugs that are used for
chemotherapy in cancer or immunosuppression in autoimmune diseases (Figure
7.1). The idea that ABC transporters have normal physiological functions, that include
active transport of metabolites and signaling molecules, was later accepted [105].
Given their altered metabolism, cancer cells rely upon membrane transport more
than normal cells. Moreover, up-regulated expression of membrane transporters was
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associated with poor overall survival and a high degree of resistant disease in acute
myeloid leukemia [313]. Another concept links aberrant membrane transport in
cancer with evasion of programmed cell death. The efflux of the pro-apoptotic second
messenger, 3',5'-cyclic adenosine monophosphate (cAMP, Figure 7.1), is proposed as
one such cell survival mechanism [6, 314]. Three transporters from the ABCC family,
ABCC4, ABCC5 and ABCC11, are reported to efflux cyclic nucleotides. Furthermore,
the increased expression of these transport proteins is known to be associated with
worse prognosis in leukemia [102, 314].
To test the hypothesis that blocking cAMP efflux triggers the accumulation of
cAMP and stimulates cAMP-dependent downstream signaling, we developed a screen
using a fluorescent cAMP analog to identify compounds that block active cAMP efflux
[315]. Surprisingly, one of the identified drugs was clioquinol. In support of our
hypothesis, treatment with clioquinol or other Inhibitors of cAMP Efflux (ICE)
resulted in increased phosphorylation of the cAMP-responsive element-binding
protein (CREB; Ser133), a classical cAMP downstream effector that activates target
genes. Furthermore, it triggered dose-dependent hallmarks of the cAMP-dependent
intrinsic apoptotic pathway. While no apparent correlation between ABCC4 (MRP4)
expression and cAMP efflux was found, we concluded that alternate ABC transporters
capable of cAMP efflux, such as ABCC5 (MRP5) and ABCC11 (MRP8), could contribute
to the removal of cAMP from different cells [6]. These studies suggest that clioquinol
and other ICE can target cAMP efflux in cancer via ABC transporters. A recent report
showed the effect of clioquinol on another ABC transporter, ABCB1 (MDR1 or P-gp)
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[316]. A combination of clioquinol with zinc and copper significantly increased the
expression of the ABCB1 protein. This was accompanied by a change in the ability of
cells to efflux the ABCB1 substrate [316]. Thus, there could be an underappreciated
connection between ABC transporters, efflux substrates and clioquinol.

7.6 ATP-binding cassette transporters, potential culprits in clioquinolassociated subacute myelo-optic neuropathy?
Clioquinol’s potential involvement with ABC transporters brings us back to
SMON. Could transporter inhibition contribute to its neuropathological symptoms?
We propose that a natural (genetic) impairment of normal transporter function or
capacity, combined with increased transport inhibition by clioquinol, could trigger
the etiology of SMON. Toward this end, we focus on the fact that SMON was almost
completely confined to the Japanese population and was seldom reported in other
countries [290, 291]. While high doses of clioquinol were sufficient to partially
recapitulate human pathology in several animal models, only a few cases of the
disease were reported outside of Japan.
The familial aggregation of the SMON cases, previously interpreted in terms of
the infectious nature of SMON etiology [290], could reflect a genetic component
related to single-nucleotide polymorphisms (SNPs; see glossary, section 7.12) in
cAMP-transporting ABC pumps. Multiple non-synonymous SNPs that can potentially
affect a transporter’s function have been identified, and surprisingly, ABCC4 and
ABCC11 SNPs are elevated in the Japanese population.
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7.7 Single nucleotide polymorphisms in ABCC4 and ABCC11 in Japanese
population dramatically increase sensitivity to nucleotide-like drugs
7.7.1 ABCC4
The ABCC4 SNP rs3765534 (G2269A, E857K) dramatically reduces transporter
function by interfering with protein membrane localization [317]. This SNP is
widespread in the Japanese population (> 18 % allelic frequency) but is significantly
less in all other studied groups: Ashkenazi Jews, Africans north of the Sahara, Pacific
Islanders, European Americans, African Americans, Middle Easterners and Chinese
Americans [317]. In Japanese patients with inflammatory bowel disease, the allelic
frequency of ABCC4 G2269A was 14.7%, with levels of the substrate 6-thioguanine
significantly higher in patients with the ABCC4 variant alone than in patients with the
WT allelotype. This result, together with experiments in murine models, suggests that
the decreased ability to efflux 6-thioguanine nucleotides (Figure 7.1) accounts for
thiopurine-induced hematopoietic toxicity in patients with the ABCC4 G2269A SNP
[317]. In another study, the relationship between ABCC4 G2269A, increased
thiopurine sensitivity and leukopenia was also reported [318].
Additional SNPs in ABCC4 with a high frequency in the Japanese population are
C912A and C559T (compare 0.3 and 0.14 respectively in the Japanese population vs.
0.02 and 0 in the Caucasian population), and these have been shown to affect 6mercaptopurine (Figure 7.1) sensitivity in childhood ALL [319]. The variant G559T
correlated with diminished ABCC4 protein expression in human liver samples [320]
and reduced drug efflux function [321]. ABCC4 expression in the livers of patients
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carrying the non-synonymous C912A variant was only ~54 % of control expression.
Hence, ABCC4 SNPs that negatively affect expression or efflux function of the
transporter and thus, increase patient sensitivity to nucleotide-like drugs are
enriched in the Japanese population.

7.7.2 ABCC11
The SNP rs17822931 (G538A; G180R) in ABCC11 was first discovered as a
genetic variant that determines earwax type in humans [322]. WT ABCC11 is
associated with brownish, sticky, wet-type earwax and axillary osmidrosis (see
glossary, section 7.12) [9, 323]. The G180R is related to the formation of dry-type
earwax [322]. The G180R variant lacks N-linked glycosylation necessary for stable
protein expression, and therefore, undergoes rapid proteasomal degradation [9]. As
a result, the secretion of earwax is dramatically changed (Figure 7.2).
In the Japanese population, the frequency of the G538A allele is very high.
Accordingly, it varies from 0.71-0.99 in different prefectures of Japan [324]. In
populations of European or African origin, it is extremely rare (0.00-0.03). The
geographical distribution of this allele is believed to be related to the migration of the
Yayoi people, who came to Japan 3000–1800 years ago [324]. It worth noting that this
distribution is somewhat similar to the distribution of the annual incidence or
prevalence rates of SMON, with the highest rates in the southwestern part of Japan,
especially in the Kinki or Kansai and Shikoku prefectures (compare maps in
references [324] and [290]).
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Similar to ABCC4, several studies also indicated the importance of this SNP in
nucleotide-like drug sensitivity. Uemura et al., 2010 analyzed the effect of the ABCC11
SNP genotype (G538A, G/G, G/A, and A/A) in a set of 13 adenocarcinoma cell lines.
They found that A/A homozygotes were significantly more sensitive to pemetrexed
(Figure 7.1), as compared to the combined G/G and G/A groups. The authors
concluded that SNP (G538A) in the ABCC11 gene represents an important
determinant of pemetrexed sensitivity [325].

Figure 7.2 Schematic illustration of the role of SNP rs17822931 (G538A; G180R) in ABCC11
functional activity (modified from ref. [5]).
The G180R variant lacks N-linked glycosylation (red circles) necessary for stable protein expression,
and is subsequently targeted for rapid proteasomal degradation [9]. The precursors of the odorous
compounds are not loaded into apocrine vesicles that are released by the cell, and therefore, the loss
of transporters results in dry earwax and odorless sweat. Loading apocrine vesicles by the WT
protein is shown by the purple arrow.
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Thus, an increased sensitivity to nucleotide-like drugs directly related to ABCC
protein polymorphisms has been reported in Japanese patients [318, 320]. The cyclic
nucleotides, cAMP and cGMP, are well known natural substrates of ABCC transporters
that exhibit significant structural similarity with anticancer drugs, including
pemetrexed,

methotrexate,

cytosine

arabinoside,

and

9’-(2’-phosphonyl-

methoxyethyl)adenine, as well as 5-fluoro-2’-deoxyuridine 5’-monophosphate, an
active metabolite of 5-FU (5-fluorouracil) (Figure 7.1) [326]. Is it plausible that the
decreased function of the ABC transporter in patients carrying SNPs, in a manner
similar to cancer drugs, also diminishes cAMP efflux? Would patients with SNPs in
ABCC4 and ABCC11 transporters be vulnerable to clioquinol, while patients carrying
wild type alleles would be resistant? While testing these hypotheses would require
additional studies, if true, clioquinol could be safe for a large fraction of the world’s
population and could allow broad repurposing. Tests for detecting mutant ABCC4 and
ABCC11 alleles have already been developed and validated in large human
populations [324], thus allowing for easy identification of good candidates for
clioquinol treatment.

7.8 Possible beneficial effects of single nucleotide polymorphisms in ABCC
transporters
It noteworthy that SNPs in cAMP transporters are not entirely harmful. They may
provide benefits for other conditions, like cancer. While the physiological function of
ABCC11 beyond earwax and axillary glands is unclear, a role in cancer is possible.
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Caucasians and African–Americans showed approximately four-fold higher rates of
breast cancer mortality as compared to women of Japanese and Taiwanese origin.
The international mortality and frequency rates for breast cancer were reported to
be associated with the frequency of the allele for wet-type earwax [327]. A direct
study of ABCC11 G538A association with breast cancer conducted in Japanese
women revealed that the WT (538G) allele frequency in cancer patients was higher
than in the control group and moderately associated with the risk of breast cancer
[328]. Since WT ABCC11 has the ability to efflux cyclic nucleotides (cAMP and cGMP),
the finding that a functionally “defective” transporter allele has a protective effect
against cancer supports the idea that cAMP efflux transporters can contribute to the
evasion of apoptosis and that impaired cAMP removal helps to eliminate cancer cells
[6]. In Caucasian women, no significant relationship between breast cancer risk and
G538A allele has been found [329] [330]. One explanation for this phenomenon could
be that the presence of fully functional ABCC11 paralogs (such as ABCC4, for example)
in the Caucasians population compensates for the function of the mutated
transporter. Since the Japanese population is enriched in SNPs that can also down
modulate ABCC4 function, it is plausible that a specific set of SNPs in ABCC
transporters (rather than a single SNP) is required to provide a cancer-protective
function.
If down-modulation of transporter function is beneficial for cancer patients, then
transporter up-regulation should have the opposite effect. Indeed, a high level of
ABCC11 expression in breast tumor tissue was associated with worse disease-free
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survival [331]. Typically, such data are interpreted as though an increased expression
of the transporter causes efflux of the chemotherapy drug, providing a survival
benefit for malignant cells. However, the authors argued that only a fraction of the
patient cohort used in this study (~ 30.9%) had received 5-fluorouracil (Figure 7.1),
a known substrate of ABCC11 used for breast cancer therapy. Therefore, they posited
that drug “efflux alone cannot explain the association” between transporter
overexpression and poor disease-free survival. The authors concluded that “some
other function of ABCC11 may contribute to the phenomenon” [332]. Thus, the efflux
of another substrate, possibly of a nucleotide nature, may provide a plausible
explanation. The recent discovery that type 10 soluble adenylyl cyclase (sAC; see
glossary, section 7.12) produces cAMP as a result of oncogenic stress and functions as
a tumor suppressor protein may also provide indirect support for the notion of a
specific role of cAMP in cancerogenesis [333].
Furthermore, it is well established that in Japan, the rates of AD are lower than in
other developed countries. This difference is usually attributed to differences in diet,
low in cholesterol and saturated fat [334]. However, since the SNPs in cAMP
transporters seem to lower, or at least negatively correlate, with the risk of breast
cancer, is it possible that a similar relationship exists in AD?
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7.9 Could clioquinol’s effect on cAMP be relevant to clioquinol’s action in
Alzheimer’s disease?
The ability to modify the efficacy of synaptic transmission in response to neural
activity is termed synaptic plasticity. It underlies the capacity of neuronal networks
to adjust to external stimuli, and to process information. Long-term plasticity,
occurring over tens of minutes to years, appears to impact memory and learning.
Experimentally studied as long-term potentiation (LTP; see glossary, section 7.12), it
may represent the measurable cellular correlate of learning and memory.
Consequently, the etiology of AD pathology is shifting from β-amyloid deposits and
neuronal death toward synaptic dysfunction as an early cause of the disease. LTP
impairment was one of the first quantifiable outcomes supporting this idea [335].
However, the molecular mechanisms of this process are unclear.
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Figure 7.3 A model for the role of integrin in consolidation of LTP.
Cellular integrins modulate their molecular conformation, rapidly and reversibly changing
from a low ligand-binding affinity non-adhesive (bent) state to a high ligand-binding adhesive state
(extended) under the control of “inside-out” signaling originating from GPCRs. The addition of
integrin antagonists or anti-integrin function-blocking antibodies, as well as their genetic disruption
in murine models, results in the reduction of LTP stabilization and a deficiency in hippocampaldependent working memory [7]. The model includes two major steps: 1) Immediately after
induction of LTP, integrins that normally stabilize synaptic structure are inactivated. This results in
integrin disengagement as well as disassembly of the postsynaptic actin network and extracellular
matrix (ECM). 2) LTP consolidation. Large morphological changes and synaptic reassembly after
LTP induction allow for the insertion of new molecules and the expansion of the synapse. After a
period of instability, new integrins are inserted and engaged stabilizing the new morphology and
function of the synapse via transition from low to high integrin affinity [7].

Because the consolidation of LTP requires a series of transitions between
engaged and disengaged cell adhesion molecules, like integrins (Figure 7.3; see
glossary, section 7.12), it is possible that the stabilization of one state due to a
signaling dysfunction would significantly perturb the outcome of the entire process.
As integrin function depends upon the cAMP/PKA/CREB pathway [336-339],
clioquinol and other ICE compounds shown to up-regulate the cAMP-signaling
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pathway were also able to deactivate integrins [6]. The observation that anti-integrin
antibodies or antagonists that inhibit adhesive interactions were capable of
preventing the β-amyloid peptide-induced inhibition of LTP [340], suggests that the
de-adhesion or integrin deactivation step of the LTP consolidation sequence (step #1,
Figure 7.3) is likely affected in AD. The fact that pharmacologically-increased
intracellular cAMP was also capable of preventing the inhibition of LTP induced by βamyloid peptides [341] additionally supports this idea. Thus, cAMP regulation of cell
adhesion through integrin receptors provides an unexpected link between clioquinol
and synaptic plasticity (Figure 7.4).

Figure 7.4 A model that summarizes hypotheses relating cAMP accumulation with the
pathogenesis of SMON, AD and other diseases.
Excessive accumulation of cAMP that may result from SNPs in ABCC4 and ABCC11 transporters
targeted by clioquinol, can trigger apoptosis that can be devastating. In certain cancers, where cAMP
efflux supports malignant cell survival, blocking the efflux represents a novel cancer targeting
mechanism. In Japanese and Taiwanese women, SNPs in ABCC transporters that lower transporter
activity can have a natural protective role against cancer. Additional accumulation of cAMP resulting
from the effects of clioquinol can enhance the expression of CRE-driven genes that may indirectly
affect synaptic plasticity. Cytosolic cAMP can directly modulate the integrin activation state and thus
regulate synaptic plasticity.
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7.10 The cAMP/PKA/CREB signaling pathway as a possible target in
Alzheimer’s disease
Discovered in a screen designed to identify compounds that block the efflux of a
cAMP fluorescent derivative, clioquinol was reported to up-regulate CREB Ser133
phosphorylation (see Figure 3 in reference [6]). It was also shown that mice
expressing a constitutively active form of CREB (VP16-CREB) in hippocampal
neurons facilitated LTP [342]. The enhanced expression of CRE-driven genes
facilitated the priming of synapses leading to the stimulation of synaptic capture
[343]. Thus, increased cAMP signaling, via administration of caffeine [344], or
environmental enrichment (see glossary, section 7.12) by means of β2 adrenergic
receptor/adenylyl cyclase stimulation, can be beneficial in animal models of AD [342].
Moreover, because impaired CREB phosphorylation represents an essential
pathological component of AD, the induction of CREB phosphorylation (Ser133) in
response to different classes of drugs/compounds has been proposed as a
mechanistic marker for identifying compounds potentially beneficial for treating AD
[345]. However, the cause of the cAMP-dependent pathway dysfunction in AD
remains unknown.
Earlier models for AD pathology proposed PKA dysfunction, where oxidative
stress mediated by the β-amyloid peptide, ROS and mitochondrial dysfunction were
envisioned to contribute to AD pathogenesis [346]. Alternative β-amyloid peptideindependent models have also been considered [347-349]. Nevertheless, the role of
cAMP efflux and cAMP-efflux transporters in AD has never been considered despite:
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1. cAMP-efflux transporter expression on neurons [350],
2. elevated ABCC4 expression in AD brains [351],
3. increased cerebrospinal fluid cAMP levels in AD patients [352],
4. increased cAMP immunostaining in cerebral cortical and meningeal vessels
correlated with β-amyloid immunostaining localized in the “selectively vulnerable
targets of neurodegeneration” [353]. Furthermore, ABC transporters are generally
considered good drug targets in neurological diseases [354].

Extracellular deposits of β-amyloid peptides and neurofibrillary tangles
(aggregates of hyper-phosphorylated tau protein) are two pathological hallmarks of
AD. However, it is difficult to correlate the severity of clinical manifestations of the
disease, such as dementia, and these pathological features [355]. We propose that
dysregulation of neuronal cAMP signaling, and specifically cAMP efflux, contributes
to the pathology of AD. The idea that these protein assemblies can cause synaptic
dysfunction and impair LTP has gotten more attention from the scientific community.
One of the first breakthrough findings here was the observation that β-amyloid
peptides were capable of inhibiting the cAMP/PKA/CREB pathway and LTP.
Elevation of the cAMP content in neurons was sufficient to reverse this inhibition
[356]. Today, a large body of literature supports the notion that additional stimulation
of the cAMP/PKA/CREB pathway leads to subsequent CREB phosphorylation in AD
(Figure 7.4).
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The cAMP-dependent signaling pathway and multiple cAMP-downstream
effectors also play significant roles in triggering neuronal apoptosis [357-359].
Numerous stress factors, including ischemia and reperfusion, traumatic brain injury,
etc., are reported to stimulate cAMP-dependent signaling. Surprisingly, the signaling
pathway that activates apoptosis in neurons is very similar to the pathway that
induces the death of cancer cells. In neurons, apoptosis induced by reperfusion after
simulated ischemia results in increased cAMP accumulation, mitochondrial
depolarization, and effector caspase activation [360]. These steps parallel the
apoptosis induced in leukemic cells by clioquinol and other ICE [6]. In both cases,
apoptosis was prevented with KH7, a specific inhibitor of the cAMP-producing
enzyme sAC. Moreover, the three transporters reported to actively efflux cAMP from
cells were detected on the protein level in neurons (ABCC5 and ABCC11), astrocytes
and microglia (ABCC4 and ABCC5), and endothelia (ABCC4 and ABCC5) [350],
providing a target for clioquinol and other ICE in the CNS. Given the potential
relationship of CNS transporters, neuronal function, and clioquinol, is it possible that
clioquinol’s capacity to inhibit cAMP efflux, rather than its chelator/ionophore
activity, provides any of the speculated benefits that were reported in AD? If true,
could other ICE compounds provide similar potential benefits? Indeed, two ICE
compounds, cryptotanshinone and parthenolide, were claimed to prevent, alleviate
or treat AD or AD symptoms ([361-364] and patent applications US 2004/0039050
Al, US 2015/0164858 Al). Thus, it is plausible that ICE may restore activation of
downstream cAMP signaling. Hence, a story that started with clioquinol and a
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mysterious disease confined to Japan, leads to novel questions and hypotheses about
AD pathogenesis.

7.11 Concluding remarks and future perspectives
The public health impact of AD is expected to increase in the next 30-50 years,
yet there is no effective preventative strategy or treatment that will dramatically
reverse its debilitating effects. The main difficulty is our lack of understanding of the
disease pathogenesis. A deeper understanding of the AD pathological process will
help us to identify better therapeutic targets and will facilitate the development of
new therapeutic strategies and drugs aimed at overcoming the disease progression
and burden.
Here, we have briefly reviewed the history of the drug clioquinol and highlighted
multiple mechanisms of action that have been attributed to the beneficial effects of
the drug, as well as its severe side effects during different historical periods. Further
interest in the use of clioquinol was aroused by the finding that it inhibited plaque
formation in AD mouse models, possibly by its ionophore properties. A key concept
here is the ability of clioquinol to block cAMP efflux from cells and thus, to trigger the
phosphorylation of CREB Ser133, a classical cAMP effector that activates target genes.
This finding provided a connection to possible targets of clioquinol: ABCC4 and
ABCC11, transporters that normally efflux numerous endogenous substrates,
including cAMP. A further analysis revealed the presence of SNPs in both ABCC4 and
ABCC11, capable of reducing transporter function and at the same time present with
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a high frequency in the Japanese population. Modern studies showed that these SNPs
are critical for patient sensitivity to cancer and immunosuppressor nucleotide-like
drugs, substrates of ABCC4 and ABCC11 transporters. Thus, this line of research
provides a plausible explanation for the SMON phenomenon: patients that carry SNPs
in ABC transporters that dramatically affect nucleotide efflux are expected to be more
sensitive to clioquinol. Since these SNPs are geographically restricted to Japan, this
also accounts for the specific distribution of the disease. Today, these hypotheses can
be experimentally verified, and as a result, might offer a path to the safer use of
clioquinol in clinical practice.
Several alternative ideas about clioquinol’s mechanism of action were explored
by others, however, they did not result in significant breakthroughs. One exciting new
concept presented here describes clioquinol’s role in blocking cAMP efflux and
increasing

CREB

phosphorylation.

Because

the

dysregulation

of

the

cAMP/PKA/CREB pathway is a hallmark of several diseases, it is plausible that the
beneficial effects of clioquinol are due to its influence on this pathway. Moreover, the
specific role of cAMP-related signaling in integrin inside-out deactivation provides an
unexpected molecular mechanism that could link clioquinol effects with synaptic
plasticity. This leads to a number of questions that can all be addressed using modern
technologies. For example, it is important to know how blocking cAMP efflux affects
LTP consolidation. Very limited data about the efflux of signaling mediators, including
cyclic nucleotides, from the tetrapartite synapse elements are available. In addition,
it is necessary to understand conformational and ligand-binding affinity changes in
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synaptic and glial integrins that occur under different conditions, and how changes in
the extracellular environment affect the synapse. On a macro scale, studies of the
signaling partners of the cAMP/PKA/CREB pathway and their alterations in aging,
health and disease are also required. And finally, will it be possible to develop novel
therapeutic strategies for AD by targeting active cyclic nucleotide efflux?
Today we still have much to learn about the pathological processes underlying
neurodegenerative diseases. As the human population ages, the overall impact of AD
is expected to grow. Recent research, surprisingly originating from studies of an old
drug, clioquinol, and implicating cAMP-related signaling in the pathogenesis of AD,
represent a promising approach that may lead to a better future for generations to
come.

7.12 Glossary
ATP-binding cassette (ABC) transporter: A superfamily of active transporters that
use energy from ATP hydrolysis to pump substrates across cell membranes. Certain
ABC pumps participate in drug efflux from cancer cells, thus contributing to drug
resistance. Defects in transport function may lead to drug sensitivity and adverse
drug reactions. ABCC (subfamily C) members are also known as multidrug resistance
proteins (MRPs). ABCC4 (MRP4), ABCC5 (MRP5) and ABCC11 (MRP8) are reported
to efflux cyclic nucleotides (cAMP and cGMP).
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Axillary osmidrosis: A condition characterized by increased foul odor in the
underarm region. Specific SNPs in ABCC11 result in a loss of transporter activity, and
therefore dramatically reduce body odor.

Environmental enrichment: Manipulations administered to laboratory animals,
including expanded living space, physical exercise and engagement with novel objects
that stimulate sensory perception and cognition.

Integrin: Integrins, cell adhesion molecules expressed on the majority of cells, are
known to be critical for cell adhesion to endothelium, extravasation, homing and
mobilization. They are also vital for the tetrapartite structure of neuronal synapses,
where impairing integrin adhesion has been shown to damage synaptic transmission
and the induction of LTP. Rapid changes in cell adhesion are controlled by integrin
conformational changes rather than by changes in expression or trafficking. Cyclic
AMP accumulation has been shown to down-modulate integrin-dependent adhesion.

Long-term potentiation (LTP): A sustained strengthening of neurological
synapses resulting from recent synaptic activity. This particular type of synaptic
plasticity is believed to underlie short-term memory and learning in mammals. LTP
and other types of synaptic plasticity are controlled at least in part by integrins.
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Mini-mental state examination (MMSE): A test administered by a health-care
professional to evaluate a patient’s mental skills (cognitive state). It includes a series
of questions, and the score interprets the degree of mental state impairment. MMSE
is one of the tests used to assess dementia.

Single nucleotide polymorphism (SNP): A common type of genetic variability
wherein a single DNA nucleotide is changed. Two major types of SNPs exist:
synonymous and non-synonymous substitutions. Non-synonymous SNPs alter the
amino acid encoded, which may or may not result in a change of a protein function.

Soluble adenylyl cyclase (sAC): The protein encoded by the ADCY10 gene catalyzes
the formation of the second messenger cAMP from ATP. Its activity is stimulated by
low pH, bicarbonate ion and CO2. Also, sAC has been implicated as a tumor suppressor
protein whose expression is down-modulated in several cancers. Decreased sAC
expression promotes cellular transformation in vitro and stimulates cancer
progression in vivo.
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CHAPTER 8: Discussion and future directions
8.1 Discussion
Since we hypothesized that cAMP efflux is an adaptation for apoptotic evasion in
malignant cells, this dissertation is aimed at documenting the ability of ICE to
modulate survival responses in acute leukemia cells. These relationships were
explored in Chapter 3 and Chapter 6, and they will be discussed further below. The
remaining chapters describe the development of methods used to support the
analysis and characterization of ICE effects on AML and B-ALL cells. Published as a
method Chapter 2 provides details of a novel assay to assess cellular efflux of a
fluorescent cAMP analog. Published as a technical note, Chapter 4 describes a high
throughput flow cytometry (HTFC) approach to assess the chemotherapeutic impact
on the viability of primary leukemia samples, in the context of hypoxia and normoxia.
Finding little difference in cell responses related to oxygen exposure, we opted to
continue subsequent work in normoxia. Published as an application note, Chapter 5
introduces SynScreen software, which we developed to facilitate the analysis of drug
interactions and to determine the potential synergism of tested combinations.
Providing benefits for the analysis of large data sets, SynScreen allows for multiple
experimental replicates to be compared simultaneously (see the Results and
Discussion section of Chapter 5 for a detailed comparison of SynScreen with other
drug combination analysis software). Published as a review, Chapter 7 explores: 1)
how the detrimental effects of an ICE compound, clioquinol, in subacute myelo-optic
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neuropathy may be related to SNPs in cyclic nucleotide transporters; and 2) the
potential association of cAMP efflux with disease states, such as Alzheimer’s disease.
In Chapter 3, we established that acute leukemia cell lines efflux F-cAMP,
whereas normal PBMCs do not. These results both support our hypothesis that cAMP
efflux is a malignancy-specific adaptation, and the fact that hematopoietic progenitor
cells have increased expression of ABC transporters [96], a phenotype that is shared
by the blast cells associated with acute leukemias. We also determined relationships
between ICE and the cAMP pathway by validating the ability of ICE compounds to
appropriately modulate downstream signaling that affected CREB activation and
integrin deactivation. We further demonstrated that the ability of ICE to reduce cell
viability was partially dependent on the activity of soluble adenylyl cyclase, a source
for cytosolic, mitochondrial, and nuclear cAMP production [13]. In terms of cAMP
efflux transporters, we assessed ABCC4 expression for cell lines. We determined that
there was no relationship between quantity of ABCC4 transporters per cell, as
determined by antibody binding to the protein, and F-cAMP efflux ability (compare
Figures 3.9 and 3.10. This leads to the possibility that protein expression was
disassociated from efflux activity, or that ICE act by alternative mechanism(s)
unrelated to transporter inhibition. Because flow cytometry compatible monoclonal
antibodies were not available during the course of the project, we did not determine
ABCC5 or ABCC11 expression on our tested cells. Work by Guo, et al. previously
showed that, of the known cAMP efflux transporters, only the expression of ABCC11
was prognostically relevant in leukemia [102]. Other studies have indicated the
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possibility for the ABCC1 and ABCG2 transporters to efflux cyclic nucleotides [99,
365]. It is therefore plausible that acute leukemia cells may reduce intracellular cAMP
by ABCC5, ABCC11, or other MRP transporters.
In Chapter 6, our approach for ICE+LCA combinations had the rationale of
increasing cellular retention of drugs that are known substrates of cyclic nucleotide
transporters in order to increase leukemic cell death. While our results showed
synergism for multiple combinations, especially those including AraC, methotrexate,
or topotecan, the ability for this work to be translated would not be simple. We
addressed several limitations of our approach in Chapter 6. One other factor that
needs to be considered regarding ICE+LCA combinations for translational
development is that transporter inhibitors combined with therapeutics in hopes of
reducing drug resistance failed to produce any clinically beneficial results [366].
However, because ICE were potent and selective against leukemia cells when used
alone, it is possible that the ‘two-hit’ approach to treatment could be beneficial
because the cells would be killed by mechanisms related to the cAMP pathway and to
cell replication. As such, it is plausible that ICE+LCA combinations may also to
improve response in vivo. In fact, synergism for some ICE compounds with LCA has
already demonstrated efficacy in vivo [284].
Aside from our assay development work in Chapter 4, we chose not to study Tcell lineage ALL (T-ALL) in the context of cAMP efflux and ICE for several reasons.
First, T-ALL is a rarer disease than AML or B-ALL, and primary samples are difficult
to acquire. Second, to our knowledge, aside from instances of acquired drug
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resistance, T lineage cells have not been reported to have aberrancies in cAMP efflux
proteins in relation to prognosis or treatment response. Lastly, in several studies, T
cells were were not subject to cAMP-induced apoptotic induction [55, 56, 367]. It has
been proposed that this may be because T cells preferentially express PDE3 isoforms,
which have 5-10 times greater affinity for cGMP in comparison to cAMP [368].
Nonetheless, the work described in this dissertation, with the exception of
Chapter 6, has been peer-reviewed and accepted by the scientific community.
Therefore, further work with ICE to explore their potential for clinical development
is justified.

8.2 Future Directions
8.2.1 Determine the effects of ICE on endogenous cAMP signaling
One important future direction for this work would be to determine how ICE
modulate endogenous cAMP concentrations. While we have demonstrated that ICE
increase cAMP pathway activity (Chapter 3), the mechanism of action of ICE on efflux
transporters has not been verified. If ICE are shown to increase accumulation of
icAMP, while also slowing the increase of ecAMP over time, then that would support
the notion that ICE compounds antagonize transporter activity. We have conducted
a preliminary study to assess cAMP concentrations in the presence of ICE (Figure
8.1). In the presence of PDE4 inhibitors, U937 (AML) cells were pre-treated with ICE
for 2 min, and then cAMP production was stimulated with the AC agonist forskolin.
Samples were collected after 5-60 min, and cells and supernatant were separated and
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washed. The cAMP concentrations from each condition were determined with the
Promega cAMP-Glo™ assay. The levels of icAMP plateau after 20 min for all conditions.
All samples treated with ICE appear to have higher icAMP concentrations than the
negative control. However, the ecAMP concentrations appear to increase over time in
a manner similar to the negative control.
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Figure 8.1 Preliminary data – ICE effects on endogenous intracellular and extracellular cAMP.
106 U937 (AML) cells were washed twice, and resuspended in 1 mL ‘induction buffer’ (IB; complete
RPMI without serum, plus PDE inhibitors 100 µM Ro-20-1724, 500 µM IBMX). The samples were
kept at 37°C on an Eppendorf MixMate, with 700 rpm shaking. At t = -2 min, ICE were added. At t =
0, forskolin (Fsk) was added to a final conc. of 10 µM (ICE were 30 µM, MK-571 was 45 µM). At t =
5, 10, 20, 30, and 60 min, 60 µL of sample was harvested and centrifuged 2 min, 300 rcf. The
supernatant (55 µL; ecAMP) was separated, the remaining cells (icAMP) were resuspended in 100
µL IB, and both were centrifuged. 50 µL of ecAMP supernatant was transferred to a new tube. From
icAMP tube, wash IB was removed and cells were resuspended in 50 µL IB. All samples were snapfrozen in a slurry of dry ice and ethanol. To determine cAMP concentrations per condition, the
Promega cAMP-Glo™ Assay was followed according to the manufacturer’s protocol for 96 well
plates, using 20 µL of collected each sample. Standard curves of cAMP were used to determine
concentrations. The data here represent the total concentration of cAMP determined from each well.
n = 3 per condition. Black lines, intracellular cAMP. Red lines, extracellular cAMP.

Nevertheless, definitive conclusions should not be drawn from this preliminary
data, as the experimental approach may not have been optimized with respect to
reagent concentrations, timing, and method of sample acquisition. It should also be
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noted that MK-571, the most commonly-used positive control for cAMP efflux
inhibition, failed to reduce the accumulation of extracellular cAMP. Hence, this
unexpected response could be an artifact. Alternatively, Wang, et al. indicated that in
triple negative breast cancer cell lines, MK-571 was less effective at reducing cAMP
efflux in comparison to probenecid [99]. However, the fact that MK-571 previously
worked in our experiments with U937 cells makes this interpretation less likely.
Accordingly, future studies need to optimize methods to analyze ICE-induced changes
in malignant cell icAMP and ecAMP over time. This may require the use of alternative
approaches, such as ELISA, radioimmunoassays, or homogeneous time resolved
fluorescence (HTRF) assays.

8.2.2 Evaluate ICE effects in vivo
The natural next step in determining the potential of ICE to be clinically
translated is to determine the efficacy of these compounds in vivo. We conducted a
pilot study to test small cohorts of mice in a B-ALL xenograft model. Female SCID mice
(12 week-old) were housed in the UNM Animal Resource Facility. The mice were
engrafted with 2x106 697 (B-ALL) cells by tail vein injection on day zero [369]. After
five days, mice received IP injections of vehicle, ICE, or MTX (positive control). The
treatments were administered twice weekly for a total of five doses. Next, mice were
sacrificed, organs were digested and disease burden was assessed using flow
cytometry [370]. Slides were prepared from formalin-fixed, paraffin embedded liver
and BM utilizing Wright and H&E stains (Figure 8.2A). There were no differences in
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tumor burden evident in the bone marrow either one day or one week after the last
ICE injection (Figure 8.2B, D). However, one day after the last treatment, clioquinol
significantly reduced tumor burden in the liver (Figure 8.2C). One week after the last
treatment, both clioquinol and dihydroartemisinin significantly reduced tumor
burden in the liver (Figure 8.2E-F). Using the same xenograft model and dosing
schedule, we also determined that dihydroartemisinin significantly improved overall
survival in comparison to untreated mice (Figure 8.2G). Hence, there is some
promise for additional in vivo studies with ICE.
It should be emphasized that the data in Figure 8.2 are preliminary. One of the
first issues that we encountered with this pilot study was that ICE had limited
solubility in water-based media. For the data presented, ICE were dissolved in HBSS
(GibcoTM) supplemented with 3% DMSO and 0.4 % Tween 20. This formulation was
empirically based on laboratory tests of drug solubility. We anticipate that better
drug formulations will contribute to improved drug efficacy. It was also evident that
both the doses of ICE used, as well as the treatment schedule, were not optimal. In a
recent AML mouse xenograft study, efficacy was achieved with 120 mg/kg artesunate
administered twice daily for five days, followed by five days of 100 mg/kg twice daily
[284]. We administered the artesunate metabolite, dihydroartemisinin, at 40 mg/kg
once every other day for five days. Because this dose was so much lower than others
have used, it is remarkable that we were able find any significant differences between
conditions. Future studies will need to further assess the effects of metabolically
relevant ICE concentrations on AML and B-ALL burden in vivo.
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Figure 8.2 Preliminary ICE in vivo data.
A) Experimental design. B and D) Percent of leukemic cells present in the bone marrow and livers
of mice 1 day after final treatment. C and E) Percent of leukemic cells present in bone marrow and
livers of mice 1 week after final treatment. F) Representative histological specimens (day 22 postengraftment) from BM and liver of DHA treated and control mice. G) Survival of mice treated with
either vehicle or DHA under the same treatment regimen as in (A). CQL, clioquinol, CTS,
cryptotanshinone, DHA, dihydroartemisinin, MTX, methotrexate. B-F, n = 3 per condition. G, n = 10
per condition. Treatment data were compared to vehicle controls by one-tailed unpaired t-tests.
*, p < 0.05, ***, p < 0.001.
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8.3 Concluding remarks
A common characteristic among many cancers is dysregulation of cAMP pathway
activity. Therefore, we propose that that the active removal of cAMP represents a
novel mechanism that can be exploited by cancer cells for evasion of apoptosis.
Accordingly, we suggest that inhibition of cAMP efflux by small molecules, especially
by repurposed drugs, could expedite the translation of cAMP pathway-targeted
therapeutics. Hence, the objective of this dissertation work was to identify
compounds that increase cAMP pathway activity and reduce the viability of acute
leukemia cells. We identified several agents that fit these criteria. In agreement with
our hypothesis that elevated cAMP efflux activity is a malignant adaptation, we
demonstrated that normal peripheral blood cells lack this trait. Furthermore, the
drugs that we identified demonstrated selectivity against AML and B-ALL cells. When
our cAMP modulatory agents were combined with leukemia chemotherapeutics,
leukemia cell sensitivity was increased. This research is expected to provide a
foundation toward the development of novel therapeutic options for leukemia and
other diseases associated with aberrant cAMP signaling.
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APPENDICES
APPENDIX A: Abbreviations used

571 – MK-571 (MRP inhibitor); ICE compound positive control
5FU – 5-fluorouracil; a LCA
6MP – 6-mercaptopurine; a LCA
ABC – ATP-binding cassette
ABCC4 – MRP4; cyclic nucleotide transporter
ABCC5 – MRP5; cyclic nucleotide transporter
ABCC11 – MRP8; cyclic nucleotide transporter
AD – Alzheimer’s disease
ALL – acute lymphoblastic leukemia
AML – acute myeloid leukemia
AraC – cytarabine, cytosine arabinoside; a LCA
ART – artesunate; ICE compound
ATP – adenosine triphosphate
B-ALL – B-cell lineage acute lymphoblastic leukemia
cAMP – 3’,5’-cyclic adenosine monophosphate; cyclic AMP
Cdk2 – cyclin-dependent kinase 2
cGMP – cyclic guanosine monophosphate
CRE – cAMP response elements
CREB – cyclic AMP responsive element-binding protein
CQL – clioquinol; ICE compound
CTS – cryptotanshinone; ICE compound
DHA – dihydroartemisinin; ICE compound
ECM – extracellular matrix
EPAC – exchange protein activated by cAMP; downstream effector of cAMP
ER – endoplasmic reticulum
GPCR – G protein-coupled receptor
HTFC – high throughput flow cytometry
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F-cAMP – fluorescent cAMP analog used in our studies
HTFC – high throughput flow cytometry
IBMX – 3-isobutyl-1-methylxanthine; PDE inhibitor
ICE – inhibitors of cAMP efflux
LC3-II – microtubule-associated protein 1 light chain 3
LCA – leukemia therapeutic agent
LTP – long-term potentiation
MDR – multidrug resistance
MDR1 – multidrug resistance protein 1, ABCB1, P-gp
MMSE – mini-mental state examination
MRD – minimal residual disease
MRP – multidrug resistance protein (members of the ABC-C family of transporters)
MTX – methotrexate; a LCA
P-gp – P-glycoprotein 1, MDR1, ABCB1
PBT2 – (5,7-dichloro-2-((dimethylamino)methyl) 8-quinolinol
PI – propidium iodide
PKA – protein kinase A; cAMP-dependent protein kinase; downstream effector of cAMP
Ro-20-1724 – 4-(3-Butoxy-4-methoxyphenyl)methyl-2-imidazolidone; PDE4 inhibitor
ROS – reactive oxygen species
sAC – soluble adenylyl cycase; generates cAMP
SMON – subacute myelo-optic neuropathy
SNP – single nucleotide polymorphism
T-ALL – T-cell lineage acute lymphoblastic leukemia
tmAC – transmembrane-associated adenylyl cyclase; generates cAMP
TPT – topotecan; a LCA
VLA-4 – very late antigen-4
WT – wild type
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APPENDIX B: Supplemental material for Chapter 4

Table S4.1 Karyotypic and molecular classification of primary T-ALL samples used for the
development of PDX.
# primary T-ALL samples used in this study; ND, not determined; R, rearrangements;
* reported by Matlawska-Wasowska et al. (2016) Leukemia [371].

6.
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Table S4.2 List of the tested inhibitors and their clinical relevance.
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Table S4.3 Ex vivo drug response profiling of T-ALL cell lines.
The cells were incubated for 72 hr with the tested agents and the EC 50 values were calculated from
three independent experiments. EC50 values were reported for inhibitors that yielded maximum
response values of 20% or greater. For EC50 values calculated to be beyond the concentration range
tested, they were reported as >100 µM. This indicate the cells that were insensitive to the inhibitors at
tested concentration range.
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Table S4.4 Cell viability (%) of T-ALL cell lines, primary samples, PDX models and PBMC at
indicated time points after incubation with DMSO (<1%).
* Mean values obtained from three independent experiments. ND, not determined.

Table S4.5 Response of T-ALL patient samples and patient derived xenografts to 31 FDAapproved inhibitors.
Response of T-ALL patient samples and patient derived xenografts to 31 small molecule inhibitors. The
cells were incubated for 48 hrs with the tested agents. EC 50 values were reported for inhibitors that
yielded maximum response values of 20% or greater. The EC 50 values that were beyond the
concentration range tested are reported as >100 µM. This indicates the cells that were insensitive to
the inhibitors at tested concentrations.
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Figure S4.1. Hypoxia Cytotoxicity Ratio (HCR) for a panel of T-ALL cell lines treated with 31
inhibitors under normoxia and hypoxia conditions, respectively (72 hr).
HCR was determined for each drug and cell line as EC 50normoxia/EC50hypoxia. Each HCR was
calculated from mean EC50 values for three independent experiments. (paired Student’s t-test,
* p <0.05; # p <0.07).
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Figure S4.2. Response of T-ALL cell lines to the highest tested dose of each inhibitor under
hypoxia.
(100 µM for each drug with the exception of *alvocidib, *bortezomib and *carfilzomib, for which the
highest tested dose was 1 µM). Heatmap indicates the percentage of dead cells (0 -100%).
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Figure S4.3.
A) The heatmap represents the mean EC50 values obtained for the samples treated with the drugs for
72 hr under normoxic conditions. The columns indicate T-ALL samples and the rows indicate the
tested drugs. The darkest red indicates the most sensitivity (lowest EC50 values) of the cells to the
tested inhibitors. EC50 values are only reported for compounds that yielded maximum response values
of 20% or greater. For those samples which yielded maximal responses < 20% and/or had EC 50 values
greater than 100 µM, we report those EC50 values as “>100 µM” (light grey). B) Response of T-ALL
patient samples and PDX to the highest tested dose of each inhibitor (100 µM for each drug with the
exception of *alvocidib, *bortezomib and *carfilzomib for which the highest tested dose was 1 µM).
Heatmap indicates the percentage of dead cells after 72 hr incubation.

208

Figure S4.4. The HTFC PI assay provides information on the morphological shift that occurs in
cells treated with the tested inhibitors.
Shown are data from one replicate experiment of CUTLL1 cells incubated with vehicle or TKIs for 72 h
in normoxia or hypoxia conditions, then interrogated with the HTFC PI assay. A) Forward- and sidescatter plots of CUTLL1 cells from individual wells in the assay at different conditions. Gated cells that
were PI-positive cells are shown in green. Top panels, vehicle-only negative control. Bottom panels,
wells treated with 3.6 µM crizotinib. Left panels, wells from the assay plate incubated at normoxia.
Right panels, wells from the assay plate incubated in hypoxia. B-C) PI stain histograms from the wells
shown in (A). The gated % PI-positive values are shown on the upper right. Grey, negative control well
for that oxygen incubation condition. B) Wells incubated in normoxia. Blue, well treated with 3.6 µM
crizotinib. C) Wells incubated in hypoxia. Red, well treated with 3.6 µM crizotinib.
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Figure S4.5. Sensitivity of peripheral blood mononuclear cells (PBMC) to 31 small molecule
inhibitors.
A) The heatmap represents the mean EC50 values obtained for normal PBMC treated with the drugs for
42 and 72 hr under normoxic conditions. The columns indicate time points and the rows indicate the
tested drugs. The darkest red indicates the most sensitivity (lowest EC50 values) of the cells to the
tested inhibitors. Light grey, the dose responses indicated EC 50 > 100 µM indicating limited/lack of
response to the tested compounds. B) Response to the highest tested dose of each inhibitor (100 µM
for each drug with the exception of *alvocidib, *bortezomib and *carfilzomib for which the highest
tested dose was 1 µM). Heatmap indicates the percentage of dead cells after 48 and 72 hr incubation.
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APPENDIX C: Supplemental material for Chapter 5

Figure S5.1. Example of spreadsheet formatting needed for files that are imported into
SynScreen. Shown are the mean response values for the plate DMSO control wells that were used to
normalize the PctKill responses listed in column H. For import into SynScreen, the import range
E1:H37 was used.
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Figure S5.2. A comparison of the synergy data analysis from the data set of Borisy, et al.
2003. Plotted are the observed responses in comparison to the predicted Bliss values determined by
each source. A) The original observed values compared to predicted Bliss additivity from Figure 4 in
Borisy, 2003. B) The observed data in comparison to predicted Bliss values from SynScreen. C) The
observed data in comparison to predicted Bliss values from Combenefit.
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Table S5.1. Metrics determined by SynScreen and their definitions. DR, dose response.
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Table S5.2. Example of single agent metrics determined by SynScreen. These are the metrics
from the single agent dose responses used for a 5 x 5 drug combination screen. Ten drugs were tested
in 15-point, two-fold dilution dose responses in duplicate for each screening run. Additionally, the
drugs were tested with each combination matrix for 7-point four-fold dilution dose responses, totaling
five replicates per run. The data provided here are from a combination of four experimental replicates.
Outliers were removed based on dose response curves generated in the SynScreen interface. See
Appendix C, Table S5.1 for an explanation of the reported metrics.
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Table S5.3. Example of combination screen summary metrics determined by SynScreen. These
are the quantification of synergistic hits determined from the data presented in Figure 1. Twenty-five
drug pairs were tested in matrix dose responses and repeated n = 4. The user set a threshold such that
synergy was only determined for data points that elicited responses ≥ 30%. See Appendix C, Table S5.1
for an explanation of the reported metrics.
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Table S5.4. Synergistic data points identified from the data presented in Figure 5.3. To
remain consistent with the original study, no minFahit (%) was used. See Appendix C, Table S5.1 for
an explanation of the reported metrics.

216

APPENDIX D: Supplementary material for Chapter 6
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